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The discovery of the gluten link
In 1888, in the Saint Bartholomew’s Hospital Reports, Dr. Samuel Gee published the first 
detailed account in “modem” times of what he called “The coeliac affection”.1 Gee did not 
consider that he had discovered a new disease, but rather that he was describing a disorder 
that had been known since classical antiquity, as reported by the Greek physician Arataeus 
the Cappadocian. He recognized the importance of diet in the management of coeliac 
patients (“To regulate the food is the main part of treatment; ...the allowance of farinaceous 
food must be small...”). 
Several observations concerning the coeliac affection in children appeared in the medical 
literature in the years to follow. In 1908 Dr. O.A. Herter first described in the American 
literature the disease reported by Gee 2, and for a time the disease was known as Gee-Herter’s 
disease. This was in fact the term used by Willem Karel Dicke, another pioneer in the history 
of coeliac disease, in his first report on the wheat-free diet, published in Het Nederlands 
Tijdschrift voor Geneeskunde in 1941 (“A simple diet for Gee-Herter’s syndrome”). 
Diet had been the main treatment for coeliac disease since the late 1920s and early 1930s: 
in 1924 Haas reported a banana diet to be successful, and Fanconi’s diet based on fruit 
and vegetables was also recommended. Dicke was convinced of the beneficial effect of a 
wheat-free diet long before 1940. A case of a patient in whom diarrhoea recurred after the 
consumption of bread encouraged his first experiments with wheat-free diets, starting in 
1934-1936. The subsequent period of war convinced him further that eating fewer cereals 
improved the clinical condition of his patients. After the war, Dicke worked closely together 
with J. H. van de Kamer, a Dutch biochemist, who was the first to develop an accurate 
and easy-to-perform method to measure faecal fat content. On the basis of experiments 
performed using standardized diets and measuring fat absorption, Dicke concluded that 
wheat and rye flour, but not wheat starch, were responsible for the steatorrhoea observed in 
his patients. Subsequently, by the same approach, he identified the toxic moiety of wheat 
flour in the alcohol-soluble or gliadin component. Since the introduction of a gluten free 
diet, mortality has decreased dramatically. By this time it had been realized that children 
with coeliac disease and patients with so-called idiopathic steatorrhoea of adult life were 
suffering from the same condition, with the majority of adult patients also responding to the 
omission of wheat and rye from their diet.3
“To regulate the food is the main part of treatment”
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The evolution of diagnostic criteria
Until the 1950s, the diagnosis of coeliac disease was made when a child or adult had 
malabsorption in the absence of infection. When techniques for peroral small bowel biopsy 
were introduced during the 1960s, patients with malabsorption were found to have either 
a normal or a grossly abnormal jejunal biopsy.4 In 1969, the diagnostic criteria for coeliac 
disease were proposed at the Interlaken Meeting of the European Society of Paediatric 
Gastroenterology and Nutrition (ESPGAN).5
These criteria were further elaborated at the Second International Symposium of Coeliac 
Disease in 1974, and are as follows (A) structurally abnormal jejunal mucosa when taking a 
diet containing gluten; (B) clear improvement of villous structure when taking a gluten free 
diet; (C) deterioration of the mucosa during gluten challenge.6, 7
These criteria were reviewed by ESPGAN in 1990.8 Challenge was no longer required except 
for children under 2 years of age. 
Through in vitro studies, Marsh demonstrated in 1992 a spectrum of consecutive stages of 
mucosal abnormalities that can be seen in gluten sensitivity.9 Subsequently, immunological 
studies demonstrated that in active coeliac disease antibodies to endomysium (EMA) and 
tissue transglutaminase (tTG) can be detected, which opened the way for new diagnostic 
strategies and population screening.10
The criteria for the diagnosis of coeliac disease in adults have been defined in 2001 by a 
working group during the United European Gastroenterology Week (UEGW) in Amsterdam.11 
It was concluded that the diagnosis of coeliac disease does not require further confirmation if it 
is based on duodenal histology showing villous atrophy, crypt hyperplasia and intraepithelial 
lymphocytosis while using a gluten containing diet, which normalizes on a gluten free diet. 
Findings of circulating antibodies such as EMA and/or tTG before a gluten free diet support 
the diagnosis, but are not essential.
Human Leucocytes Antigen (HLA)-DQ2 or HLA-DQ8 are still considered circumstantial 
evidence. Gluten challenge might be useful for minor histological abnormalities, such as 
intraepithelial lymphocytosis.12 Immunogenetic research located coeliac related patterns on 
the HLA region on the short arm of chromosome 6, giving way to the formation of new 
concepts of the aetiology of the inflammatory response that is seen in coeliac disease. 
Subsequently, more research have been conducted to verify the relationship between 
different HLA-DQ haplotypes and the risk of developing a complicated form of coeliac 
disease, including the progression to malignancies particularly enteropathy associated T-cell 
lymphoma (EATL).13,14,15 In chapter 4 of the present thesis, we will present our results on the 
correlation between HLA-DQ2 homozygosity and the development of serious complications 
of coeliac disease, in particular RCD II and EATL.16 
A landmark development in the workup of coeliac disease was the application of 
immunophenotyping and the analysis of T-cell receptor gene using PCR studies.17, 18, 19 These 
studies paved the way to the current understanding and classification of coeliac disease 
in its different forms. In Chapter 2 we will discuss the impact of these informations on the 
classification of refractory coeliac disease. 
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Recent advances in small intestine enteroscopy, particularly the video capsule endoscopy 
20 and the double-balloon enteroscopy 21 have revolutionized the diagnostic approach of 
refractory coeliac disease and EATL. Chapter 5 of the present thesis deals with the impact of 
the introduction of the double-balloon enteroscopy on the management of refractory coeliac 
disease 22, while chapter 6 is devoted to discuss the applicability of computed tomography in 
the diagnostic work-up of refractory coeliac disease and EATL.23 
Historical phases in Coeliac Disease diagnosis
Before 1950s Coeliac disease is diagnosed when a child or adult had malabsorption in the absence of infection.
In 1960s Discovery of peroral small bowel biopsy. 
1969/1974 ESPGAN criteria the diagnostic criteria for Coeliac Disease. 
1990 ESPGAN Challenge was no longer required except for children under 2 years of age.
1992 Marsh demonstrated a spectrum of consecutive stages of mucosal abnormalities of gluten sensitive 
enteropathy.
In 1990s Immunological discoveries and HLA typing
2001 UEGW in Amsterdam: the diagnosis of Coeliac Disease is based on duodenal histology showing 
villous atrophy, crypt hyperplasia and intraepithelial lymphocytosis while using a gluten containing 
diet, which normalizes on a gluten free diet.
Gluten challenge might be useful for minor histological abnormalities, such as intraepithelial 
lymphocytosis.
2000s Small bowel endoscopy and radiology have made great steps: Double-Balloon Enteroscopy, Video 
Capsule endoscopy, CT and MR-enteroclysis.
The quest for effective medical therapy
Several trials and case reports were published dealing with medical therapies of the refractory 
forms of coeliac disease, 24, 25, 26 in addition to gluten free diet. Steroids have been tried since 
the eighties of the last century with mixed results. The best results were achieved in those 
patients with refractory forms of coeliac disease currently classified as refractory coeliac 
disease type I (without aberrant T-cells). On the other hand those patients with aberrant T-cells 
(refractory coeliac disease type II) were refractory to steroids and most of the subsequently 
studied immunosuppressives, particularly azathioprine.
Our results on treating those refractory patients with new medications, specifically cladribine 
(2-CDA) are to be presented in chapter 7.27 Furthermore, chapter 8 deals with a novel and a 
promising approach to try change the natural history of the refractory coeliac by using high 
dose chemotherapy followed by autologous stem cell transplantation.28 
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Enteropathy Associated T-cell Lymphoma
The relation of coeliac disease and lymphoma has been recognised since the first reported 
case in 1937 by Fairley et al.29, while the association of coeliac disease with adenocarcinoma 
of the small bowel was described in the late fifties of the last century.30,31,32 Prior to 1950 
malabsorption in lymphomatous patients was considered to be the result of either mesenteric 
lymphomatous lymphadenopathy (with lymphatic block) or diffuse lymphomatous infiltration 
of the small bowel.33 In 1950 the presence of mucosal abnormalities in the small bowel 
of such patients was suspected by Bjerkelund,34 and subsequently cases of lymphoma and 
malabsorption with jejunal mucosal changes resembling those in adult coeliac disease have 
been recorded.35, 36 In these patients the lymphoma has been considered to be the primary 
disease. In 1962 the hypothesis that small bowel reticulosis may develop as a complication 
in patients with coeliac disease (at that time called idiopathic steatorrhoea) was offered by 
Gough et al.37 It is not until the late seventies when the terminology has been changed to 
lymphoma and called coeliac- related lymphoma. 
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Definition/ Criteria of diagnosis of Refractory Coeliac Disease
Coeliac disease is life-long inflammatory condition of the small intestine in genetically 
susceptible individuals. On small bowel biopsy there is a characteristic, although not specific, 
mucosal lesion that impairs nutrient absorption by the involved bowel. Prompt improvement 
of nutrient absorption and healing of the characteristic intestinal mucosal lesion is seen upon 
withdrawal of dietary gluten.1
Non-responsive coeliac disease can be described in terms of the clinical scenario of a lack 
of initial response to a prescribed gluten free diet, or the recurrence of symptoms despite 
maintenance of gluten free diet in a patient who responded initially to gluten free diet.2 
Although clinical improvement is usually followed by histological improvement most of 
the time, on occasions there is evidence for histological improvement with persistence of 
clinical symptoms that could be related to other causes.3 Clinical improvement is usually 
evident within the first few weeks of starting gluten free diet; however, it might take up to 2 
years before a complete restoration of intestinal mucosa is evident.
Non-responsive coeliac disease
a lack of initial response to a gluten free diet, or the recurrence of symptoms despite 
adherence to diet in a patient who responded initially
Currently, true refractory coeliac disease (RCD) is being defined as persisting or recurring 
villous atrophy with crypt hyperplasia and increased intraepithelial lymphocytes in spite 
of a strict gluten free diet for more than 12 months or when severe persisting symptoms 
necessitate intervention independent of the duration of the dietary therapy.2 RCD may not 
respond primarily or secondarily to gluten free diet.4 All other causes of malabsorption must 
be excluded and additional features supporting the diagnosis of coeliac disease must be 
looked for, including the presence of antibodies (tTG) in the untreated state and the presence 
of HLA-DQ markers.3, 5, 6 
Two categories of RCD are being recognized: type I without aberrant T-cells and type II 
with aberrant T-cells detected by immunophenotyping by flowcytometric analysis or 
immunohistology of the intestinal mucosa.2, 7, 8 Arbitrarily, based on our experience, a 
percentage of aberrant cells CD7+CD3- of CD103+ IEL or cytoplasmic CD3+ surface CD3- 
% of CD103+ IEL of ≤ 10% can be regarded as normal, and more than 20% as definitively 
abnormal.
14
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Diagnostic criteria
RCD I – Villous atrophy persisted or recurred despite strict adherence to a gluten free diet.
–  At least partial villous atrophy (Marsh IIIA) according to the modified Marsh criteria 
–  Excluding other causes of villous atrophy.
–  When ≤ 10% aberrant T-cells in intestinal biopsy.
–  Intraepithelial lymphocyte phenotype is normal with the expression of surface CD3, CD8 and 
TCR
RCD II – The same as RCD I, in addition to the presence of ≥ 20% aberrant T-cells in intestinal biopsy. 
– The intraepithelial lymphocytes have normal morphology, but exhibit an aberrant phenotype 
(normal expression of CD103 and CD7, downregulation of surface CD3 to intracytoplasmic 
CD3, and the lack of surface T-cell markers: CD4, CD8 and TCR).
–  EATL has been confidently excluded.
Genetic and environmental factors in the pathogenesis of RCD
In the last few years, great progress has been made in understanding the pathogenesis of 
coeliac disease. It has become clear that ingestion of gluten by coeliac disease patients 
results in an improper T-cell mediated immune response. 
The environmental factor is mainly ingestion of gluten, while several genes contribute to the 
genetic predisposition. The main genetic factors, as mentioned before, are given HLA-DQ 
genes, i.e. the genes encoding DQ2 or DQ8 in the HLA complex on 6p21.
9,10 Approximately 
95% of coeliac patients have a DQ2 heterodimer comprised of DQB1*02 and DQA1*05 and 
most of the remaining 5% have a DQ8 heterodimer comprised of DQB1*302 and DQA1*03. 
A small number of individuals lacking either of those heterodimers have DQB1*02 or 
DQA1*05 alone. Gene dosage also affects coeliac disease susceptibility, e.g., homozygous 
individuals who carry DQB1*02 and DQA1*05 in cis on both chromosomes have a greater 
risk of disease.9 Non-HLA complex genes seem to contribute, but the nature and effects 
of these genes are less well known. The identification and knowledge of the function of 
additional genetic factors should improve the understanding of the actual pathogenesis of 
coeliac disease and lead to new diagnostic strategies in case-finding and screening high risk 
groups.11, 12 
The pathogenesis of coeliac disease is illustrated in figure 1. In coeliac disease, HLA-DQ 
molecules bind and present gluten peptides to antigen-specific T-cells. These HLA-DQ-
peptide complexes induce inflammatory responses in the small intestine consisting of 
lymphocytic infiltration of the lamina propria, expansion of the intraepithelial lymphocyte 
population, hyperplasia of the crypts and atrophy of the villi. In RCD the number of 
intraepithelial lymphocytes is markedly raised and it is from these cells that EATL may arise. 
There is now strong molecular and immunophenotypic evidence showing that a monoclonal 
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neoplastic T-cell population may emerge from intraepithelial lymphocytes in RCD. Clonal 
expansion of this monoclonal T-cell population eventually leads to frank EATL.7 The genesis 
and expansion of these monoclonal T-cells involve both inappropriate immune responses 
to gluten and acquisition of genetic abnormalities. Although the monoclonal intraepithelial 
lymphocytes in patients with RCD are neoplastic, they are not cytologically abnormal and do 
not form tumour masses which differentiate these patients from EATL patients, in addition to 
the absence of radiological and bone marrow evidence of lymphoma.13, 14
Much less is known about non-HLA genes in this disorder.11,12 There are several reports 
that imply involvement of the gene for the negative co-stimulatory molecule CTLA4, or a 
neighbouring gene (such as those encoding CD28 or ICOS). However, the overall effect of 
this gene is small.11, 12
Figure 1. pathogenesis of coeliac disease. 1 and 2: innate response; 3: adaptive response. IL-15=interleukin-15. 
MAbs=monoclonal antibodies. (From Maiuri et al) 15
Diagnostic Approach to Refractory Coeliac Disease
Revision of the initial diagnosis of coeliac disease
In a patient with villous atrophy refractory to a gluten free diet, the first step requires to 
reassess the initial diagnosis of coeliac disease, in order to exclude other diseases (Table 
1). The presence of circulating antigliadin, EMA or tTG antibodies before the institution of 
the gluten free diet, an HLA DQ2 or DQ8 status and an initial clinical and histological 
improvement after a strict gluten free diet are strongly suggestive of coeliac disease. Regarding 
16
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the histological features, an increased number of intraepithelial lymphocytes (more than 30 
lymphocytes per 100 epithelial cells) is seen in almost all active coeliac disease patients.4
Table 1. Other causes than refractory coeliac disease for persisting villous atrophy (Adapted from Daum et al.) 16
Mostly increased number of Intraepithelial lymphocytes
Giardiasis
Tropical sprue
Postinfectious diarrhoea
Collagenous sprue
Protein intolerance (cows milk, soya)
Mostly normal number of Intraepithelial lymphocytes
Tuberculosis (including atypical)
AIDS
Common variable immunodeficiency syndrome
Whipple’s disease
Radiation enteritis
Immunoproliferative small intestinal disease
Crohns disease
Eosinophilic gastroenteritis
Autoimmune enteropathy
Assessment of the gluten-free diet 
The most important cause of non-responsive coeliac patient is failure to adhere to a gluten 
free diet, which has been reported in up to 50% of adult coeliac disease patients.17, 18 The 
presence of persisting circulating EMA or tTG antibodies is strongly suggestive of dietary 
mistakes.15 However, the absence of circulating antibodies cannot rule out minor, inadvertent 
or voluntary, ingestion of gluten in the diet. On the other hand persisting antibody titres, 
especially EMA, may also be found in rare patients on a strict gluten free diet with RCD.2 tTG-
antibodies mostly return to normal within 2-3 months. A careful dietary inquiry performed 
by a skilled dietician in coeliac disease should be performed as the first line of investigation 
in a supposed RCD patient. 
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Exclude other causes of diarrhoea with/without villous atrophy
In case of persisting diarrhoea despite demonstrable improvement in the histologic lesion 
and exclusion of dietary mistakes, other associated disorders should be considered. Well 
known causes responsible for symptoms mainly include microscopic colitis and more 
rarely intermittent pancreatic insufficiency in coeliac disease, secondary lactase deficiency, 
bacterial overgrowth, coexisting inflammatory bowel disease, irritable bowel syndrome but 
also anal incontinence.5, 6, 19 (Table 1)
There are many other causes of villous atrophy besides coeliac disease. Clinical history 
should investigate longer stays near the equator for detection of tropical sprue. Small bowel 
enteropathy seems to occur often in southern parts of Africa.20 Giardiasis should be excluded 
by immunofluorescence of stool samples and may be diagnosed by duodenal histology.21 
Crohn’s disease with involvement of the duodenum may mimic or even coexist with coeliac 
disease.22 The term collagenous sprue should be used with caution, as this disease is not an 
established independent entity. There exists no definition for collagenous sprue unlike for 
collagenous colitis. However, a subepithelial matrix broader than 10-20 µm should point to 
the diagnosis of collagenous sprue. Deposition of excess of extracellular matrix underneath 
the basement membrane is an unspecific reaction, which can be seen in gluten-responsive 
coeliac disease, as well as in several other entities of RCD and also in EATL.23, 24 Collagenous 
band like structures regress to a large part in responsive coeliac disease.23 Autoimmune 
enteropathy is seen mainly in children and young adults, but may occur also in elderly 
patients.25, 26 The histological picture often shows a diminished number of paneth cells. The 
number of intraepithelial lymphocytes often is normal and patients present frequently with 
concurrent autoimmune diseases.27 
We have to realize that villous atrophy has also been reported in association with the presence of 
a thymoma, with protein intolerance, in conjunction with common variable immunodeficiency 
syndromes 28, 29 and eosinophilic enteritis.30 In common variable immunodeficiency antibody 
testing for coeliac disease-associated antibodies is not useful. Only histological and clinical 
improvement on a strict GFD may reveal underlying coeliac disease in single cases of common 
variable immunodeficiency.31 
Exclude malignant complications of coeliac disease
Unexplained weight loss, abdominal pain, fever and night sweating should alarm physicians 
of an overt EATL. Other markers for overt EATL may be positive stool blood tests, increased 
LDH or beta2-microglobulin.32, 33 In patients on gluten free diet, EATL need not necessarily 
be accompanied by duodenal villous atrophy.34 A high index of suspicion for an overt 
lymphoma should lead to an extensive work-up including upper and lower endoscopy, ENT-
workup, CT-scan of thorax and abdomen with enteroclysis, video-capsule enteroscopy (VCE) 
and double-balloon enteroscopy (DBE) in order to obtain histological specimens. In some 
cases laparotomy, intra-operative enteroscopy and full thickness biopsies are necessary, as 
the operative procedure may come to an earlier diagnosis what may be essential. 
Positron Emission Tomography (PET) scan has been investigated in patients with EATL and 
RCD. Hadithi et al 35, in a prospective cohort of 8 EATL patients and 30 patients with RCD, 
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demonstrate that PET can visualize in all patients sites affected by EATL as confirmed on biopsy. 
Patients with complicated coeliac disease showed more bowel wall thickening, 
lymphadenopathy and intussusception, less increase in number of small mesenteric vessels 
and a smaller splenic volume compared with uncomplicated coeliac disease.36, 37
The diagnosis of overt T-cell lymphoma is based on histological and immuno-histochemical 
features with mainly evidence of large or medium size T-cell proliferation expressing a CD3+ 
CD8+/- and CD103+ phenotype. The majority presents as CD3+, CD8-, CD30+ large cell 
lymphoma, however small cell lymphomas often are CD3+, CD8+, CD30-.32, 33 
Diagnosis of small bowel adenocarcinoma may even be more difficult than lymphoma. 
Especially tumours located in the jejunum and ileum, which are not reached by standard 
endoscopic techniques, require extensive investigations. Diagnosis may often be made 
only after operative procedures.38 Obscure gastrointestinal bleeding, obstructive symptoms, 
stenotic lesions on radiological examinations and retention of a video capsule enteroscope 
should raise the suspicion of these malignancies.
The evolving role of Double-balloon Enteroscopy 
First described by Yamamoto and colleagues in 2001, DBE is a new endoscopic technique 
with the potential to allow complete visualization of the entire small bowel.39 
The full description of the scope specifications and the technique of enteroscope insertion 
and withdrawal are provided in our review article.40 In the European retrospective study, 
enteroscopy was diagnostic in all patients suspected of having refractory coeliac disease.41 
We have performed double-balloon enteroscopy in a total of 21 consecutive patients with 
refractory coeliac disease. EATL was found in five patients (24%) as circumferential, discrete, 
or confluent ulcerations, while excluding EATL in another 4 patients.42
Establishing the diagnosis of RCD
Finally, RCD is a diagnosis of exclusion, defined as a persisting villous atrophy that does not 
respond to a strict gluten free diet. Demonstration of an aberrant clonal intraepithelial T-cell 
population and/or loss of antigen on intraepithelial lymphocytes seem to characterize this 
patient population on high risk for development of overt lymphoma and differentiates RCD 
II from RCD I, which shows low or almost absent aberrant T-cells. RCD II is also referred 
to as cryptic intestinal T-cell lymphoma; Sprue-like intestinal T-cell lymphoma). Detection 
of a clonal T-cell population by testing for TCR rearrangement was thought to be highly 
predictive of EATL development. However, oligo- or monoclonal intraepithelial lymphocytes 
populations can be detected in the large majority of both RCD I and RCD II patients, also in 
patients that do not develop an EATL. Clonality is therefore of limited use in establishing the 
diagnosis of RCD and to predict the development of EATL.14, 43- 45
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Steps required to establish the diagnosis of Refractory Coeliac Disease
Revision of the initial diagnosis of coeliac 
disease
The presence of antigliadin, EMA or tTG antibodies before 
the institution of gluten free diet, an HLA DQ2 or DQ8 status 
and an initial clinical and histological improvement after a 
strict diet
Assessment of the diet The presence of persisting EMA or tTG antibodies is strongly 
suggestive of dietary mistakes
Exclude other causes of diarrhoea ±villous 
atrophy
See table 1
Exclude malignant complications of coeliac 
disease
EATL or small bowel adenocarcinoma
Establishing the diagnosis and differentiate 
RCD I from RCD II
Clinical behaviour, presence/absence of aberrant clonal 
intraepithelial T-cell population and/or loss of antigen on 
intraepithelial lymphocytes 
Comparison between RCD I versus RCD II
Clinical and biological behaviour
Patients with RCD I may represent an earlier stage of the disease than RCD II and the prognosis 
may be better, and the risk of developing an overt lymphoma is almost non-existent. In RCD 
I adherence to the gluten free diet should be carefully investigated since a strict gluten free 
diet may induce remission in some patients.46
In RCD I patients often develop concomitant autoimmune diseases, infectious and 
thrombembolic complications. Retrospective data from our patient population suggest that 
RCD I patients have a low mortality rate, which is not different from that of the general 
population.47 The presence of mucosal ulcerations (ulcerative jejunitis) should alert the doctor 
for the possible presence of an early EATL.48
RCD II is seen mostly in adults and the mean age at diagnosis of RCD II is between 50 
and 60 years old but younger cases may be observed.7 Most of the patients develop severe 
malabsorption with weight loss, abdominal pain and diarrhoea. Some patients may also 
have skin lesions mimicking pyoderma gangrenosum or ulcerations mostly in legs, arms and 
face, chronic chest or sinusoidal infections or unexplained fever.7 The link between coeliac 
disease and RCD II is usually suggested by the detection of circulating antigliadin, anti-EMA 
or anti-TG antibodies before the initiation of the gluten free diet in almost two-thirds of 
patients, an HLADQ2 or DQ8 status in almost all patients 47 and an initial response on GFD 
in about one-third of patients with RCD II.7 
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Endoscopic and radiological features
The same pattern of endoscopic abnormalities is usually seen in RCD I and II as in classical 
active coeliac disease. The finding of mucosal ulcerations, mostly in the jejunum, defines the 
clinical picture of ulcerative jejunitis.48 In some cases of RCD II also stomach and/or colonic 
ulcerations may be found.50 Enteroscopy using push- or DBE or VCE should be performed in 
such patients with RCD II in order to search for overt lymphoma and ulcerative jejunitis.50 CT-
scan and/or MRI-enteroclysis may be useful to exclude overt lymphoma and may demonstrate 
a mesenteric cavitation syndrome and hyposplenism (volume<100 cm3) in 30% of cases.36, 37 
Enlarged mesenteric lymph nodes often accompany RCD, without necessarily being specific 
for a T-cell lymphoma. 
Histopathology of small bowel biopsies 
At least 10 duodenal biopsies are to be taken for histological, immunohistochemical and 
flow cytometric examination. Four to six biopsies are fixed and preserved in 10% formalin 
for histopathological and immunohistochemical evaluation. Three-4 biopsies for TCR gene 
rearrangement studies are taken separately, preserved on histocon and frozen at -20°C. For 
immunophenotypical evaluation 3-4 biopsies are taken and preserved in RPMI medium. Usually 
the same spectrum of villous atrophy is observed as in active uncomplicated coeliac disease.
Immunophenotyping of Intraepithelial lymphocytes
Lymphocytes and enterocytes are isolated from small bowel biopsies. The released cells 
are subsequently washed and labelled by 4-color staining with various combinations of 
fluorescein isothiocyanate, phycoerythrin, peridinin chlorophyll protein and allophycocyanin 
labelled monoclonal antibodies against CD3, CD4, CD8, CD7, CD103, CD19, CD45, 
CD16/56, γδTCR and cytoplasmic CD3. 
Cell surface immunophenotyping of Intraepithelial lymphocytes are performed on a 4 colour 
FACS Calibur flow cytometer. Nonviable cells and debris are excluded based on forward 
and sideward light scatter properties and a gate on CD45 positive cells is used for selecting 
lymphocytes. Intraepithelial localisation of lymphocytes is confirmed by surface expression 
of CD103 (αEβ7 integrin, a gut homing receptor for E-cadherin). Intraepithelial lymphocytes 
are analysed based on their expression of cell markers: cytoplasmic CD3, surface CD3, 
CD4, CD7, CD8, CD16/56, CD19, CD103 and TCR-γδ on CD45+gated intraepithelial 
lymphocytes.
Arbitrarily, from our own experience, a percentage of aberrant cells CD7+CD3- of CD103+ 
Intraepithelial lymphocytes or cytoplasmic CD3+ surface CD3 - % of CD103+ Intraepithelial 
lymphocytes of ≤ 10% has been regarded as normal, and more than 20% as definitively 
abnormal (Figure 2).
TCR gene rearrangement study
 DNA is extracted from cryosections of duodenal biopsies. T-cell receptor (TCR) - gamma 
(TCR-γ) gene rearrangements are analysed by multiplex PCR amplification under standardized 
conditions. A monoclonal and polyclonal control is included in each experiment. 
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Figure 2. Showing approximate differntial percentages of lymphocytes.
HLA-DQ typing
Typing of HLA-DQA1*and DQB1* alleles can be performed on whole blood samples. In 
our immunology laboratory, this typing is being performed with a combined single stranded 
conformation polymorphism/heteroduplex method by a semi-automated electrophoresis 
and gel staining method on the Phastsystem (Amersham-Pharmacia-Biotech, Uppsala, 
Sweden).49
Reports by Zubillaga et al 9 and Congia et al 10 have shown that DQ2 homozygosity may 
predispose a person to an earlier onset and to more severe disease manifestations. We found 
a highly significant correlation between HLA-DQ2 homozygosity and the development of 
serious complications of coeliac disease, in particular RCD II and EATL.47 The link between 
HLA-DQ2 homozygosity and development of RCD II and coeliac disease-associated 
lymphoma of intraepithelial origin thus suggests that the strength of the gluten-specific T-
cell response in the lamina propria directly or indirectly influences the likelihood of RCD 
II and lymphoma development. It has been reported earlier by Vader et al 50 that HLA-
DQ2 homozygous antigen-presenting cells induce higher T-cell proliferation and cytokine 
secretion than HLA-DQ2/non-DQ2 heterozygous antigen-presenting cells. This may explain 
the strongly increased risk for disease development in HLADQ2 homozygous individuals. 
This would indicate that the adherence to a GFD is particularly important for CD patients 
who are HLA-DQ2 homozygous.
Summary of data on RCD I
Histology of the small bowel mucosa in most cases is indistinguishable from active untreated 
coeliac disease. The number of intraepithelial lymphocytes may be lower than in RCD II 
and active coeliac disease although this has not been proven in prospective studies.45 The 
intraepithelial lymphocytes phenotype is normal with the expression of surface CD3,CD8 
and TCR-β as in classical active coeliac disease.7,45 The number of CD8− and TCR-β positive 
intraepithelial lymphocytes should exceed 50% of intraepithelial lymphocytes; a lower 
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expression seems to be quite sensitive for distinction of RCD I from RCD II but not very 
specific.45,53 
Summary of data on RCD II 
An aberrant clonal population of intraepithelial lymphocytes may be observed in 80% of 
patients with RCD on small bowel biopsies. Although these intraepithelial lymphocytes have 
a normal cytological feature, they exhibit an abnormal phenotype with the expression of 
intracytoplasmic CD3e, surface CD103 and the lack of classical surface T-cell markers such 
as CD8, CD4 and TCR-αβ. Furthermore the aberrant intraepithelial lymphocytes phenotype 
is associated with clonal TCR gene rearrangement. This aberrant intraepithelial lymphocytes 
population usually represents more than 50% of the intraepithelial lymphocytes and may 
also be observed in gastric and/or colonic epithelium in around 2/3 of patients and may be 
found in the peripheral blood in 1/3.7, 53 It may be also detected in skin lesions or in the chest 
in single patients, suggesting that RCD II is a diffuse gastrointestinal disease.50 The use of CD3 
and CD8 on fixed biopsies is a very reliable method in order to assess the presence of this 
aberrant IEL phenotype, even retrospectively.45, 53 
More recently, it has been shown that recurrent chromosomal abnormalities including a 
recurrent 1q trisomy may be found in these patients.53 The diagnostic yield of these cytogenetic 
features has not been evaluated so far. These chromosomal abnormalities, the clonality of the 
T-cell receptor gene and the loss of antigens on intraepithelial lymphocytes, indicate that this 
clonal intraepithelial lymphocytes population can be considered as a cryptic intraepithelial 
lymphoma.8 
Therapeutic options
Supportive treatment
The first line of treatment should be to correct nutritional status, if necessary through parenteral 
nutrition. The gluten free diet should be maintained as strict as possible and reassessed since a 
minority of patients may have a long-term benefit of a strict gluten withdrawal. Corticosteroid 
therapy is often useful to induce clinical remission.7 There exist no prospective or even 
randomized trials in the use of corticosteroids. Locally acting corticosteroids like budesonide 
may be clinically effective and may spare corticosteroid side effects.55 Corticosteroids often 
induce a clinical remission, although small bowel morphology does not improve significantly 
in almost all patients. Relapses during tapering of corticosteroids are observed in the majority 
of cases.8 
Oligopeptide diet has not only been shown to reduce increased cytokine synthesis of the 
mucosal immune system, but also to improve clinical and morphological parameters in single 
patients with RCD.56 However, patients do not tolerate long-term nutrition with oligopeptide 
diet and other treatment concepts had to be sought. Parenteral nutrition has to be considered 
in patients with persistent malabsorption and severe weight loss in spite of maximal medical 
treatment. Vitamins have to be checked and often iron, zinc, copper, Magnesium, folic acid 
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and vitamin B12 have to be supplemented. For protection against osteopenia, vitamin D and 
calcium should be supplied. In single cases with proven osteopenia intravenous therapy with 
biphosphonates has to be considered. 
Treatment of Refractory Coeliac Disease I
In contrast to patients with high percentage of aberrant T-cells, patients with RCD I seem to profit 
from an immunosuppressive treatment.46 According to the data of Goerres et al 46, azathioprine 
should be first line therapy after induction of clinical remission with corticosteroids. 
In contrast to RCD II, long-term treatment with corticosteroids or locally acting budesonide may 
be considered only in patients who have contraindications to other immunosuppressants. 
Cyclosporine A, infliximab and tacrolimus have been reported to be effective in case reports, 
but further data are required particularly in the light of severe side effects.57, 58 These agents 
should only be considered in case of clinical deterioration despite corticosteroid therapy 
or intolerance to azathioprine. Intestinal absorption of cyclosporine A is worse than that of 
tacrolimus, what has to be considered in the acute treatment. Also parenteral administration 
of tacrolimus has to be considered. Close monitoring of renal function is inevitable. Treatment 
with infliximab may induce prompt clinical and histological response but this effect has to be 
weighed against its possible acute allergic and chronic immunosuppressive side effects.58
Treatment of Refractory Coeliac Disease II
RCD II is usually resistant to medical therapies. Response to corticosteroid treatment does 
not exclude underlying EATL. In case of RCD II with persistent clinical symptoms and/or 
high percentage of aberrant T-cells in bowel biopsies in spite of a corticosteroid treatment, 
more aggressive therapeutic options should be considered. However, no therapy seems to 
be curative in RCD II. Some patients may benefit from azathioprine.46 Cautious is needed in 
instituting immunosuprressive therapy, as this may induce a high risk of progression to an 
overt lymphoma.46, 47 In most cases CHOP-like regimens have been applied, but also other 
agents used for nodal NHL may be applied. Maurino et al 59 reported the results of treating 
7 RCD II patients with azathioprine. Clinical and histologic improvement was noted in 5 
of 7 treated patients, although 3 patients died (1 from leucopenic fever and 2 died early). 
However, in their follow-up report on treating 13 patients with azathioprine, they reported 
a 46% mortality rate.60 A recent report on the anti-tumor necrosis factor agent infliximab 
for treatment of RCD has been published, but no data were provided on aberrant T-cells (T 
flow cytometry or immunohistology).61 Recognizing that some patients with RCD II, and 
especially with ulcerative jejunitis, are suffering from a low-grade EATL, we treated a group of 
these patients with cytotoxic chemotherapy. Cladribine (2-chlorodeoxyadenosine [2-CDA]) 
is a synthetic purine nucleoside with cytotoxic activity. In the past few years clinical trials 
with 2-CDA have confirmed its effectiveness in selected autoimmune disorders. We have 
treated 17 patients with 2-CDA therapy.62 This therapy was well tolerated without serious 
side effects. Six of 17 patients (35.8%) responded with clinical improvement and another 
6 had a significant decrease in aberrant T-cell percentages. Interestingly, one of our patients 
developed a complete clinical, immunologic (aberrant T-cell percentage decreased from 70% 
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to 15%), and histologic recovery (Marsh classification MIIIC- M-I) and remained symptom 
free during more than 4 years of follow-up evaluation. Furthermore, ulcerative jejunitis, an 
endoscopic feature of RCD-II, was seen to disappear in the 5 patients (29.4%) who had it 
initially. Seven patients (41.1%) developed EATL within 6-38 months after starting treatment 
and subsequently died despite multiagent chemotherapy (cyclophosphamide, adriamycin, 
vincristine, and prednisone). Although EATL was excluded adequately at inclusion, 3 patients 
died of EATL within 5-7 months after therapy. Thus therapy with 2-CDA seems to have a role, 
although based on our data it is less than optimal in the treatment of RCD with aberrant 
T-cells. It may be considered, however, as the only medical treatment thus far studied that 
showed significant reduction of aberrant T-cells, seems to be well tolerated, and may have 
beneficial long-term effects in a subgroup of patients showing significant reduction of the 
aberrant T-cell population. The antiCD52 (alemtuzumab) has been used in one patient with 
RCD II with a good response demonstrated by histological recovery and a clear decrease in 
the aberrant T-cell population.63
Autologous Stem Cell Transplantation (ASCT) in RCD II. Is preventing EATL development a 
reality or a myth?
In the last decade, stem cell transplantation has become an increasingly accepted treatment 
option for patients with severe autoimmune diseases refractory to conventional treatment.
The application of this treatment option in gastroenterology is being explored in the last few 
years. Its applicability has been tested and proved successful in treating refractory Crohn’s 
disease.64 We have tested the applicability of ASCT in a selected group of refractory coeliac 
patients with aberrant T-cells.65
The concept of intensive immunosuppression is based on findings in animal models 
of autoimmune diseases, as well as results obtained in patients who underwent SCT for 
haematologic or oncologic diseases while coincidentally having an autoimmune disease.66 
Clinical observations in patients with autoimmune disease who were treated with bone 
marrow transplantation because of a concomitant severe haematologic disorder have 
paralleled the results from experimental animal studies.67, 68 These experimental studies 
and clinical observations paved the way for collaborative efforts to further explore the 
clinical potential of stem-cell grafting in human autoimmune disease. The lack of alternative 
treatment options for severe, uncontrolled autoimmune disease prompted development of 
this treatment strategy.
We have treated seven patients [4M, 3F, mean age 61.5 years (range 51-69 years)] with ASCT. 
After conditioning with fludarabine and melphalan, ASCT was performed. All 7 patients 
completed the mobilization and leucopheresis procedures successfully and subsequently 
received conditioning and transplantation. Engraftment occurred in all patients. No major 
non-haematological toxicity or transplantation-related mortality was observed. There was a 
significant reduction in the aberrant T-cells in duodenal biopsies associated with improvement 
in clinical wellbeing, and normalization of haematological and biochemical markers (mean 
follow-up 15.5 months, range 7-30 months). These preliminary results showed that high-
dose chemotherapy followed by ASCT seems feasible and safe, and might result in long-term 
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improvement of RCD II patients whose condition did not respond promptly to available drugs. 
Controlling the inflammatory reaction and resetting the immune response might theoretically 
prevent or delays the development of EATL. 
Follow-up of patients with RCD
RCD, particularly RCD II, is a serious disorder with a 5-year survival less than 50% and 
the most frequent cause of death is the occurrence of an overt T-cell lymphoma and 
recurrent infections. The presence of a clonal IEL population is significantly associated with 
a poor survival and a high risk of progression to overt lymphoma. The same clonal TCR-
gene rearrangement initially identified in patients with clonal RCD may be subsequently 
observed in lymphomatous specimens suggesting a continuum between RCD and high-grade 
lymphoma.7, 69 The risk of developing an overt T-cell lymphoma in patients with RCD II seems 
to be favoured by immunosuppressive drugs.70
It remains to be proved whether a close monitoring with vigilent clinical and laboratory 
observation, video capsule, double-balloon enteroscopy and/or PET-scan are capable of 
detecting earlier lesions in RCD before development of an overt lymphoma and consequently 
result in a better outcome. 
Treating EATL with Autologous Stem Cell Transplantation
EATL has a very poor outcome with 1- and 5-year survival rates in the range of 31-39% and 
11-20% respectively.71, 72 In a prospective multicentre study of 35 patients with EATL treated 
with high dose chemotherapy, the cumulative 2-year survival was only 28%.73 
It has been stated that adherence to a gluten free diet in coeliac disease for more than 5 years 
has been shown to reduce the incidence of EATL to that of the general population.74
EATL can present in two ways. There are patients with well-established coeliac disease who 
have responded to a gluten free diet but then deteriorate because of the development of RCD 
II and/or EATL. In the other group, the diagnoses of coeliac disease and EATL are made more 
or less simultaneously (de novo EATL).
In the largest case series investigating treatment and clinical outcomes in EATL, more than 
half of the patients could not complete treatment secondary to poor nutritional status.75 
Chemotherapy was complicated by small bowel perforation, gastrointestinal bleeding, and 
development of enterocolic fistulae. 
The results from thus far reported case studies of EATL treated with ASCT after high dose 
chemotherapy are disappointing and conflicting.75-79 These reports described very small 
groups of patients with a complete remission and disease-free survival ranging from (0 
- 64 months post ASCT). Encouraging results came from a recent report 79 describing the 
treatment of six patients with ASCT after receiving two cycles of IVE (ifosphamide, etoposide, 
epirubicin), followed by two cycles of high-dose methotrexate (3 g/m2) with folinic acid 
rescue and BEAM (carmustine, etoposide, cytarabine, melphalan). Four patients remain alive 
in complete remission at 1.83-4.32 years; two have relapsed. 
Between 2001 and 2006, we have treated four adult patients (2Males:2Females) with EATL 
with high dose chemotherapy followed by ASCT.80  The first patient has complete remission 30 
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months post transplantation, while the other 3 patients had died because of recurrence few 
months post transplantation. Combining immunotherapy (adalimumab) with chemotherapy 
in the preconditioning regimen was also not successful in the single patient who received 
that combination. It seems that our current chemotherapy and preconditioning regimens are 
not effective. 
In conclusion, the current treatment of patients with intestinal T-cell lymphomas is 
unsatisfactory with only a few long-term survivors. Therefore, earlier diagnosis, the 
development of more effective treatments including antiCD52 agents, better preconditioning 
regimens and possibly the use of T-cells-depleted grafts or allogeneic stem cell transplantation 
with or without primary central nervous system prophylaxis are urgently required to improve 
the prospects of these patients. 
General Conclusions 
Before diagnosing patients as having RCD, other specific diseases like autoimmune entero-
pathy or tropical sprue and especially gluten contamination have to be excluded. In recent 
years molecular, phenotypic and clinical characterization of patients with RCD has found 
this entity to comprise a heterogeneous group of diseases. Based on immunohistological and 
TCR-gene rearrangement investigations, mainly two entities RCD I and RCD II have been 
differentiated.
In RCD I the intraepithelial lymphocytes show a normal phenotype and absence of aberrant 
T-cells. In contrast RCD II is characterized by the presence of high percentage of aberrant 
intraepithelial lymphocytes and in some cases development of overt EATL. 
New therapeutic strategies for RCD II consider early chemotherapeutics, but also ASCT after 
high dose chemotherapy seems promising. 
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Abstract
Haematopoietic Stem cell transplantation (HSCT) can be used to cure or ameliorate a wide 
variety of non-malignant diseases. These range from inherent defects of haematopoietic cell 
production or function, through metabolic diseases (where blood cells are providing in vivo 
enzyme therapy to solid organs), to severe autoimmune diseases. 
In the last decade, SCT has been explored in treating patients with severe autoimmune 
diseases refractory to conventional treatment.
The rationale for this strategy is based on the concept of immunoablation by intense 
immunosuppression using high dose chemotherapy, with subsequent regeneration of naïve 
T lymphocytes derived from reinfused haematopoietic progenitor cells. Possibly the use of 
SCT allows the administration of high dose chemotherapy resulting in a prompt remission in 
these therapy refractory patients.
The application of HSCT in gastroenterology is being explored in the last few years. We 
have tested its applicability in a selected group of refractory coeliac patients with aberrant 
T-cells. These patients are usually resistant to any known therapy and has a high risk of 
developing enteropathy associated T-cell lymphoma (EATL) (60-80% within 5 years). The 
short term results thus far are promising. HSCT has also been tested and proved successful in 
treating refractory Crohn’s disease. In cryptogenic cirrhosis, basic research and unpublished 
data concerning mesenchymal SCT are encouraging.
In gastrointestinal oncology, there are reported cases and case series on the use of SCT in 
gastric, colorectal and cholangiocarcinomas, mucosa- associated lymphoid tissue lymphomas 
and EATL.
In refractory autoimmune gastrointestinal diseases, it seems that high-dose chemotherapy 
followed by HSCT is feasible and safe, and might result in long-term improvement of disease 
activity.
This review highlights the major scientific developments and defines the areas of successful use 
of HSCT in gastrointestinal disorders and gives a perspective of possible future developments 
and applications.
Introduction
For more than 40 years, radiation or chemotherapy or both have been given in myeloablative 
doses to cancer patients while their autologous haematopoietic cells were stored for infusion 
to restore bone marrow function. The initial preclinical studies were performed in canine 
and murine models.1-5 It is important to use agents (radiation, drugs) that are associated with 
a steep dose-response curve and a relatively short half-life. In addition, excellent supportive 
care measures are required to bridge the time between high-dose chemotherapy (HDC) 
followed by haematopoietic stem cell transplantation (HSCT) and recovery of bone marrow 
function.
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During the past 4 decades, important observations were made in animal models; several 
anticancer drugs suitable for use at high doses have been developed; a vast amount of new 
knowledge concerning the safer administration of total body irradiation (TBI) has been 
generated; extensive information concerning the characteristics, collection, and manipulation 
of haematopoietic stem cells (HSC’s) from marrow and peripheral blood has been gained; 
potent antibiotics to prevent or treat serious infections during the time of marrow aplasia have 
become available; transfusion support has become available; and haematopoietic growth 
factors to “mobilize” HSC’s into the circulation and to shorten the time to recovery of marrow 
function have been developed. With these important support modalities, HDC followed by 
HSCT is increasing rapidly with more than 200,000 patients treated worldwide.6 
Autologous cells were initially obtained by multiple bone marrow needle aspirations while 
the patient was under general or regional anaesthesia.7-9 The observations that peripheral 
blood from mammals and humans contain viable HSC’s 10-14 subsequently made the clinical 
use of circulating HSC’s for haematological reconstitution a reality.15, 16 The potential of 
peripheral blood HSC’s was further enhanced by the fact that these cells could be “mobilized” 
from the marrow into the bloodstream, where they can easily be collected by aphaeresis. 
High doses of cyclophosphamide (CY), growth factors (granulocyte colony stimulating factor 
[G-CSF], granulocyte-macrophage colony stimulating factor [GM-CSF], stem cell factor, or 
combinations of these agents greatly increase the number of HSC’s in the peripheral blood.17,18 
A prospective randomized trial demonstrated that “mobilized” blood HSC’s are superior to 
unstimulated marrow cells with respect to speed of engraftment, requirements for platelet 
transfusions, and duration of hospitalization.19 
In the last decade, SCT is becoming an increasingly accepted treatment option for patients 
with severe autoimmune diseases refractory to conventional treatment.
The application of this treatment option in gastroenterology is being explored in the last few 
years. Its applicability has been tested and proved successful in treating refractory Crohn’s 
disease. We have tested the applicability of ASCT in a selected group of refractory coeliac 
patients with aberrant T-cells. The short term results thus far are promising. 
In hepatology, the efficacy of mesenchymal SCT in patients with cryptogenic cirrhosis is 
being evaluated and seems promising.
In gastrointestinal oncology, there are case reports and small series showing some success. 
This review highlights the major scientific developments and defines areas of successful use 
of SCT in gastrointestinal disorders and gives a perspective of possible future developments 
and applications. 
Gastrointestinal inflammatory diseases
Background
The concept of intensive immunosuppression is based on findings in animal models 
of autoimmune diseases, as well as results obtained in patients who underwent SCT for 
haematologic or oncologic diseases while coincidentally having an autoimmune disease. 
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HSCT as a treatment option in autoimmune diseases was first evaluated in lupus models 
in rodents.20, 21 It was subsequently shown that infusion of bone marrow derived from non-
susceptible donors could prevent autoimmune diseases after immunoablation of the host 
predisposed to develop autoimmune diseases.22, 23 
Following these observations, animals with induced forms of AD were treated with bone 
marrow transplantation (BMT) from a healthy donor and pseudo-autologous BMT (i.e., bone 
marrow from affected animals of the same strain).24 
In the case of adjuvant arthritis in rats, heat-killed Mycobacterium tuberculosis is used 
for induction of disease. A myeloablative regimen followed by allogeneic and also, 
unexpectedly, by autologous and syngeneic SCT not only prevented the disease but also 
induced remission.25 Spontaneous relapses after syngeneic BMT occurred more frequently in 
experimental allergic encephalomyelitis, a model for multiple sclerosis (30% after syngeneic 
vs. 5% after allogeneic transplantation).26 Subsequent studies suggested that relapses in 
encephalomyelitis were due to residual host activated T lymphocytes and lymphocytes in 
the graft, respectively.27, 28 This was supported by studies in adjuvant arthritis demonstrating 
superiority of more intense conditioning.29 
In summary, valuable lessons have been learned from the animal studies that may be relevant 
in the application of SCT in autoimmune diseases: (1) myeloablative therapy, followed by 
BMT, has curative potential, (2) allogeneic SCT may be more effective than autologous SCT 
if a graft-vs.-autoimmunity effect exists and if intrinsic stem-cell defects play a role in the 
disease pathogenesis, and (3) in vivo T-cell depletion may be a prerequisite for a sustained 
response.
Clinical observations in patients with autoimmune diseases who were treated with BMT 
because of a concomitant severe haematological disorder have paralleled the results from 
experimental animal studies.30-32
These experimental studies and clinical observations paved the way for collaborative efforts 
to further explore the clinical potential of stem-cell grafting in human autoimmune diseases. 
The lack of alternative treatment options for severe, uncontrolled autoimmune diseases 
prompted development of this treatment strategy. Until recently, mortality and morbidity 
of HSCT were considered too high to justify such a procedure in patients with chronic 
autoimmune diseases where prevention of morbidity instead of mortality is the major goal. 
This is particularly the case with allogeneic SCT (allo-SCT), with its attending transplant-
related morbidity and mortality rates of 15% -30%. Autologous SCT (ASCT), however, carries 
a transplant-related mortality rate of less than 5%.33-35 Therefore, priority was given to ASCT. 
In 1995 an international committee was established that developed guidelines on entry 
criteria and transplant protocols for severe autoimmune diseases.36 Furthermore, a database 
was created to collect clinical data that would enable monitoring of feasibility, toxicity, and 
efficacy of the different treatment protocols. Analysis of the pooled data has yielded relevant 
information on trends with regard to mortality, type of protocols used, and diseases targeted. 
Patients who undergo autologous HSCT proceed along a 4-step sequence: autologous cells 
are secured, processed, and cryopreserved (step I); myeloablative therapy is administered (step 
II); the graft is infused (step III); the patient receives supportive care until recovery (step IV). 
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Reports in inflammatory diseases
Crohn’s disease
Crohn’s disease is a relapsing- remitting disorder causing life long impairment of health 
and quality of life. It has a strong genetic component as evidenced by a high proportion 
of patients with a family history and the specific contribution of mutations of the NOD2-
gene. The mechanisms by which interactions between genetic and environmental factors 
lead to Crohn’s disease are unclear.37 Crohn’s disease involves a loss of immune tolerance, 
characterized by an overactive TH-1 immune response.38, 39 Given that HSCT has been of 
some value in diseases characterized by loss of immune tolerance and/or a TH-1 predominant 
immune response, it is possible that it could be of value in Crohn’s disease. 
On such an analysis, allo-SCT could be of benefit by replacing the genetic predisposition to 
Crohn’s disease in circulating leucocytes, while ASCT might be of benefit because clearing 
the body of committed lymphocyte clones might restore the patient to the status quo ante of 
being predisposed to but not suffering from Crohn’s disease. 
An alternative explanation is that ASCT simply allows more intense immunosuppression to 
be given. Immunosuppressive agents are of considerable value in Crohn’s disease although 
relapse occurs on their cessation. It is possible that more intense immunosuppression in some 
way achieves a more fundamental switch in immune activity. On this basis, the transplant 
plays a secondary role in enabling intense immune suppression to be given relatively safely. 
Recently, interesting insights into possible mechanisms by which HSCT could affect the 
gut have emerged. In both animal and patient studies, sex mismatched transplants have 
been given, enabling donor cells to be identified by staining for the Y chromosome. These 
have shown in both mice and women that a population of myofibroblast derived from the 
donor populates the intestinal mucosa, particularly in the sub-epithelial segment.40 Given 
the importance of myofibroblasts in orchestrating the function of epithelial cells, these data 
suggest a mechanism other than one targeted at immunosuppression that could beneficially 
reset patient functions, for example enhancing barrier function following SCT.
Evidence for the effectiveness of SCT in Crohn’s disease
The possibility that SCT might be an effective treatment for Crohn’s disease arose initially 
from reports of improvements in Crohn’s patients who had SCT or BMT for other reasons 
41 followed by case reports and case series of transplantation specifically performed for 
Crohn’s patients. Tables 1 and 2 summarise the literatures on direct and indirect evidence of 
efficacy.
Indirect evidence
Allogenic Transplantation
In 1993 there was a report of a patient with Crohn’s disease receiving an allo-BMT for 
lymphoma.42 Following the transplant Crohn’s disease improved although evaluation was not 
fully systematic and the follow up restricted to 6 months. Five years later a report of 6 patients 
undergoing allo-SCT, who incidentally had Crohn’s disease, substantially increased interest 
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in the possibility that SCT could be of value in this disease.43 Of 5 patients whose disease 
was active before transplantation, 3 achieved long lasting remission, despite discontinuation 
of immunosuppression. Other patients did less well. One patient developed recurrence18 
months after transplantation and required surgery. 
From these data it is clear that allo-SCT could benefit Crohn’s disease but that benefit is not 
universal. 
A report by Ditschkowski et al concerning 11 patients (7 Crohn’s disease, 4 ulcerative colitis) 
has been published.44 These patients had inflammatory bowel disease for a median of 10 
(range 0.5 - 22) years with a post-transplant follow-up of 34 (range 3 -117) months. Ten of the 
11 patients became, and remained, inactive following transplantation.
Because these studies were not designed to investigate Crohn’s disease itself, follow-up was less 
systematic than if they had been. However, they support the concept that the patients’ immune 
system plays a central role in Crohn’s disease and that replacing it with a transplanted one may 
be beneficial. This concept is further supported by a case report in which a healthy patient 
undergoing allo-SCT developed aggressive Crohn’s disease soon afterwards.45 Investigations 
showed that the transplanted stem cell had a pathogenetic mutation of the NOD2-gene, 
compatible with the notion that the Crohn’s disease developed when a healthy immune system 
was replaced by one, which, from the point of view of Crohn’s disease, was an unhealthy one. 
Autologous Transplantation 
Several studies have reported the clinical course of patients with Crohn’s disease receiving 
ASCT for another condition.46-49 Perhaps the most impressive concerned a patient who was 
diagnosed with Crohn’s disease at age of 13 year and who required substantial treatment over 
the next 7 years.46 Following an ASCT for non-Hodgkin’s lymphoma it was reported that there 
was no evidence of recurrence of his Crohn’s disease in the next 7 years. 
SCT done specifically for Crohn’s disease
Burt et al published in 2003 the first report of SCT for Crohn’s disease concerned 2 patients.50, 
51 In both patients Crohn’s disease activity index (CDAI) was more than 250 (normal range 
<150, pathological range 220 - 600) despite treatment with infliximab. Peripheral blood stem 
cells (PBSC) were mobilized and enriched ex-vivo by CD 34+ selection. Cyclophosphamide 
and anti-thymocyte globulin (ATG) were used for immune conditioning. The first patient 
was a 22 year old woman with a history of a right hemicolectomy and had severe ileocolic 
Crohn’s disease causing intractable diarrhoea, fistula and peri-anal sepsis. The second was a 
16 year old boy who had been ill for 6 years and receiving immunosuppressives with Crohn’s 
colitis. In both patients, following transplantation, diarrhoea resolved, CDI normalized, CRP 
was within normal limits and the albumin remained or became normal.
These cases were accompanied by extensive colonoscopic evidence. Prior to transplantation 
both patients had areas of severely active Crohn’s disease. Following transplantation the 
bowel remained abnormal though changes were much more trivial. 
A second case report 52 illustrates many of the issues surrounding Crohn’s disease and SCT in 
that on the one hand the clinical course is relapsing-remitting and on the other that complete 
_______________________________________  Approach to the management of Refractory Coeliac Disease  ____
37
histological remission was maintained only with low dose prednisone and methotrexate. 
Overall, the prospect of transplantation for Crohn’s disease ranges from no difference 
compared to conventional management through substantial improvement to possible cure.
Rectovaginal fistulas in Crohn’s disease are difficult to resolve, and surgical failure is very 
frequent. Recent studies have shown that mesenchymal adult stem cells extracted from 
certain tissues, such as adipose tissue, can develop into different tissues, such as muscle. 
Garcia-Olmo et al 53 reported a young Crohn’s patient who had a recurrent rectovaginal fistula 
that was treated by ASCT with a lipoaspirate as the source of stem cells. Three months after 
transplantation, the patient has not experienced vaginal flatus or faecal incontinence through 
her vagina. Subsequently, they reported a prospective Phase I clinical trial to test the feasibility 
and safety of ASCT in the treatment of Crohn’s fistulas.54 They inoculated nine fistulas in four 
patients with autologous adipose tissue-derived stem cells. In six fistulas, the external openings 
were covered with epithelium at the end of week 8, and were considered healed (75 percent) 
at the end of the follow-up period (average 22 months; range 12- 30 months). In the other two 
fistulas, there was only incomplete closure of the external opening, with a decrease in output 
flow (not healed; 25 percent). This was the first report of a clinical trial of cell therapy using 
autologous stem cells obtained from a lipoaspirate. The results indicate that the protocol is 
feasible, safe and encouraging to perform further studies in Phase II.
Table 1. Indirect evidence for efficacy of SCT in Crohn’s disease
Author/  
year No.
Type of  
SCT 
Original 
indication
Conditio- 
ning Results Remarks
Drakos/ 
1993
1 Allo- SCT NHL NA Remission Only 6 months follow 
up
Castro/  
1996
1 ASCT NHL NA Asymptomatic, 
recurrence after 3yrs
Before ASCT diffuse 
pancolitis
Kashyap/  
1998 
1 ASCT NHL Cy, VP16 
+ TBI
No recurrence 7 yrs Crohn’s at age of 13 yr, 
ASCT at 20 yrs
Lopez-Cubero/  
1998
5 Allo- SCT Leukaemia NA 3 pts had lasting 
remission
--
Soderholm/  
2002
1 ASCT AML Cy +TBI Remission for 5 yrs Persisting subclinical 
inflammation 
Ditschkowski/  
2003 
7 BMT, ASCT 
(±CD34 deplete) 
AML,CML, 
MDS
Variable 6/7 Crohn’s became/ 
remained inactive 
+ 4 UC * all in 
remission. Follow up 
34 m (3-117m) 
UC= ulcerative colitis, NA=not available, NHL=non-Hodgkin lymphoma, CY=cyclophosphamide, TBI=total body irradiation, 
AML=acute myeloid leukaemia, CML= chronic myeloid leukaemia, MDS=Myelodysplastic syndrome
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Oyama et al 55 conducted a phase I HSCT study in 12 patients with refractory Crohn’s 
disease. Candidates were younger than 60 years with a CDAI of 250-400 despite therapies 
including infliximab. The initial median CDAI was 291 (range= 250-358). Symptoms and 
CDAI improved before hospital discharge, whereas radiographic and colonoscopy findings 
improved gradually over 
months to years following HSCT. Eleven patients entered a sustained remission. After a 
median follow-up of 18.5 months (range, 7-37 months), only one patient has developed a 
recurrence 15 months after HSCT. 
From all these reports we can conclude that ASCT may be performed safely and has a marked 
salutary effect on Crohn’s activity. Randomized multicentre studies will be needed to confirm 
the efficacy of this therapy. 
Table 2. Direct evidence for efficacy of SCT in Crohn’s disease
Author/  
year No.
Type of  
SCT Indication
Conditio- 
ning Results Remarks
Burt/2003 2 ASCT – Fistulas 
–  Colitis 
CDAI >250
Cy +ATG CDAI, CRP, Albumin 
normalized. Remission 
for more than 1 yr
CD34 enriched 
stem cells. The first 
ever report on SCT 
specifically for Crohn’s
Kreisel/2003 1 ASCT Ileocolic  
Crohn’s
Cy* 9 m complete remission 
without treatment
T-cell depleted SCT
Garcia-Olmo/  
2003 
1 ASCT/  
lipo-aspirate
Recurrent 
rectovaginal 
fistula
None 
necessary
3 m asymptomatic Adipose tissue 
obtained by liposuction 
under local anesthesia.
Scime/2004 1 ASCT Severe colitis Cy+ ATG** improved Disappearance 
of extraintestinal 
manifestations
Garcia-Olmo/ 
2005 
5 Mesench- 
ymal SCT
Fistulas None  
necessary
75% healing Follow up 22m  
(12-30 m). Different 
types of fistulas.
Oyama/2005 12 ASCT Refractory 
Crohn’s
Cy +ATG 11 sustained remission -
*Cy=cyclophosphamide. **ATG=Anti-thymocyte globulin
Ulcerative colitis
Two patients with a long history of psoriasis and ulcerative colitis underwent an ASCT 
for leukaemia. The colitis, psoriasis, and leukaemia remained in remission for four years 
following transplantation.56 Another 4 patients remained in remission after receiving ASCT 
for leukaemia.44
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Refractory Coeliac Disease
In coliac disease (CD), HLA-DQ molecules bind and present gluten peptides to antigen-
specific T-cells. These HLA-DQ-peptide complexes induce inflammatory responses consisting 
of lymphocytic infiltration of the lamina propria, expansion of the intraepithelial lymphocyte 
population, hyperplasia of the crypts and atrophy of the villi.57 In a small percentage (2-
5%) of coeliacs diagnosed as adults a refractory state develops despite strict adherence to a 
gluten-free diet (GFD).58 In RCD the number of IEL is markedly raised and it is from these IEL’s 
that enteropathy associated T-cell lymphoma (EATL) may arise.58, 59 Immunophenotyping of 
the intraepithelial lymphocytes 60- 62 identifies two groups of RCD patients: those with normal 
intraepithelial lymphocytes (RCD I) and those with aberrant intraepithelial lymphocytes, 
lacking surface expression of CD3 and often of CD8 (RCD II).59 The latter group (RCD II) is 
usually resistant to any known therapy 63-68 and has a high risk of developing EATL (60-80% 
within 5 years).69 
We have assessed the feasibility, safety and efficacy of HDC followed by ASCT in patients 
with RCD type II.70
Between March 2004 and August 2005 four patients [(3 males, 1 female, mean age 64,2 years 
(range 61-69 years)] with RCD-II underwent ASCT. EATL has been excluded by endoscopic 
examination, computed tomography, body positron emission tomography and bone marrow 
biopsy.
HSC were harvested from the peripheral blood after mobilization using G-CSF. The 
conditioning regimen consisted of T-cell depletion with fludarabine and myeloablation with 
melphalan. 
Within 3 months of ASCT all patients had normalization of stools frequency, disappearance of 
abdominal pain and improvement in biochemical markers. Also improvement of body mass 
index and serum albumin level was documented. Endoscopically there was disappearance 
of erosions and ulcerations in the jejunum in all patients, and histology of the small intestine 
showed significant regeneration as documented by down-staging of the Marsh class. 
Aberrant [CD7+CD3-] T-cell percentage of CD103+ lymphocytes decreased from a mean 
of 61,8% (range 36-95%) at baseline to 33,5% (range 7-47%) three to four months post-
transplantation.
Two years after transplantation, our first patient is showing further improvement in his 
immunopathology status as demonstrated in further decline in the percentage of aberrant 
T-cells and histologically improved from Marsh III-A to Marsh-I. 
Although the short term results in these patients are very promising, follow up at present is 
too short to permit firm conclusions as to efficacy. The selection of patients for this treatment 
should be restricted to those patients with a substantial population of aberrant T-cells.
HDC followed by ASCT seems feasible and safe, and might result in long-term improvement 
of disease activity in RCD II whose condition previously did not respond to treatments, 
and possibly prevents or delays the development of EATL. Longer-term follow up and 
additional pilot studies with larger groups of patients are needed to confirm the efficacy of 
this therapy.
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Reports in hepatology
Cirrhosis represents a late stage of progressive fibrosis characterized by distortion of the hepatic 
architecture and formation of regenerative nodules. Liver transplantation is considered the 
standard treatment in advanced decompensated cirrhosis. However, it has several limitations 
such as long waiting list, high cost and several complications.71-73
Studies have shown that circulating stem cells can differentiate into mature hepatocytes 
or cholangiocytes in the human body.74 Bone marrow is a reservoir of various stem cells, 
including HSC, mesenchymal stem cells (MSC), and multipotent adult progenitor cells. While 
MSC’s have been shown to be capable of mesodermal and neuroectodermal differentiation, 
but they have endodermal differentiation potential; and their differentiation into functional 
hepatocyte-like cells has been demonstrated very well in animal experiments.74 Recent 
animal studies have shown that infusion of MSC’s can protect against experimental rat liver 
fibrosis.76 Also, infusion of non-haematopoietic bone marrow stem cells can lead to regression 
of liver fibrosis in mice.77 Thus, bone marrow SCT is a potential strategy in liver cirrhosis. Four 
patients thus far received MSC through a peripheral vein, and another 4 received CD 34+ 
through the hepatic artery. (Dr. M Mohammadnejad, DDRC, TUMS, Tehran, Iran, personal 
communication). All patients had Child B/C cirrhosis with some elevation of liver enzymes. 
Patients who received MSC’s had better response than CD 34+ve stem cell recipients with 
significant improvement of albumin level, prothrombin time, and Model End Stage Liver 
Disease (MELD) score in 3 of 4; although the follow up has not been completed.78 
Reports in Gastrointestinal malignancies
The literature is rich in reports dealing with HSCT after HDC in some of gastrointestinal 
cancers. Reports have been summarized in table 3
Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type 
Due to their homing properties, extranodal marginal zone B-cell lymphoma (MZBL) of 
mucosa-associated lymphoid tissue (MALT) type remain localized for long periods of time, 
and therefore have an excellent prognosis. However, if generalization and/or transformation 
into a diffuse large-cell lymphoma occur, the prognosis deteriorates and no established 
treatment concepts are yet available. One report 79 described a patient with relapsed 
transformed stage-IV extranodal MZBL of MALT type of the entire gastrointestinal tract who 
was successfully treated using salvage chemotherapy followed by ASCT. Follow-up revealed 
a sustained complete remission for 22 months.
Another case report by Rosler et al described complete remission of lymphoma after HSCT 
in a patient with Sjogren syndrome.80
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Table 3. Summarizes reports in gastrointestinal oncology
Author/  
year No.
Type  
of SCT Indication
Conditio- 
ning Results Remarks
Rosler/  
1998
1 ASCT MALT type lymphoma +  
Sjogren syndrome
BEAM CR* of lymphoma.  
Died 20 m post-ASCT  
from PCP**
Steroid dependent 
Sjogren
Neumeister/ 
2000
1 ASCT Stage-IV MZBL  
of MALT type
BEAM CR 22 m -
Suzuki/ 
1990
3 ASCT Advanced gastric 
carcinoma
EAP Stenosis, lymph node 
metastasis, pancreas 
invasion were  
reduced
-
Ueda/ 
2004
1 ASCT Gastric carcinoma EAP HDC+HSCT and  
dendritic cells (DC)- 
based immuno- 
therapy is feasible
One pt underwent 
ASCT followed by 
cancer vaccine therapy 
with DC
Hentschke/  
2003
6 Allo-SCT  Colorectal carcinoma Fludarabine 
+TBI***
Poor Low intensity 
conditioning
Jantunen/  
2003
5 ASCT EATL BEAM Median survival 2 m Surgery + CHOP
Author’s  
experience
5 ASCT EATL BEAM/ or 
Fludarabine 
+Melphalan
Poor results. Only  
one long term  
survival (>30m)
Unpublished data
*CR= Complete remission ** PCP= Pneumocystis carinii pneumonia ***TBI=Total body irradiation
Gastric carcinoma
The EAP combination of etoposide, doxorubicin and cisplatin has been reported to be highly 
active for advanced gastric cancer. However, it is associated with severe myelotoxicity. 
Few reports examined whether PBSC’s could be mobilized during haematopoietic recovery 
after EAP, and assessed the possibility of using multimodal cell therapy with PBSC’s for the 
treatment of advanced gastric cancer.
The first report 81 dates back to 1990 and describes three patients with advanced gastric 
cancer were treated with EAP and then ASCT. All patients were recovered from aplastic period 
without any severe complications. The second report 82 described five men with advanced 
gastric adenocarcinoma. EAP was given to each patient, and myelotoxicity was carefully 
monitored. G-CSF was administered after the neutrophil nadir, and PBSC’s were collected by 
leucopheresis during haematopoietic recovery. Sufficient numbers of PBSC’s [CD34 (+) cells] 
could be mobilized in 4/5 patients. A 45-year-old patient with extended lymph node metastasis 
received high-dose EAP with HSCT, followed by cancer vaccine therapy with dendritic cells 
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(DC’s), induced from cryopreserved PBSC’s. Although associated with severe myelotoxicity, 
EAP can mobilize sufficient numbers of PBSC’s during haematopoietic recovery. Multimodal 
cell therapy combining HDC with HSCT and DC-based immunotherapy is feasible and can 
be a reasonable approach in advanced gastric cancer.
Berdel et al 83 reported a phase-II-pilot trial on preoperative HDC with stem cell rescue in 
patients with locally advanced cancers of the upper gastrointestinal tract. This pilot trial in16 
patients shows that the approach is feasible with tolerable toxicity and can lead to prolonged 
disease-free survival in responding patients.
Colorectal carcinoma (CRC) 
The immune system is known to induce tumour regression 84 following HSCT, graft-versus-host 
disease (GVHD) has been found to contribute to an antileukaemic effect.85, 86 An alloresponse 
of donor T lymphocytes is most probably the cause of GVHD and the graft-versus-leukaemia 
(GVL) effect.87 An allogenic graft-versus-tumour (GVT) effect has also been reported in breast 
and renal metastatic carcinoma.88, 89
 This approach of using lethal myeloablative conditioning has been challenged by using 
lower doses and less toxic conditioning to induce immunosuppression and take advantage of 
the GVT effect later rather than the antitumour effect of chemoradiotherapy.90-92
Hentschke et al 93 used a low-intensity conditioning protocol in treating six patients with 
CRC. They noted response in two patients. Since a high tumour load may increase the risk 
of progression, tumour debulking before transplantation was done in all but two of the 
patients. 
Interestingly, they saw regression of metastases mainly in the lungs and lymph nodes, but 
not in the liver and bone. The tumour response in the lymph nodes may be expected if 
haematopoietic recipient cells are replaced by haematopoietic donor cells, which may also 
induce antitumour activity. The discrepancy between the higher responses seen in the lungs 
than in the liver is unclear.
To improve the results and perhaps even have complete responses, patients should probably 
be selected at an earlier stage with a lower tumour burden.
Enteropathy associated T-cell Lymphoma (EATL)
EATL is a rare lymphoma type frequently associated with CD and originating from 
intraepithelial lymphocytes of small bowel mucosa. It has a very poor outcome with 1- and 
5-year survival rates in the range of 31-39% and 11-20% respectively.94, 95 
 Techniques of immunocytochemistry, together with gene rearrangement studies, now make 
the histological diagnosis of EATL more straightforward.96-98 Once diagnosed, combination 
chemotherapy should be considered for all patients. A variety of regimens, including CHOP 
99, have been used with limited success. Prognosis, in part, reflects late diagnosis and poor 
performance status at the time of presentation. Associated malabsorption and malnutrition 
make tolerance of chemotherapy difficult, and treatment-related complications such as 
gastrointestinal bleeding and perforation also worsen prognosis.100, 101 Nutritional support 
should always be considered in these patients. Efforts should therefore be made to diagnose 
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EATL early. The diagnosis should be considered in all patients who present in midlife with CD 
and in those who experience a clinical deterioration after a period of stability on a GFD.102 In 
a proportion of patients there is no preceding celiac history (de novo EATL), making diagnosis 
more difficult.
Jantunen et al 103 reported a series of 5 patients with EATL and histologically proven CD. Four 
patients had been treated with partial small bowel resection. Subsequently all five received 
HDC followed by ASCT. Two patients died early from transplant-related complications. The 
3 patients who survived the immediate post-transplant period relapsed and progressed 0-14 
months after HSCT. The median survival is only 2 months.
Another report 104 from the United Kingdom in an abstract form revealed no early mortality 
in 8 patients but no long term results reported yet. 
We have transplanted a total of 5 patients, four of them after performing debulking of 
lymphoma with partial small bowel resection. The patients received HDC followed by ASCT. 
The short term results are not encouraging. (Unpublished data)
Problems with transplantation 
The age limit of transplantation candidates has been raised over time, especially with 
improved supportive care. It is now clear that cancer patients in their eighth decade of life 
can be considered for ASCT provided they have no other serious comorbid conditions.
If one uses a cytotoxic drug at maximum tolerated dose, often in combination with other agents 
or TBI, regimen - related toxicity becomes obvious, especially in the form of oropharyngeal 
mucositis, gastroenteritis, diffuse alveolar haemorrhage, veno-occlusive disease, or other 
organ function impairment. Such toxicity can sometimes lead to fatal multiorgan failure 
syndromes. Fortunately, through judicious use of regimens, such serious problems have been 
reduced to less than 5%, even into the 1% to 2% range. 
Graft failure leads only rarely to early or late post-transplantation pancytopaenia. If an 
adequate quantity of CD34+ cells has been cryopreserved and infused, this problem occurs 
most frequently in patients who develop severe viral infections with cytomegalovirus or 
human herpes virus type 6. The incidence of opportunistic infections after ASCT is much 
lower than in allo-SCT recipients. Occasionally, pre-existing infections with Aspergillus 
species are reactivated.
It is the goal to integrate patients as soon as possible after ASCT into their personal and 
professional environment. Quality-of-life studies show that patients are able to return to their 
daily lives within 6 to 12 months and achieve a high quality of life.105 
Because inflammatory disease does not fulfil the criteria of clearly increased mortality to 
justify HSCT, it seems prudent that the patient must be fully informed and ongoing results 
should be analyzed by a safely board. Allo-SCT has a transplant-related mortality rate of 15% 
-30%. Autologous SCT (ASCT), however, carries a transplant-related mortality rate of less 
than 5% 33-35 and therefore gains more preference over allo-SCT. 
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Future perspectives 
Prospective multicenter studies are needed to confirm the results of case reports and small case 
series. Criteria for selection of patients, in addition to timing of transplantation particularly in 
malignant and premalignant conditions are strongly needed. Furthermore, new technologies 
of tracking the stem cells, determining the number of cells to be transplanted and the need 
for T-cell depletion or CD34 lymphocytes enrichment need to be further elaborated. Still 
more work need to be done mainly on intensification of immunosppression regimens, graft 
manipulation and optimizing conditioning regimens.
We think that HSCT in gastroenterology gains steadily more grounds in the treatment of 
inflammatory disease, lymphomas and possibly also malignancies. Possible indications that 
deserve more attention are mainly autoimmune liver diseases, e.g., autoimmune hepatitis, 
primary biliary cirrhosis and primary sclerosing cholangitis.
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Milestone in Gastrointestinal Endoscopy 
Double-balloon Enteroscopy of the small bowel
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Abstract
The small bowel has been largely bypassed by flexible endoscopy because of inaccessibility. 
Push enteroscopy is now in the past, with recent innovations now making visualization of 
the small bowel possible. Wireless capsule endoscopy (VCE) and double-balloon endoscopy 
(DBE) have been introduced. In this review, we focus on the diagnostic and therapeutic 
modalities of DBE, which may be a suitable replacement for push enteroscopy, preoperative 
endoscopy and to some extent of small bowel follow through and CT scan. DBE is a 
new method of endoscopy developed and described by Yamamoto et al. in Jichi, Japan, 
in cooperation with Fujinon®. Introduced to the market in 2003, it is possible with this 
endoscope to observe the entire small bowel in steps of 20-40 cm. Measuring the depth of 
insertion is also possible. Obscure gastrointestinal bleeding can be explained and treated in 
the majority of cases. Biopsy sampling, hemostasis, polypectomy, dilatation and tattoo are 
possible in the small bowel.
Guidelines for familial adenomatosis polyposis (FAP) and Peutz-Jeghers syndrome will 
probably be reviewed in the next few years. The safety and efficacy of DBE have been 
demonstrated. DBE improves small bowel disease management and can substitute for more 
complex investigations. Additional data will come to light in years to come. Combining 
DBE with VCE, CT/MRI enteroclysis in a new era for SB work-up and treatment is the likely 
future.
Introduction
Endoscopy has a pivotal role to play in the diagnosis and treatment of gastrointestinal 
diseases, including those of the oesophagus, stomach, duodenum and colon. However, the 
small bowel has been largely bypassed because of the relative inaccessibility of the flexible 
endoscope. The small bowel accounts for 75% of the total length of the gastrointestinal tract, 
measuring about 580 cm, and has some of the most important functions.1 Until recently, the 
only technique available for observing the entire SB was intra-operative endoscopy. Sonde-
type enteroscopy, introduced in the early 1970s for total enteroscopy, has been abandoned.2, 
3 Difficulty in handling and a long preparation time have hampered its universal use. Since 
then, the push method, with use of a long endoscope, has been regarded as the standard 
procedure and no major improvement has been made in regard to enteroscopy until recently. 
Although push enteroscopy can usually reach as far as the upper jejunum, about 50 cm from 
the ligament of Treitz, most of the small bowel is beyond reach.4 Features about position and 
anatomy of the small bowel limit how far the endoscope can be introduced. Specifically, the 
tight curve of the bulb and its relatively fixed retroperitoneal posterior position as it proceeds 
to the ligament of Treitz, where it passes downwards as a loosely supported looped structure 
on a mesentery, challenges the endoscopist. Recent innovations in endoscopy have made 
it possible to visualize the entire small bowel. Two new methods have been introduced: 
wireless capsule endoscopy (VCE) and double-balloon endoscopy (DBE). In this article, 
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we review recent reports, focusing on DBE, because of the possibility to take biopsies and 
intervene therapeutically.
Double-balloon Enteroscopy
Technique
First described by Yamamoto and colleagues in 2001 5, DBE is a new endoscopic technique 
with the potential to allow complete visualization of the entire small bowel. The first 
commercially available enteroscope (Fujinon EN-450P5/20; Corporation, Saitama, Japan) 
is 200 cm in length, with an 8.5 mm diameter and a 2.2 mm working channel, and is 
equipped with a 145 cm soft overtube with a diameter of 12.2 mm (Fujinon®). For the oral 
route, an extremely flexible enteroscope is necessary, i.e. the EN-450P. For the anal route, 
by contrast, a slightly greater degree of rigidity is desirable in order to pass the colon and 
reach a stable position in the ileum. In addition, improved suction is mandatory because of 
faecal debris. This is met by the EN-450T with its external diameter of 9.5 mm and 2.8 mm 
working channel. Latex balloons are attached at the tip of both the enteroscope and the 
overtube, and can be inflated and deflated with air using a specifically designed pressure-
controlled pump system. By inflating the overtube balloon and thereby obtaining a stable 
position in the intestine, which can occur at a balloon pressure of 45 mmHg or 6 kPa, the 
endoscope can be inserted further in the SB without creating redundant loops. After inflating 
the endoscope balloon and deflating the overtube balloon, this overtube can be advanced 
to the distal end of the endoscope (push). Subsequent inflation of the overtube balloon 
straightens the system (pull), thereby pleating the intestine onto the overtube. This method 
effectively uses the working length of the endoscope and allows for insertion deep into the 
small bowel in steps of 0-40 cm, with a mean of 20 cm, either by the anterograde (oral) 
approach or by the retrograde (anal) approach. The preferred approach depends upon the 
suspected location of the responsible lesions (usually achieved by prior VCE or other small 
bowel imaging techniques). This technique, also known as ‘‘push-and-pull’’ enteroscopy, 
allows the endoscopist to visualize the small bowel, to obtain tissue biopsy specimens and to 
perform therapeutic interventions. Experience with DBE in Japan 6 and Europe 7, 8 illustrates 
how total small bowel enteroscopy can be performed using a combination of oral and/or 
anal approaches, and with a good safety profile and patient tolerance for the procedure.
Feasibility
The DBE can be inserted via either the oral or anal route, reaching about two-thirds or one-
third, respectively, of the entire small bowel. Intubation of the caecum via the oral approach 
is in general not possible, but was achieved by Yamamoto 6 in 2/123 (1.6%) patients and by 
May 7 in 2/137 (1.5%) patients. However, observation of the total small bowel is frequently 
possible by a combination of both routes.Yamamoto reported that the entire small bowel 
could be observed in 24/28 (86%) of the cases in which total enteroscopy was attempted, 
documented by India ink injection at the most distal point during the oral or anal approach 
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and advancement of the endoscope to the tattoo during the opposite approach.6 This result 
is comparable to the 79% success rate obtained by VCE.9 May et al. reported a lower, but 
probably more realistic success rate of 45% (25/55) total enteroscopies in the subgroup 
where total enteroscopy was aimed for.7 
Failure of total enteroscopy can be due to technical difficulties with the DBE method 
caused by adhesions following abdominal surgery, i.e. as reported by Yamamoto in 4/28 
procedures.6 Furthermore, the floppy nature of the endoscope makes the retrograde approach 
more difficult, and passing the caecal valve can be cumbersome. Ell reported a failure of 
5/35 (14%) and May a failure of 7/87 (8%) of introducing the endoscope in the ileum.7,8 The 
new EN-450T enteroscope might be advantageous in the case of the anal access route, but 
comparative studies are lacking. Termination of the procedure because of patient discomfort 
due to a lack of sedation or because of the insufflated air can also be a reason for failure. 
For this reason, it can be advantageous to commence with the oral approach unless prior 
imaging techniques predict a more distal small bowel lesion.
Although there is a lack of data regarding patient tolerability, the published studies attribute 
unsuccessful procedures merely to technical problems, thus suggesting acceptable or good 
tolerability.
Table 1. Dosage of medication (mean ± SD) used for conscious sedation in DBE studies.
Propofol Midazolam Diazepam Meperidine Fentanyl Reference
630 ± 310 mg
range 100-1420
9 ± 4 mg
range 2-5
10 ± 4 mg
range 2.5-20
60 ± 20 mg
range 25-100
350 ± 190 µg
range 100-600
Ell 8
575 ± 250 mg
range 200-1200
9 ± 3 mg
range 3-15
9 ± 3 mg
range 2.5-20
57 ± 20 mg
range 25-150
Not used May 7
Not used 10.3 ± 4 mg Not used Not used 60 ± 0,03 µg Heine 10
Only May reported a prematurely stopped oral procedure caused by intolerance 1/153 
(0.6%).7 The sedation and analgesia used in the different studies were heterogeneous: 
propofol, meperidine, midazolam, diazepam and fentanyl. One major complication in the 
May study was attributed to sedation; aspiration pneumonia after an epileptic attack induced 
by propofol sedation.
Complications and safety
Yamamoto et al. reported two major complications out of 178 examinations.6 However, 
surgical treatment was required in only one case: perforation after an endoscopy for post-
chemotherapeutic evaluation of a malignant lymphoma of the small bowel. The other 
complication occurred in a patient diagnosed with Crohn’s disease of the small bowel by 
DBE. The subject had abdominal pain and fever after the endoscopy, requiring fasting and 
administration of antibiotics, but the symptoms subsided in a few days and laparotomy was 
not necessary.
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The European Multicentre Study, with a total of 100 patients and 147 procedures, showed no 
major complications such as perforation, bleeding of relevant injury to the small bowel tissue 
or mesentery. Minor complications, occurring in 12% of the patients, included abdominal 
pain, throat-ache with a need for medical treatment, fever without an infection focus and 
therefore not treated with antibiotics, and vomiting after the procedure. Reddening of the 
mucosal tissue with or without intramucosal haemorrhage was noted in 26%.8
May et al. reported comparable results with no major complications and minor procedure-
related symptoms such as mucosal reddening (10%) abdominal pain (9%) of the patients 
and spontaneously vanishing fever.7 Both studies reported a propofol-related epileptic attack 
resulting in aspiration pneumonia, probably mentioning the same patient from Wiesbaden.7, 8
Heine et al. documented two mild and one moderate severe pancreatitis as complications in 
addition to the already mentioned mild procedure related symptoms.10
In conclusion, since no other cases of complications have been reported, DBE seems to be 
a safe procedure.
Indications and diagnostic and/or therapeutic yield
Obscure gastrointestinal blood loss 
The major indication for enteroscopy is OGIB (obscure and/or overt gastrointestinal blood 
loss). The Yamamoto et al. series contained 66/123 (54%) patients with OGIB.6 
Table 2. Medication, combinations or single use, used for sedation in DBE studies
Sedation and analgesia used
Ell et al. 8
(145 procedures)
May et al. 7
(248 procedures)
Yamamoto 6 Heine et al. 10
(316 procedures)
Propofol + fentanyl N=5 N
O
D
A
T
A
Propofol + meperidine N=5
Propofol + midazolam N=9
Propofol N=no numbers
Midazolam and/or diazepam + merepidine N=82 N=no numbers
Midazolam + fentanyl N=316
Non-combination (drug not mentioned) N=46
The source of bleeding was found in 76% of these patients. Ulcerations and/or erosions were 
found in 22 (40%) patients (NSAIDs 7/22, blind loop 3/22, Crohn’s disease 2/22, Meckel’s 
diverticulum 2/22, Behcet disease 2/22 and other ulcers 6/22), polyps or tumours in 10 
(20%) and arteriovenous malformations in 7 (14%). In the prospective study by May et al 7, 
the majority of the patients had obscure gastrointestinal bleeding (90/137; 66%). Pathologic 
lesions thought to be the origin of the bleeding were identified in 109/137 (79%) patients. 
The most common finding was angiodysplasia treated with argon plasma coagulation. A 
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new diagnosis was established in 47/137 (34%) of the patients, confirmation of a diagnosis 
established by other methods in an additional 30%, determination of the extent of a diagnosis 
in 12%, and correction or exclusion of a previous diagnosis in 10%. Twenty percent of the 
patients had no pathological findings. DBE resulted in a change of therapy in 104/137 (76%) 
patients. Therapeutic endoscopic interventions were administered in 41.5% of the patients, 
17% received new or a change in medication and surgical therapy was indicated in 17.5%. 
The European Multicentre Study included 64/100 (64%) patients for OGIB.8 The data from 
this article did not really describe the relationship between the indication and diagnostic 
yield. In general, most patients suffered from angiodysplasia 34/100 (34%), ulcerations 
and/or erosions 16/100 (16%), and polyps or tumours (13%). Endoscopic intervention 
was possible in 42/100 (42%) patients and consisted of argon plasma coagulation 37%, 
polypectomy 2%, dilatation 2%, and foreign body extraction in 1%. Changes with regard 
to medical treatment were made in 12 patients and surgical resection was indicated in 8 
patients. The European retrospective study included 38/62 (61%) patients with OGIB and 
in 30/38 (79%) the enteroscopy was diagnostic.11 Treatment was performed in 42% of the 
patients. The outcome of this study is also competitive with the outcome of VCE (30%-80%). 
DBE has changed our management of small bowel bleeding and has taken over the lead in 
treating bleeding sources endoscopically and/or by guiding surgeons to the marked lesions 
(submucosal tattoo).
Crohn’s disease and coeliac disease
In the group of patients included in Yamamoto’s series for OGIB, 2 patients from a total 
of 50 were diagnosed with Crohn’s disease and 1/50 with Behcet disease. In the group of 
‘‘other’’ indications there were 5/32 with suspected Crohn’s disease. No data of a diagnostic 
affirmation are available in the report.6 May included 6/137 patients with known Crohn’s 
disease and subileus or severe abdominal pain.7 The group in which a diagnosis was 
established or confirmed contained 18/109 patients with Crohn’s disease and 1 patient with 
Behcet disease. Ell et al. reported a diagnostic yield of 72%, and in this group 11 patients 
were diagnosed with Crohn’s disease. It was not stated with which presenting symptoms these 
patients were included.8 In the European retrospective study, enteroscopy was diagnostic in 
all patients suspected of having refractory coeliac disease and in 2/3 patients with Crohn’s 
disease.11
Hereditary polyposis syndromes
Small bowel problems with Peutz-Jeghers syndrome could only be handled by push 
enteroscopy and/or intraoperative endoscopy. Recurring intussusception of benign, 
hamartomatous polyps, sometimes with ischaemia of the small bowel and necrosis, results 
in surgical interventions. Even the surgeon estimating that there are no polyps remaining is 
no guarantee for the future. Intraoperative endoscopy was a breakthrough for this condition 
in the 1980s.12 DBE appears superior to this approach in a recent case report.13 Adequate 
data about the influence of DBE on further management and outcome in comparison with 
MRI enterography and/or CT enteroclysis are mandatory.
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Miscellaneous
No data are available about patients referred for malabsorption, protein-losing enteropathy 
and staging of B- and T-cell lymphomas. Potential indications for DBE, such as difficult 
colonoscopy, will be investigated as well.
Interventions
Since a stable position in the whole small bowel can be obtained by the inflated balloon at 
the tip of the overtube, the endoscope can be moved back double-balloon enteroscopy of 
the small bowel 35 and forth past a point of interest for repeated observation. Moreover, the 
endoscope has a working channel enabling targeted biopsy and/or endoscopic treatment.6 
Diagnosis using a DBE has been reported for a GIST 14, an inflammatory fibroid polyp 15 and a 
lymphoma.16 Endoscopic treatment includes obtaining hemostasis in bleeding, polypectomy, 
endoscopic mucosal resection, balloon dilatation and stent placement in the SB. When 
lesions are located in the distal portion of the SB, a DBE can shorten the intestine, leading to 
the lesions with the overtube and simplifying the endoscopic route. Endoscopic observation 
and biopsy sampling are useful in the diagnosis of small-intestinal tumours. In addition, the 
endoscope can be inserted even in a bypassed intestine, including the afferent loop in a 
Roux-en-Y anastomosis.17 The access in the afferent loop enabled EMR of early carcinoma; 
ERCP, too, has been shown feasible. Selective contrast-enhanced X-ray examinations can be 
performed by occluding the intestine with a balloon to prevent reflux of the contrast medium. 
Three case reports have been published describing the retrieval of entrapped capsules from 
the small bowel.18-20 The capsules were entrapped in Crohn’s patients (n=3) and a patient 
with a surgically removed solitary EATL who had the capsule entrapped in a blind loop. 
The report shows that the foreign bodies can be removed by means of the double-balloon, 
thereby preventing laparotomy.
Polypectomy
Polypectomy of the entire small bowel has been reported for Peutz-Jeghers polyps of polyposis 
syndrome in all series without complications. Ohmiya et al. described two patients with 
Peutz-Jeghers syndrome in which 18 pedunculated polyps (10-60 mm in size) were resected 
endoscopically.13 Resection was not complicated by subsequent bleeding or perforation. 
These results show that polypectomy by DBE is a relatively safe procedure and might prevent 
the known complications of small bowel polyps, including intussusceptions, bleeding and 
tumour genesis, which often require multiple laparotomies. Data about larger patient groups 
with polyps managed by DBE are mandatory.
Argon plasma coagulation
Argon plasma coagulation is a safe procedure/treatment for angiodysplasia. Unfortunately, 
no data have been reported about the settings of the ERBE module.
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Tattooing
Aiming for total enteroscopy, with the knowledge of a low success rate in intubating the 
caecum via the oral approach, makes it necessary to mark the most distal site reachable in 
the small bowel with ink. Also, lesions observed during enteroscopy can be marked with 
ink for the surgeon after biopsies are obtained for histological diagnosis. In the study by 
Heine et al., Indian ink was used for tattooing after injecting a small amount of saline into 
the submucosal space prior to ink injection, so avoiding transmural injection of ink into the 
abdominal space resulting in pain or colouring the total abdominal space.10
Dilatation
DBE can be performed when stenosis of the small bowel is suspected as a result of a neoplasm 
or as in Crohn’s disease or refractory coeliac disease. Sunada et al. reported 17 cases of 
stenosis of the small bowel for which DBE was used.21 The series included three patients 
with a neoplasm, eight with inflammatory disease and five with a narrowed lumen without 
mucosal changes, suggesting adhesions or postoperative stricture. In four cases, including 
Crohn’s disease, post-traumatic stricture and inflammatory stricture, an endoscopic balloon 
dilatation was performed. All the procedures were completed without complications.
Table 3. Comparison of the data from the published DBE studies
European 
retrospective 11
European 
prospective 8 Wiesbaden 7 Yamamoto 6 Amsterdam 10
Patients (N) 62 100 137 123 275
DBE procedures 89 147 248 178 316
Panendoscopy
One session
Two sessions
10/62 (16.2%)
-
-
16%
-
-
2/137 (1.4%)
25/55 (45%)
2/128 (1.5%)
24/28 (86%)
14/275 (5.1%)
12/36 (33%)
Insertion depth in cm
Oral
Anal
254 ± 174 
180 ± 150
220 ± 90
130 ± 80
240 ± 100
140 ± 90
No data
No data
270 ± 121
120 ± 110
Duration of procedure
Oral
Anal
-
70 ± 30
90 ± 35
75 ± 19 (32-150)
-
-
73 ± 25 (25-131)
72 ± 23 (30-131)
75 ± 28 (25-130)
47 (27-100)*
73 (30-123)*
90 ± 47
110 ± 37
Diagnostic yield 80% 72% 79 % 76 % 83%
Endoscopic therapy 42% 62% 76% 20% No data
Complications None None
1 propofol- 
related
None
1 propofol- related
2/178 (1.1%) 3/316 (0.9%) §
* median and range of initial (2 oral and 20 anal) and opposite approach (2 anal and 20 oral) in the group with a total 
enteroscopy § 3/316; 2 mild and 1 moderate severe pancratitis
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Video Capsule Endoscopy and Double-balloon Enteroscopy
The VCE was introduced in the late 1990s and since then several studies have demonstrated 
the diagnostic value of this method in patients with OGIB, inflammatory bowel diseases and 
coeliac disease.22, 23 Two recent studies compared the results of VCE with DBE in obscure 
gastrointestinal bleeding.24, 25 Matsumoto et al. examined 22 patients with OGIB (13/22) 
and polyposis (9/22) using both modalities. Positive findings were identified with DBE in 12 
patients (54.5%). VCE detected positive findings in the area explored by DBE in 8 patients 
(36.4%) and in the unexplored area in 11 patients (50.0%). The overall diagnostic yield 
between the procedures was comparable. DBE appeared to be superior to VCE in identifying 
polyps. 
Moreover, there was a trend towards a higher number of polyps detected with DBE as 
compared with VCE. Hadithi et al. evaluated 35 patients OGIB.25 In 28 patients (80%), 
positive findings were identified by VCE in comparison with DBE in 21 patients (60%). DBE 
could not confirm or identify the polyps diagnosed by VCE in two patients, suggesting a false-
positive finding.
In conclusion, DBE and VCE show a comparable overall diagnostic yield, whereas DBE is 
superior to VCE in patients with polyposis.
Conclusions
In the past, surgeons have been confronted with problematic blood loss from the 
gastrointestinal tract, and unrewarding ‘‘blind’’ resections of stomach or colon have been the 
standard. Gastroscopy and colonoscopy have changed this attitude since the 1960s. DBE, 40 
years after the introduction of endoscopy, is now changing this for the small bowel.
Indications for DBE are now well recognized.
– Obscure blood loss of unknown origin with negative proximal and distal endoscopy is a 
reason for DBE with or without prior screening. Overt bleeding of the small bowel is an 
indication for DBE because of its superior diagnostic (suction, rinsing, and biopsies) and 
therapeutic properties.
– Suspected inflammatory bowel diseases such as Crohn’s disease and coeliac disease for 
establishing a diagnosis and or treatment (dilatation).
– Locating and tattooing lesions, not suitable for endoscopic treatment, can guide surgeons 
in theater.
– Therapeutic removal of foreign bodies such as capsules, etc., bridging stenotic areas with 
dilatation, insertion of tubes, endoprosthesis, etc.
– Proper management of hereditary polyp syndromes such as FAP and Peutz-Jeghers.
– Staging B- and T-cell small bowel lymphomas.
Capsule endoscopy for screening and DBE for histology, confirmation and treatment, whether 
or not in combination with coagulation, argon plasma coagulation and polypectomy, 
are more than promising in daily practice. Chronic blood loss and the need for multiple 
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transfusions are now manageable.Achieving a ‘‘clean’’ polyp-free small bowel in FAP 
and Peutz-Jeghers will result in fewer operations and probably better quality of survival. 
Polypectomy of small bowel polyps by DBE can prevent the complications of larger small-
intestinal polyps, including intussusceptions, bleeding and dedifferentiation to cancer. The 
duration of interventions during DBE demands mutual understanding between endoscopist, 
nursing staff and patients. Since the small bowel is stretchable, and no landmarks such as the 
hepatic flexure, etc., are recognized, the method of measuring the depth of the introduction 
by May et al. is the standard for the moment. The literature of the years to come will guide 
us about when to use the DBE as first approach and when to start with VCE as screening. The 
complication rate reported in the current literature is promising; however, the pancreatitis 
rate reported by the Amsterdam group has to be kept in mind.10 Meta-analysis of the first 
10,000 cases, to be reported in literature in the near future, will help us to determine the 
actual complication risks. Small bowel, the terra incognita of flexible endoscopy, is rapidly 
being discovered and false answers of the past will be corrected in the coming years. DBE 
has established itself in record time and is recognized as a milestone in endoscopy.
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Abstract
Background: Enteropathy-associated T-cell lymphomas (EATL) are T-cell non-Hodgkin 
lymphomas of the small bowel, which are associated with coeliac disease. EATL’s arise in 
patients with either previously known or newly diagnosed coeliac disease. In a subgroup of 
patients EATL is preceded by a progressive deterioration, a refractory form of coeliac disease. 
There is little information about the incidence of EATL’s. 
Aim: To study the demographic characteristics of patients with EATL and its association with 
coeliac disease.
Design and Methods: A survey in the nationwide network and registry of histo- and 
cytopathology in the Netherlands (PALGA) was performed including all T-cell lymphomas 
with an initial presenting tumour in the small bowel. The data on patients diagnosed with 
small bowel T-cell lymphomas between 2000 -2004 were analysed. 
Results: Clinico-pathological data were gathered for 91 cases of EATL; 19% occurred in the 
duodenum, 20% in the jejunum, 7% in the ileum, 5% in more than one site and 49% in non-
specified sites of the intestine. There is a predominance of males (65%) versus females (35%) 
(p=1.00). The overwhelming majority (89%) of patients are 50 years and over.
Conclusions: This study indicates that EATL is a rare complication of therapy- refractory 
coeliac disease with an incidence of 0.12 per 100.000 inhabitants per year. EATL occurs 
mainly in patients over the age of 50, mean age 60 years (range 39-75, SD± 8,6), primarily 
in the proximal small bowel. Because coeliac disease in old age patients is sometimes not 
noted, it is possible that the actual incidence is considerably higher. It would be interesting to 
look for coeliac disease associated T-cell lymphomas outside the gastrointestinal tract.
Introduction
Enteropathy-associated T-cell lymphoma (EATL) is a rare form of high-grade, T-cell non-
Hodgkin lymphoma (NHL) of the small intestine that is specifically associated with Coeliac 
disease.1 EATL in coeliac disease patients can present in two ways.2; 3 There are patients 
with well-established coeliac disease who have responded to a gluten free diet but later 
deteriorate because of the development of refractory coeliac disease with aberrant T-cells. In 
the other group, the diagnosis of coeliac disease is made following the diagnosis of EATL (de 
novo EATL). In 60-80% of patients with refractory coeliac disease with aberrant T-cells, EATL 
develops within 5 years.4 
A prospective, multi-centre, case-control study in 10 European countries 5 has found that 
patients with coeliac disease have an increased risk of developing NHL (both T and B 
lymphomas) [odds ratio (OR) 2,6, 95% confidence interval (CI) 1,4-4,9] and that clinically 
silent coeliac disease is rare in patients with NHL. This risk was only present in patients with 
coeliac disease diagnosed clinically before the study (OR 3,3, 95% CI 1,4-7,9), but not in 
those with silent coeliac disease detected by screening (OR 1,3, 95% CI 0,6-2,7).
EATL has almost always dismal prognosis. In a British national lymphoma investigation, 16 
cases of EATL were described with survival of only 25% at 18 months.6 Egan et al 7 reported 
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30 patients with EATL having survival of only 31% at one year and 11% at 5 years. In our 
own series of 39 EATL patients, the 2 year survival is only 15-20% (CJJ Mulder: submitted). 
The magnitude of the prevalence of EATL and the association with coeliac disease has never 
been established through a national survey. To address this, we have carried out a search in the 
nationwide network and registry of histo- and cytopatholgy in the Netherlands (abbreviated 
as PALGA), which is a central database for all histopathological diagnosis in the country.
Design and Methods
The PALGA registry
The PALGA database is a central archive containing the abstracts of all histopathological and 
cytological reports from all hospitals in the Netherlands since 1991. Every record contains a 
summery of the reports and diagnostic codes similar to the Systematized Nomenclature of 
Medicine (SNOMED).8
Analysis of the data
The present survey was based on the data recorded between 2000 and 2004. 
All lymphomas diagnosed as EATL were included. In addition all T-cell lymphomas with 
a first presentation in the small intestine (duodenum, jejunum, and ileum) were included, 
whether or not an association with coeliac disease was noted. 
The following terms were used in the search: Small bowel, small intestine, lymphoma, 
enteropathy associated lymphoma, coeliac disease, villous atrophy, gluten sensitive 
enteropathy. 
From the data gained we have looked for the combination EATL or T-cell lymphoma and 
coeliac disease. The records were checked for reporting specific anatomical sub-sites and 
the presence of features associated with coeliac disease, such as enteropathy, gluten sensitive 
enteropathy, sprue and villous atrophy. The data were further analysed looking for age-
specific incidence (for 10-years age group), gender and gender-specific incidence, method of 
establishing the diagnosis (endoscopic, surgical resection, autopsy or a combination of these), 
localization and the association with the presence of coeliac disease or villous atrophy.
Results
Between 2000 and 2004, a total of 640 entries of small bowel lymphoma were found, only 
91 (59 males: 32 females) entries of them fulfilled the criteria for EATL. Data on a total of 549 
patients were discarded because of the following: the diagnosis of mantle cell, MALT, Burkitt 
and B-cell lymphoma. 
Patients’ characteristics by diagnostic year are shown in table 1. The mean age at diagnosis of 
EATL is 60 years (range 39-75, SD= 8,6, CI= 59,8-65,3). Eighty-nine percent of the patients 
were diagnosed after their 50th birthday, with a male: female ratio of 1,8 : 1.
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Table 1. Patients characteristics by diagnostic year
Characteristic
2000
 No. %
2001
 No. %
2002
 No. %
2003
 No. %
2004
 No. %
Total
 No. %
Age (yrs)
<50  2 14  2 15  2 8  3 14  1 6  10 11
50-59  4 29  4 31  7 28  7 33  8 44  30 33
60-69  7 50  4 31  6 24  6 29  6 33  29 32
70-79  1 7  3 23  10 40  5 24  3 17  22 24
Gender
Male  9 64  6 46  17 68  15 71  12 67  59 65
Female  5 36  7 54  8 32  6 29  6 33  32 35
Total  14 100  13 100  25 100  21 100  18 100  91 100
The age-specific incidence is shown in figure 1. The incidence is 0,4/100,000 population in 
those between 40 and 49 years old, 1,5/ 100,000 in those between 50-59 years, 2,1/100,000 
in those between 60-69 years and 2.0/100,000 in those between 70-79 years old. Furthermore, 
the gender-specific incidence is 0,74/100,000 males and 0,39/100,000 females.
Figure 1. Shows the age-specific incidence 
Table 2 shows Localization of EATL by diagnostic year. EATL is mostly localised in the 
proximal small intestine, 39% in duodenum and jejunum compared to only 7% localised 
primarily in the ileum. No localisation was provided in 49% of patients.
The relation of EATL to coeliac disease is shown in table 3 and 4. Twenty-four of patients had 
Marsh IIIA-C at diagnosis of EATL (Table 3), meanwhile in 76% of the cases only a diagnosis 
of coeliac disease was made, but no marsh classification was provided. We studied the time-
lag between the diagnoses CD and EATL in the 40 intestinal T-cel lymphomas registered 
as EATLs in PALGA. Of these 40 cases registered 50% of the patients were known to have 
coeliac disease at forehand, while a diagnosis of coeliac disease was established in a total of 
47.5% (range 20-40%) simultaneously with the diagnosis of EATL (de novo EATL) (Table 4). 
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In the other 51 intestinal T-cell lymphomas villous atrophy was not mentioned, thus studying 
the time-lag was not possible. In only two patients (2.5%) no data is available on the time 
interval between coeliac disease diagnosis and EATL development. Furthermore, most cases 
of EATL developed in the first 5 years after coeliac disease diagnosis. 
Table 2. Localization of EATL by diagnostic year
Localization
       2000
No. %
      2001
 No. %
      2002
 No. %
     2003
 No. %
      2004
 No. %
Total
 No. %
Duodenum  3   22  4   31  4   16  3   14  3   17  17   19
Jejunum  2   14  2   15  7   28  4   19  3   17  18   20
Ileum  1  7  0  0  2  8  2   10  1  5  6  7
Multifocal  1  7  0  0  2  8  1   5  1  5  5  5
Not specified  7  50  7  54  10   40  11   52  10  56  45  49
Total  14  100  13  100  25  100  21  100  18  100  91  100
Table 3. Marsh stage by diagnostic year
Marsh  
Classification
       2000
No. %
      2001
 No. %
      2002
 No. %
      2003
 No. %
      2004
 No. %
Total
 No. %
Marsh IIIA  0  0  1  7.6  2  8  0  0  0  0  3  3
Marsh IIIB  1  7  4  30.7  4  16  2  9.5  2  11  13  14
Marsh IIIC  0  0  1  7.6  1  4  3  14  1  5.5  6  7
Not specified  13  93  7  53.8  18  72  16  76  15  83  69  76
Total  14  100  13  100  25  100  21  100  18  100  91  100
Table 4. Time lag in years between the diagnoses CD and EATL by diagnostic year (total= 40)
Time lag (yrs)
CD-> EATL
       2000
No. %
      2001
 No. %
      2002
 No. %
      2003
 No. %
      2004
 No. %
Total
 No. %
0  1  20  1  25  4  28.5  5  41.6  2  40  19  47.5
1-5  3  60  3  75  4  28.6  4  33.3  3  60  17  42.5
6-10  1  20  0  0  2  14.3  2  16.6  0  0  1  2.5
10+  0  0  0  0  3  21.4  0  0  0  0  2  5
Not available  0  0  0  0  1  7.1  0  0  0  0  1  2.5
Total  5  100  4  100  14  100  12  100  5  100  40   100
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Discussion
Patients with refractory coeliac disease and aberrant T-cells are at a greater risk of developing 
malignancy, particularly EATL (60-80% within 5 years).4 EATL ultimately develops in 7-10% 
of patients with long-standing coeliac disease with a relative risk of 42,7.2, 9 
The annual incidence rate of EATL has been reported to be 0,5-1 per million people in Western 
countries.1 We report here an annual incidence in the Netherlands of 0,8-1,5/ million people. 
We found a male: female ratio of 1,8:1. Other studies also reported a predominance for EATL 
in males, with a peak in the 6th decade of life, 1,11,12 however the majority of uncomplicated 
coeliac disease patients are females.13 
Here we report that 89% of the patients were diagnosed after their 50th birthday (between 
50-79 years). Patients with coeliac disease who develop worsening of symptoms of diarrhoea 
and malabsorption, particularly patients older than 50 years should be considered for 
complete endoscopic and radiologic evaluation to exclude EATL. In patients without a prior 
diagnosis of coeliac disease, EATL is a very rare disorder and the diagnosis in such cases is 
often difficult and delayed due to the non-specific nature of the symptoms and a very low 
index of clinical suspicion.2-4 
It seems that older age, male sex and the presence of HLA-DQ2 homozygosity 14 are 
associated with a higher risk for development of EATL in coeliac disease.
We found that EATL is mostly localised in the proximal small intestine, 39% in duodenum 
and jejunum compared to only 7% localised primarily in the ileum. This is consistent with 
reports of others1 that EATL commonly develops in the jejunum but may also be found in the 
ileum and lymph nodes and less frequently in the stomach and colon. It is often multifocal 
with ulcerative lesions, which explains the high perforation rate at presentation or during 
chemotherapy.3 
Concerning the time lag between diagnosis of coeliac disease and subsequent development 
of EATL, variable intervals have been reported reported intervals ranging from 3 to 21 years.16, 
17 In this survey, we found that most cases (90%) are diagnosed within 5 years from the 
diagnosis of coeliac disease. This is consistent with the findings of Holmes et al10 that GFD 
for more than 5 years will reduce the risk of intestinal lymphoma to that of the general 
population. 
Several studies reported that in about 50% of cases, the patient presented with an EATL, 
while the underlying coeliac disease was still silent and coeliac disease was only recognized 
after the diagnosis of lymphoma had been made.1, 3 In this survey we found that the diagnosis 
of coeliac disease was established in a total of 47.5% simultaneously with the diagnosis of 
EATL (de novo EATL). This underscores the importance of taking endoscopic biopsies even 
from grossly normal appearing mucosa to exclude coeliac disease since GFD needs to be 
instituted.
Only in a minority of patients with localization of lymphoma in the proximal small bowel can 
the diagnosis be established on endoscopic biopsies. In most cases laparotomy is necessary 
to establish the diagnosis as well as being part of the treatment.18 Approximately 50% of the 
patients require laparotomy for complications of haemorrhage, perforation or obstruction.7
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With the advent of the new small bowel endoscopy techniques, particularly the video capsule 
endoscopy 19 and the double-balloon enteroscopy (DBE) 20 and the developments in small 
bowel radiological imaging (PET scan, MR enteroclysis and CT enteroclysis) 21,22 we think 
that will improve earlier detection of malignant and pre-malignant lesions and will boost the 
standard of care of the patients with currently dismal outcome. 
Methodological considerations
There might be some degree of underreporting of EATL cases in PALGA since only 91 cases 
were reported during a period of 5 years. This might be due to the fact that patients with EATL 
usually present with non-specific worsening symptoms of diarrhoea and malabsorption in 
their fifth or sixth decade, and that imaging techniques do not recognize abnormalities in a 
subgroup at this stage.3, 7 In this subgroup of patients EATL is not recognized. If no surgery for 
obstruction or perforation takes place, these patients might die of malnutrition or cachexia 
and not be registered in the PALGA database unless autopsy is done.
Another possible explanation of the underreporting might be that, as put forward earlier, 
almost 50% of these patients are treated with partial resection without due consideration to 
take biopsies from the normal appearing mucosa. In these cases coeliac disease would be 
overlooked; hence these patients are not registered in PALGA as EATL’s. 
Lastly, EATL’s can present as extra-intestinal T-cell lymphomas in 20% of patients.3 In this 
case the presence of coeliac disease will probably be overlooked and these cases will be 
labelled as T-cell lymphomas but not specifically EATL. In these cases, considering the search 
used in the present study, there will be underreporting in PALGA. Furthermore, a better 
characterisation of the Marsh stage at diagnosis, reporting the immunophenotype of EATL 
are needed. 
Conclusions
Taking the possibility of an underreporting under consideration, this study reflects the 
incidence of EATL registered by all hospitals in the Netherlands. The incidence reported in 
this study is rather low and EATL is seen almost always in patients of 50 years and over.
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Abstract
Background & Aims: Coeliac disease (CD) is a common gluten-sensitive enteropathy associated 
with human leukocyte antigen (HLA)-DQ2 and HLA-DQ8. The aim of this study was to determine 
if a particular HLA-DQ subtype predisposes to complications such as refractory CD with (RCD 
II) or without aberrant T-cells (RCD I), and enteropathy-associated T-cell lymphomas (EATL). 
Methods: Molecular HLA-DQ typing was performed on 43 RCD I, 43 RCD II, and 30 EATL 
patients, and compared with age-matched groups of 121 patients with histologically defined 
uncomplicated CD and 183 healthy controls. All individuals were Dutch Caucasians and 
were at least 21 years of age.
Results: HLA-DQ2 was present in 79% of RCD I, 97.7% of RCD II, and 96.6% of EATL 
patients. The differences were significant when compared with 28.9% in controls but not 
with 91.7% in uncomplicated CD. Homozygosity for HLA-DQ2 was observed in 25.5% of 
RCD I, 44.1% of RCD II, and 53.3% of EATL patients vs 20.7% of uncomplicated CD patients 
and 2.1% of controls. HLA-DQ8 was present in 10.7% of CD, 16.2% of RCD I, 9.3% of RCD 
II, and 6.6% of EATL patients vs 20.2% of controls. 
Conclusions: Homozygosity for HLADQ2 is associated with RCD II and EATL. Early 
identification of HLA-DQ2 homozygous CD patients may help to recognize CD patients at 
risk for developing these severe complications.
Introduction
Coeliac disease (CD) is a common gluten-sensitive enteropathy affecting 1/150 to 1/300 
individuals worldwide.1, 2 CD is strongly associated with the class II human leukocyte 
antigen (HLA)-DQ2 heterodimer encoded by the DQA1*0501 and DQB1*02 alleles. The 
DQ2 glycoprotein is present in 90-95% of Caucasian CD patients.3, 4 The majority of DQ2-
negative CD patients are positive for the haplotype DQA1*03-DQB1*0302 (HLA-DQ8).5-7 A 
small number of CD patients lacking these heterodimers have either DQA1*05 or DQB1*02 
alone.8 CD-associated HLA-DQ molecules bind and present gluten peptides to antigen-
specific T-cells. These HLA-DQ-peptide complexes induce inflammatory T-cell responses in 
the small intestine with villous atrophy, crypt hyperplasia and intraepithelial lymphocytosis.4, 
9 HLA-DQ2 homozygous antigen-presenting cells (APC) induce higher T-cell proliferation 
and cytokine secretion than HLA-DQ2/non-DQ2 heterozygous APC.9 This may explain the 
strongly increased risk for disease development in HLA-DQ2 homozygous individuals.10-13
In a small percentage of patients serious complications develop. CD patients may be regarded 
as suffering from refractory disease (RCD) when symptoms persist or recur after a former good 
response despite strict adherence to a gluten-free diet. When normal expression of T-cell 
antigens and polyclonal TCR-gene rearrangement occur (RCD I) the prognosis is less dismal 
than when an aberrant clonal intraepithelial T-cell (IEL) population and/or loss of antigen on 
IELs is present (RCD II). These patients have a high risk of developing intestinal lymphoma.14-
17 Patients with refractory CD are at a greater risk of developing malignancy.18 EATL has 
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histological and immuno-histochemical features of large or medium size T-cell proliferation 
expressing a CD3+ CD8+/- and CD103+ phenotype. The majority of these lymphomas present 
as CD3+ CD8- CD30+ large cell lymphoma, however small cell lymphomas, often CD3+ 
CD8+ CD30- may occur.19
We have investigated whether a distinct HLA-DQ subgroup represents a risk factor for the 
development of refractory disease and the development of EATL.
Materials and Methods
Subjects
Forty-three patients with RCD I (12 males and 31 females; mean age at diagnosis 49 years, 
range 23-86), 43 patients with RCD II (19 males and 24 females; mean age at diagnosis 
59 years, range 47-88) and 30 patients with EATL (16 males and 14 females; mean age 
at diagnosis 61.5 years, range 52-79) were studied. Patients were referred to the Rijnstate 
Hospital or the VU University Medical Centre, tertiary referral centres for CD and were 
recruited from all provinces in the Netherlands from 1992 to 2003. The patients with RCD I 
and II were followed over a mean follow-up period of 5 years (range 2-12 years) for evidence 
of transition to a more severe state, i.e., the transition from RCD I to RCD II and /or EATL, 
and from RCD II to EATL.
We have used for comparison data on a total of 121 unrelated and uncomplicated Dutch 
Caucasian CD patients (24 males and 97 females; mean age at diagnosis 45.9 years, range 22-
75) selected on age to match the age groups under study. All these patients had villous atrophy 
(Marsh type III) on a normal gluten containing diet who responded with histological and 
clinical improvement to withdrawal of gluten from the diet.20 Table 1 shows the demographic 
characteristics of these patients and the age at diagnosis of both CD and the complicated 
state (RCD and EATL). A group of 183 unrelated healthy Dutch Caucasians (85 males and 
98 females, mean age at participation 38.7 years, range 24-89), previously typed for HLA-
DQ served as controls.20 In complicated CD, possible underlying diseases (except EATL), 
such as bacterial overgrowth, giardiasis, amyloidosis, intestinal lymphangiectasia, Whipple’s 
disease, hypogamma-globulinemia, eosinophilic enteritis, inflammatory bowel disease were 
excluded. In addition to endoscopic and histopathological evaluation, all patients with 
complicated coeliac disease underwent clinical, laboratory and radiological assessment 
including: intraepithelial lymphocytes phenotyping for signs of (cytotoxic-) monoclonality, 
small bowel x-ray and/or magnetic resonance, serological results for anti-gliadin, anti-
endomysium and tissue transglutaminase (tGA), thyroid function tests, stool examination 
for giardia and other parasites, HIV serology and DEXA-scan as part of a routine work-
up.1, 17 When indicated, computed tomography scans of the abdomen, positron emission 
tomography, video capsule endoscopy and/or double-balloon enteroscopy were performed. 
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Criteria for diagnosis
The histology in the gluten-sensitive spectrum was categorized according to the modified 
Marsh’s criteria adapted by the working group of the 2001 United European Gastroenterology 
Week (UEGW) in Amsterdam.21 The diagnosis of CD was confirmed by histological 
examination with a documented histologic response to gluten withdrawal.21 Patients with CD 
were considered to be refractory when symptoms of malabsorption due to villous atrophy 
persisted or recurred after a former good response despite strict adherence to a gluten-free 
diet. The diagnosis of RCD was established as type 1 when no aberrant T-cells were present in 
intestinal biopsy specimens and type II with aberrant T-cells detected by immunophenotyping 
using flow-cytometric analysis or immunohistology of the intestinal mucosa.17, 21 In RCD I 
the IEL phenotype is normal with the expression of surface CD3 CD8 and TCR-β. In RCD II 
the IELs have normal cytological features, but they exhibit an abnormal IEL phenotype with 
the expression of intracytoplasmic CD3ε, surface CD103 and the lack of classical surface 
T-cell markers such as CD4, CD8 and TCR-αβ.18 The diagnosis of EATL was established 
according to the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.19, 
22, 23 The immunohistochemical features of EATL are evidence of large or medium size T-cell 
proliferation expressing a CD3+ CD8+/- and CD103+. The majority are CD3+ CD8- CD30+ 
large cell lymphoma; however, small cell lymphomas often are CD3+ CD8+ CD30-.19
HLA-DQ typing
Whole blood was obtained for typing of HLA-DQA1* and DQB1* alleles, performed with 
a combined single-stranded conformation polymorphism (SSCP)/heteroduplex method by a 
semi-automated electrophoresis and gel staining method on the PhastsystemTM (Amersham-
Pharmacia-Biotech, Sweden).20, 24
Statistical analysis
Statistical data were analyzed by the student t test, and results were considered statistically 
significant at a P value < 0.05. Odds ratios (OR) and their 95% confidence intervals (CI) were 
used to assess the significance of association between the dosage of haplotypes HLA-DQ2 
and/or DQ8 and the risk of having RCD I, RCD II and EATL.
Results 
Table 1 shows the age and sex distribution of the patients with histologically-defined 
uncomplicated CD (Marsh III), RCD I and RCD II, EATL, and controls. 
Table 2 shows the distribution of carriers of HLA-DQ2 and DQ8 allelic combinations in 
the patients with histologically-defined uncomplicated CD, RCD I and RCD II, EATL, and 
controls. Fourty-nine out of 183 (26.8%) controls were found to be HLA-DQ2 heterozygous. 
Four (2.1%) controls were homozygous for DQ2. Thirty-seven controls (20.2%) carried HLA-
DQ8, among them two individuals (1.1%) were homozygous for HLA-DQ8. Ten controls were 
positive for both HLA-DQ2 and DQ8. Altogether, eighty controls (43.7%) were positive for 
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HLA-DQ2 and/or DQ8. Of note, in 103 controls (56.3%) HLA-DQ2 and DQ8 are absent. 
In the patients with histologically-defined uncomplicated CD (Marsh III), 111 out of 121 
(91.7%) patients carried at least one copy of the combination of genes DQA1*0501 and 
DQB1*02, i.e., were HLA-DQ2-positive, and 25 out of 121 (20.7%) were DQ2 homozygous. 
Thirteen patients (10.7%) carried the haplotype HLA-DQ8 and 8 (6.6%) were positive for 
both HLA-DQ2 and DQ8. Therefore, 95.9% of patients with uncomplicated CD carried DQ2 
and/or DQ8 markers. 
In the RCD I group, 34 out of 43 (79%) patients were DQ2-positive, and 11 out of 43 
patients (25.5%) were DQ2 homozygous. Seven patients (16.2%) carried the haplotype 
HLA-DQ8. Overall, 86% of RCD I patients carried HLA-DQ2 and/or DQ8. Six out of 43 
(14.0%) patients with RCD I had neither HLA-DQ2 nor DQ8, however, three of them had 
the allele DQB1*02.
Table 1. Age and sex distribution of the patients with histologically defined uncomplicated CD (Marsh III), 
refractory CD (RCD I and RCD II), EATL, and controls
Mean age at diagnosis  
CD in years (range)
Mean age at diagnosis RCD I,  
RCD II, and EATL in years (range) Male:Female
Uncomplicated CD (n=121)
RCD I (n=43)
RCD II (n=43)
EATL (n=30) 
Controls (n=183) 
45.9 (22-75)
47 (21-75)
57 (40-69)
59 (46-69)
38.7 (24-89) at participation
-
49 (23-86)
59 (47-88)
61.5 (52-79)
-
24:97
12:31
19:24
16:14
85:98
In the RCD II group, 42 out of 43 (97.7%) patients were HLA-DQ2-positive and 19 patients 
(44.1%) were HLA-DQ2 homozygous. Four patients (9.3%) carried the haplotype DQ8. 
Therefore, all RCD II patients carried HLA-DQ2 and/or DQ8. 
In the EATL group, 29 out of 30 (96.6%) patients were HLA-DQ2-positive and 16 (53.3%) 
were HLA-DQ2 homozygous. Two patients (6.6%) carried the haplotype DQ8. Therefore, all 
patients with EATL carried HLA-DQ2 and/or DQ8. 
The mean age for CD diagnosis in the RCD II subgroup was 57 years (range 40-69) and 59 
years (range 46-69) in EATL. Over a mean follow-up period of 5 years (range 2-12), none of 
the RCD I patients had progressed to RCD II or EATL. Furthermore, of the 30 patients with 
EATL, the diagnosis was established in five without preceding known history of CD and/or 
RCD II, in other words, 25 patients have progressed from RCD II to EATL. 
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Table 2. Distribution of carriers of HLA-DQ2 and DQ8 allelic combinations in the patients with histologically defined 
uncomplicated CD (Marsh III), refractory CD (RCD I and RCD II), EATL, and controls. X = non-DQ2 and non-DQ8
Controls
(n=183) (%)
Uncomplicated CD  
(n=121) (%)
RCD-I
(n=43) (%)
RCD II
(n= 43) (%)
EATL
(n=30) (%)
DQ2/X 
DQ2 homozygous
DQ2/DQ8
DQ2 positive
DQ8/X
DQ8 homozygous
DQ8 positive
Non DQ2/non DQ8
DQ2 or DQ8 positive
39 (21.3)
4 (2.1)
10 (5.5)
53 (28.9)
25 (13.6)
2 (1.1)
37 (20.2)
103 (56.3)
80 (43.7)
 78 (64.5)
 25 (20.7)
 8 (6.6)
 111 (91.7)
 4 (3.3)
 1 (0.8)
 13 (10.7)
 5 (4.1)
 116 (95.9)
19 (44.1)
11 (25.5)
4 (9.3)
34 (79)
3 (6.9)
0
7 (16.2)
6 (14.0)
37 (86.0)
20 (45.4)
19 (44.1)
3 (6.9)
42 (97.7)
1 (2.3)
0
4 (9.3)
0
43 (100)
12 (40.0)
16 (53.3)
1 (3.3)
29 (96.6)
1 (3.3)
0
2 (6.6)
0
30 (100)
Data on HLA-DQ2 homozygosity in RCD I, RCD II and EATL and a comparison made to 
the histological-defined uncomplicated CD (Marsh III) and controls are presented in Table 
3. The difference in HLA-DQ2 homozygosity between RCD II (44.1%) and EATL (53.3%) 
was not significant (P >0.05). RCD II and EATL patients have a statistically significant 
higher frequency of DQ2 homozygosity compared to uncomplicated CD (20.7%), (P = 
0.0046; OR= 3.04 (95 % CI: 1.44 - 6.41) and P=0.0003; OR =4.39 (95% CI: 1.91 - 10.08), 
respectively). No statistically significant differences were found in the carrier frequencies of 
HLA-DQ8 between uncomplicated CD, RCD I, RCD II and EATL. In relation to carriage of 
HLA-DQ2, the difference between RCD I and uncomplicated CD is significant (P=0.048, 
OR 3.0, 95% CI: 1.169 to 7.700), the difference between RCD II and RCD I does reach 
significance (P=0.0148; OR=11.118, 95% CI: 1.341 to 92.198) and the difference between 
EATL and RCD I is significant (P=0.0399, OR=7.676, 95% CI: 0.917 to 64.28). The difference 
in frequency of DQ2 homozygosity between RCD I (25.5%) and uncomplicated CD (20.7%) 
is not statistically significant (P=0.503, OR =1.32 (0.59-2.94). 
Table 3. HLA-DQ2 homozygosity and the risk of having RCD I, RCD II and EATL compared to the patients with 
histologically-defined uncomplicated CD (Marsh III) and controls as defined by OR and 95% Confidence Intervals
Disease
complication
Odds ratios (95% CI) 
vs. uncomplicated CD
P- value vs. 
uncomplicated CD
Odds ratios (95% CI) 
vs. controls
P-value vs. 
controls
RCD I
RCD II
EATL
1.32 (0.59-2.94)
3.04 (1.44-6.41)
4.39 (1.91-10.08)
0.503
0.0046
0.0003
15.3 (4.8 - 48.5)
35.4 (11.5 - 107.6)
51.1 (15.5 - 165.8)
<0.0001
<0.0001
<0.0001
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Discussion
The relationship between HLA-DQ2, DQ8 and CD has become clearer in recent years. 
Through the activity of the enzyme tissue transglutaminase (tTG) glutamine residues in gluten 
are converted into glutamic acid. Subsequently, a multitude of gluten-derived peptides is 
generated that when bound to either HLA-DQ2 or DQ8 can induce T-cell responses in CD 
patients.25, 26 A particular glutamine and proline rich 33-mer α-gliadin peptide that contains 
6 different T-cell stimulatory sequences and is resistant to gastric and duodenal proteolysis 
might be the primary initiator of the inflammatory response to gluten.27, 28 In the large majority 
of patients, even in children with CD, inflammatory T-cell responses to other gluten peptides 
are also observed, implicating multiple gluten peptides in the disease process.29 
Although reports by Zubillaga et al.7 and Congia et al.30 have shown that DQ2-homozygosity 
may predispose a person to an earlier onset, and to more severe disease manifestations, 
Greco et al.31 found no correlation of clinical features of CD with different HLA-DR/DQ 
genotypes. Howell et al. 32 using frozen or paraffin-embedded biopsy tissue from 43 British 
EATL patients found that EATL arises in individuals with the DQA1*0501, DQB1*02 CD-
predisposing genotype, however, the patients were not homozygous for HLA-DQ2. In the 
present study, we found a highly significant correlation between HLA-DQ2-homozygosity 
and the development of serious complications of CD, in particular RCD II and EATL. We have 
no explanation for this discrepancy. However, Howell et al. found 40% of EATL patients to 
possess the HLA-DRB1*0304 genotype. Since 32.6% of the EATL patients carries allele HLA-
DQB1*0302 that is in strong linkage disequilibrium with HLA-DRB1*04 a similar frequency 
of the haplotype DQA1*03-DQB1*0302 (HLA-DQ8) was to be expected in these Caucasian 
patients. The authors do not comment on the unexpectedly low frequency (16.3%) of carriers 
of DQA1*03 suggesting some problems with genotyping these samples.
The link between HLA-DQ2-homozygosity and development of RCD II and CD-associated 
lymphoma of intraepithelial origin thus suggests that the strength of the gluten specific T-
cell response in the lamina propria directly or indirectly influences the likelihood of RCD 
II and lymphoma development. It has been reported earlier by Vader et al that HLA-DQ2 
homozygous antigen-presenting cells (APC) induce higher T-cell proliferation and cytokine 
secretion than HLA-DQ2/non-DQ2 heterozygous APC.9 This may explain the strongly 
increased risk for disease development in HLA-DQ2 homozygous individuals.10-13 This would 
indicate that the adherence to a gluten-free diet is particularly important for CD patients who 
are HLA-DQ2 homozygous.
Interestingly, none of the RCD II and EATL patients have been diagnosed with these 
complications below the age of 45 years and only one of these patients was diagnosed 
with CD below the age of 45. These observations suggest that the specific tests such as CD3 
cytoplasmic positive T-cells (IEL’s) with immunohistology or T-cell flow cytometry should be 
indicated in all patients with CD who are not responding to a gluten-free diet above the age 
of 45 years. Since the prognosis is very serious we propose to evaluate all “old-age coeliacs” 
diagnosed with coeliac disease above the age of 50 years.18 The availability of a simple 
and reliable immunohistochemical method makes the distinction between CD and RCD 
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feasible.33 Although in this study we have not observed a transition from RCD I to RCD II, 
a prospective follow-up with immunohistochemical techniques is indicated in particular in 
HLA-DQ2 homozygous patients. We strongly advise that for the time being at least full low 
resolution HLA-DQA1 and DQB1 typing in CD is performed. Techniques that recognize only 
the presence of HLA-DQ2 or DQ8 miss the few patients with CD that are non-HLA-DQ2 
non-HLA-DQ8 and the possibility to diagnose HLA-DQ2 or DQ8 homozygotes. 
Our observations require further confirmation in a larger group of patients and the set up of 
prospective studies. HLA-DQ typing is feasible and it may be an efficient test to recognize 
individuals at risk for these conditions with a poor prognosis, in particular nowadays that 
some evidence has been given to support the hypothesis that autologous haematopoietic 
stem cell transplantation can alter disease progression in severe autoimmune disease.34, 35
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Abstract
Objective: Patients with refractory coeliac disease can develop enteropathy-associated T-cell 
lymphoma (EATL) or ulcerative jejunitis. Double-balloon enteroscopy allows examination of 
the entire small bowel. We investigated prospectively the value of this technique in patients 
with refractory coeliac disease. 
Methods: The small bowel enteroscopy was performed in a total of 21 consecutive patients 
for lesions like ulcerations. Biopsy specimens were taken from macroscopical lesions and 
from three different levels from the examined small bowel. Tissue specimens were evaluated 
for the modified Marsh classification and for the presence of EATL. 
Results: Twenty-four procedures were successfully performed without complications. EATL 
was found in five patients (24%) as circumferential, discrete, or confluent ulcerations. In 
three of them Marsh III was found while in the other two patients with EATL Marsh I was 
found. Another two patients (9%) had ulcerative jejunitis in absence of EATL and histology 
was compatible with Marsh III. In the remaining 14 patients (54%) no high-risk lesions were 
found. Double-balloon enteroscopy could exclude the presence of EATL in four patients that 
was suggested by abdominal computerized tomography. 
Conclusions: Complications of refractory coeliac disease like ulcerative jejunitis or EATL could 
efficiently be detected, its extent delineated or excluded by double-balloon enteroscopy. This 
technique should be reserved for patients with refractory coeliac disease or patients with a 
past history of EATL.
Introduction 
Coeliac disease is characterized by villous atrophy of the small bowel secondary to gluten 
ingestion which recovers upon gluten withdrawal from the diet in the majority of patients.1 
However, 2-10% of patients with coeliac disease seem to develop refractory coeliac 
disease.2-4 In this specific population, the relative risk for developing ulcerative jejunitis 5 or 
enteropathy-associated T-cell lymphoma (EATL) 6, 7 is markedly increased.
Endoscopic examination of the small bowel in patients with coeliac disease, including 
direct visualisation and the possibility of obtaining biopsy specimens for histological 
assessment has previously been done using conventional upper gastrointestinal endoscopy 
8-11 or push enteroscopy.5, 12-14 Using these techniques, it is possible to examine a limited 
extent of the small bowel, whereas only the distal ileum can be reached with classical ileo- 
colonoscopy.15 Endoscopy of the remaining small bowel in patients with coeliac disease 
could only be performed using surgical enteroscopy in theatre.16 Video capsule endoscopy 
was recently introduced as a diagnostic method for patients with coeliac disease.17 Double-
balloon endoscopy allowed a new era in small bowel endoscopy with its potential for full-
length examination of the small bowel, obtaining biopsies, and performing endoscopic 
interventions, however the procedure describes lesions without the ability to obtain samples 
for histological examination.14
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Double-balloon enteroscopy allowed a new era in small bowel endoscopy with its 
potential for full-length examination of the small bowel, obtaining biopsies, and performing 
endoscopic interventions.18-21 In the present study we investigated for the first time whether 
double-balloon enteroscopy detects mucosal lesions, including ulcerative jejunitis and EATL 
in a population of refractory coeliac disease patients in segments of the small bowel that 
are usually not accessible to standard endoscopy. Biopsies of the lesions were taken for 
histological confirmation of the presence of ulcerative jejunitis or EATL.
Patients and Methods
Patients
The base-line characteristics of 21 patients with coeliac disease who were referred for 
double-balloon eteroscopy between February 2004 and July 2005 are summarized in Table 
1. All patients were symptomatic on a strict gluten-free diet for a median period of 60 months 
(range 3-384 months). Surgical removal of EATL took place in seven patients and additional 
therapy consisting of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) 
22, 23 in six, within a median interval of 13 months (range 3-48 months) before double-balloon 
enteroscopy. In three of these seven patients, histological evidence of EATL was found in 
surgically removed tissue just 3-5 months prior to double-balloon enteroscopy. These patients 
were referred for small bowel endoscopy to detect or exclude other EATL lesions. The other 
14 patients were suffering from persistent villous atrophy in duodenal histology despite 
adherence to gluten-free diet for at least 12 months. Previous medical treatment included 
steroids (n=6) and azathioprine (n=2).
All patients underwent a diagnostic work-up, before undergoing double-balloon enteroscopy, 
which included the measurement of the coeliac disease specific serological tests [IgA anti-
transglutaminase antibodies (TGA) and IgA anti-endomysium antibodies (EMA)] 24, HLA-DQ 
typing [HLA-DQ2 (encoded by DQA I*0501 and DQB I*02 alleles) and HLA-DQ8 (encoded 
by DQA I*0301 and DQB I*0302 alleles)] 25 as well as gastroduodenoscopy.1 Additional 
diagnostic examinations included abdominal computerized tomography (CT) scan (n=14), 
and video capsule endoscopy (n=7).
Criteria for diagnosis of RCD
Patients with coeliac disease were considered to be refractory when symptoms of 
malabsorption due to villous atrophy persisted or recurred after a former good response 
despite strict adherence to a GFD for at least one year. Furthermore, possible underlying 
diseases such as autoimmune enteritis, bacterial overgrowth, giardiasis, amyloidosis, 
intestinal lymphangiectasia, Whipple’s disease, hypogamma-globulinemia, eosinophilic 
enteritis, EATL and inflammatory bowel disease were excluded.3
Immunophenotyping of the IEL’s identifies two groups of RCD patients: those with normal 
IEL’s (RCD I) and those with aberrant IEL’s, lacking surface expression of CD3 and CD8 (RCD 
II).2, 3
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Table 1. Base-line characteristics of patients with refractory coeliac disease referred for double-balloon 
eteroscopy. 
Characteristic Total number 21*
Age, y † 61  (41-89)
Men, n (%) 11  (52%)
Body mass index † 21.2  (16-27)
Family history of coeliac disease, n (%) 1  (5%)
Caucasians, n (%) 20  (95%)
Duration of coeliac disease, y † 5  (0.3-33)
Autoimmune diseases, n (%) ‡ 6  (28%)
Surgery for EATL, n (%) § 7  (33%)
Chemotherapy, n (%) 6  (28%)
Duration of gluten free diet, m † 60  (3-384)
Symptoms, n (%)
 Diarrhoea
  Weight loss
  Abdominal pain
  Anaemia 
17  (81%)
11  (52%)
3  (14%)
3  (14%)
* Twenty-one patients were evaluated by double-balloon enteroscopy. † Values are the median (range).
‡ Autoimmune diseases consisted of autoimmune thyroid disease (n=4), Sjögren’s syndrome (n=1), and dermatitis 
herpetiformis (n=1). § Enteropathy-associated T-cell lymphoma.
The diagnosis of RCD was established as type II when ≥ 20% aberrant T-cells were present. 
Detection of a clonal T-cell population by testing for TCR rearrangement was thought to be 
highly predictive of EATL development. However, oligo- or monoclonal IEL’s populations 
can be detected in the large majority of both RCD I and RCD II patients, also in patients that 
do not develop an EATL. Clonality is therefore of limited use in establishing the diagnosis of 
RCD and to predict the development of EATL.26, 27
The diagnosis of T-cell lymphoma was based on histological features with mainly evidence 
of large or medium size T-cell proliferation and immuno-histochemical features with 
expression of CD3+, CD8+/-, CD103+, TIA-1/GranzymB 7, TCRγ gene rearrangements and 
lack expression of CD30, CD21, bcl-2 and bcl-6, by immunofenotyping of T-cell infiltrate in 
biopsy specimens or resection material.4
Double-balloon enteroscopy 
All patients underwent double-balloon enteroscopy within 4-8 weeks of the initial 
gastroduodenoscopy. The double-balloon enteroscopy system (Fujinon EN-450 P5, Fuji 
Photo Optical Incorporated Company Fujinon Inc., Japan) was used for examination of the 
small bowel. The system and method, previously described in detail 18, 19, 21, 27, consists of an 
endoscope (length 200 cm, outer diameter 8.5 mm, working channel 2.2mm), and a flexible 
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overtube (length 140 cm, outer diameter 12 mm) that are both provided with soft latex balloons 
connected through a built-in air route to a controlled pump system. Advancement or withdrawal 
of the scope is achieved by, deflating (- 45 mmHg) or inflating (+ 45 mmHg) the balloons, 
respectively. The endoscope was introduced antegradely (orally) in all patients. The length of 
the visualized small bowel was estimated by calculating the sum of each sequential progressive 
extension of the scope through the overtube (10-40 cm each sequence), starting the calculation 
from the pylorus onwards.28 The calculation of scope advancement was corrected for looping. 
Patients were prepared for proper endoscopic examination by prior bowel cleansing (1 liter 
Klean prep ®). A median dose of 7.5 µg (range 5-10µg) of fentanyl and 10 mg (range 5-15 mg) 
of midazolam was used for conscious sedation. Diagnostic biopsies were taken via a 2.2 mm in 
diameter working channel. Following the procedure, all patients were monitored in a recovery 
room for at least 2 hours, and were discharged in the absence of complications. 
The small bowel was assessed for a priori defined low-risk lesions including; a reduction 
(≤3 per endoscopic field of view) or loss of folds; 8 scalloping, that is a coarse and notched 
appearance of small bowel folds; 28, 29 nodularity of mucosa or mosaicism that is cobblestone 
or micronodular appearance of the mucosal surface 30; and presence of visible vessels, 31 after 
air insufflation.32 Ulcerations, defined as mucosal defects of at least 5 mm in diameter, and 
stenosis were considered high-risk lesions for their potential risk of harboring malignancy.5 
Endoscopic findings were considered jejnunal if they were found in the proximal 2-3 meters 
of the calculated endoscopic insertion depth.27 In addition, the small bowel being examined 
and visualized by double-balloon enteroscopy after the ligament of Treitz was subdivided into 
proximal, middle and distal segments where four biopsies were taken from each segment.
Histology of small bowel biopsies
Small bowel biopsy specimens were fixed and preserved in 10% formalin for histopathological 
and immunohistochemical evaluation. Besides hematoxylene-eosin staining, anti-CD3 
(DakoCytomation, Glostrup, Denmark) staining was performed for optimal assessment of 
the number of intra-epithelial lymphocytes (IEL). Duodenal and small bowel biopsies were 
evaluated according to the modified Marsh criteria.35 Tissue samples from suspicious lesions 
were assessed for the presence of EATL according to the WHO Classification of Tumours of 
Haematopoietic and Lymphoid Tissues.23 
Immunophenotyping of IEL
IEL’s were isolated from 3 duodenal biopsies by passing them through nylon filters (1x100µm, 
1x 40µm, BD Falcon). Cells were stained with fluorescent labeled monoclonal antibodies to 
CD3, 7, 8, 45, 103, and TCRγδ, as well as with relevant isotype controls.
All monoclonal antibodies were from BD Falcon (BD biosciences, CA USA), except for 
CD103, which was from IQ-products, Groningen, The Netherlands) and analyzed by 4-color 
flow-cytometry (FACS-Calibur, BD). Leucocyte common antigen (CD45) was always included 
to identify the lymphocyte population. In some tubes cell surface CD3 staining (anti-CD3-
APC) was followed by permeabilization (Cytofix /cytoperm, BD Biosciences Pharmingen, CA 
USA) and subsequent cytoplasmic staining with anti-CD3-FITC or isotype control. 
_____________________________________  Double-Balloon Enteroscopy in Refractory Coeliac Disease  ____
93
Aberrant T-cells were defined either as CD7+ surface CD3- cells (expressed as % of CD103+ 
lymphocytes) or as cytoplasmic CD3+, surface CD3 negative cells (expressed as % of CD103+ 
lymphocytes).36, 37
All flow-cytometry analyses were performed by an analyst and interpreted by the same 
medical immunologist, while histopathology was performed by the same pathologist to 
ensure uniformity, reproducibility and consistency of results. 
Assessment of TCR gene rearrangement by Polymerase Chain Reaction (PCR)
T-cell receptor-gamma (TCR-γ) gene rearrangements studies were performed in separate 
three-four duodenal specimens that were preserved on histocon and frozen at -20°C. 
DNA was extracted from cryosections of duodenal specimens by a standard procedure 
using proteinase-K digestion and ethanol precipitation of the genomic DNA. TCR-γ gene 
rearrangements were analyzed by multiplex polymerase chain reaction (PCR) amplification 
under standardized conditions. A monoclonal and polyclonal control was included in 
each experiment. Clonality assessment for TCR-γ gene rearrangements was done using the 
BIOMED-2 multiplex TCR PCR protocol.
Informed consent
Informed consent was obtained from all patients after receiving information about the 
experimental nature of the procedure and its risks according to institutional review board 
guidelines.
Statistical analysis
Results are presented in median (range) for continuous data and in frequencies (percentages) 
for categorical data, respectively. McNemar’s test was used to compare histology between 
different small bowel segments in the same patient. A p value of less than 0.05 was considered 
to be statistically significant. 
All statistical analysis was performed using the Statistical Software Package version 11.0 
(SPSS Inc., Chicago, Illinois, USA).
Results
Procedure characteristics
Twenty-four double-balloon enteroscopy procedures were successfully performed in 21 
patients. No major procedure-related complication occurred. Self-resolving abdominal pain 
was observed following the double-balloon enteroscopy procedure in six (29%; 95% CI 
13 to 49) patients. No relevant technical problems were encountered. The scope could be 
advanced into the small bowel to a median depth of 310 cm (range 160-440 cm) beyond the 
pylorus. The median examination time required was 100 minutes (range 30-200 minutes). 
94
____  Chapter 5  __________________________________________________________________________________________
Endoscopic and histologic features 
Jejunal ulcerations, histology of which revealed the presence of EATL, were found in five of 
21 patients (24%). Three of them have already been operated upon for EATL EATL and in two 
patients the diagnosis was made by double balloon enteroscopy. The endoscopic features of 
EATL (colour plate A-1) consisted of circumferential, discrete, or confluent ulcerative lesions, 
which were associated with stenosis in one patient. In three of these patients, Marsh III was 
found, while Marsh I was found in mucosal biopsies adjacent to EATL ulcerations in the other 
two patients. 
Ulcerative lesions in absence of histological evidence of EATL were found in another two 
patients (9%) (colour plate A-2). In these two patients, small bowel histology of non-ulcerative 
mucosa was classified as Marsh III and therefore they were considered to have ulcerative 
jejunitis.5 Table 2 summarizes the clinical, endoscopic and histologic features of patients with 
coeliac disease complicated by development of EATL or ulcerative jejunitis. 
In the remaining 14 patients (66%; 95% CI 45 to 82), low-risk endoscopic features like 
flattened villi, loss of folds, scalloping, and nodularity were found by double balloon 
enteroscopy (colour plate A-3). Table 3 summarizes the clinical characteristics, proportions 
(average) of aberrant T-lymphocytes (CD7+sCD3-CD103+ and CD7+sCD3-cytCD3+), 
endoscopic and histologic features of these patients. These 14 patients were considered to 
suffer from refractory coeliac disease according to the currently accepted definition since 
persistent villous atrophy despite gluten free diet for at least 12 months was documented in 
duodenal biopsies.4 
Small bowel histology revealed Marsh III in all 14 patients, while eight of them had the same 
changes more distally. Figure 4 illustrates that 19 patients (90%) of all included had villous 
atrophy in proximal bowel segments while only 13 patients (62%) had villous atrophy in distal 
bowel segments (p= 0.031; odds ratio 0.17, 95% CI 0.03 to 0.93). Whitish villi were observed 
in three patients. Extensive histological examination of these lesions revealed mucosal changes 
characterized by the presence of dilated lymph channels in the villi with different levels of 
inflammation (Marsh I-III) and the absence of EATL. 
Gastroduodenoscopy could demonstrate low-risk lesions in duodenum, but could neither 
detect EATL nor ulcerative jejunitis in any patient.
Figure 4. Small bowel histology from proximal, middle and distal bowel segment biopsies taken by double-balloon 
endoscopy in 21 patients with coeliac disease.
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Abdominal CT-scan was abnormal in four patients with EATL, but was normal in one patient 
with EATL and both patients with ulcerative jejunitis. Moreover, CT scan and video capsule 
endoscopy have suggested the presence of EATL in another 4 of 7 and one in 7 respectively. 
Double-balloon enteroscopy, however, did not find high-risk lesions in these specific 
patients. After a median interval of 36 months of follow-up, no evidence of lymphoma 
appeared in these patients. Video capsule endoscopy showed low-risk lesions like scalloping 
or nodularity, as reported previously 38, in the other six patients.
Double-balloon enteroscopy was repeated in two patients after three chemotherapy courses 
(standard CHOP-therapy). These patients had initially EATL diagnosed during double-balloon 
enteroscopy examination. In one patient previously documented ulcerative EATL lesions had 
disappeared while in the other patient ulcerative EATL lesions remained unchanged. Double-
balloon endoscopy was further repeated in one patient with ulcerative jejunitis, stenosis, and 
prestenotic intestinal dilatation (80-150 cm distal to pylorus) in order to exclude the presence 
of EATL. This patient underwent surgical resection of stenotic segments and subsequently 
high dose chemotherapy followed by autologous peripheral stem cell transplantation. He 
showed an impressive clinical, histological an immunological recovery.38
Immunophenotyping of intraepithelial lymphocytes and TCR gene rearrangement 
All patients with RCD had significantly high percentage of aberrant T-cells (ranging from 
25-80%) at the time of diagnosis of the refractory state. In addition, all patients had a clonal 
rearrangement of the TCRγ gene.
Discussion
Small bowel examination by double-balloon enteroscopy in patients with coeliac disease 
established the diagnosis of ulcerative jejunitis in two patients and ulcerative EATL lesions 
in five. In 2 of these 5 patients the diagnosis was made by double-balloon enteroscopy. 
Due to its limitations in introducing the endoscope beyond the ligament of Treitz, the usual 
standard gastroduodenoscopy failed to diagnose those patients. Moreover, double-balloon 
enteroscopy, with the help of tissue sampling, could adequately exclude the presence of EATL 
that was suggested by abdominal CT scan in 4 patients and by video capsule endoscopy in 
one. Small bowel endoscopy seems to be valuable even in patients who are already known 
to have EATL especially when therapeutic options are considered or effect of surgery and/or 
chemotherapy requires evaluation. Furthermore, localizing and marking with ink can be 
indispensable to help the surgeon to plan and perform partial small bowel resection. All 
three patients who were previously operated for small bowel EATL were destined to receive 
additional chemotherapy upon the exclusion of other EATL lesions in the small bowel by 
double-balloon enteroscopy. 
Contrary to the low-risk lesions of coeliac disease, ulcerations are more severe lesions that 
can harbor EATL 5. EATL usually affects the jejunum and grossly presents as multiple ulcers 
without the formation of definite tumor masses. Double-balloon enteroscopy is suitable 
examination for patients with refractory coeliac disease in order to detect multifocal or 
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distally located lesions because ulcers are more commonly located in the jejunum 5, and the 
ileum rather than the duodenum.40 
Remarkably, EATL has been found in small bowel segments next to mucosa with normal 
villous/crypt ratio and lymphocytic intraepithelial infiltrate in two patients (Marsh I). In most 
cases, the changes in the histology of the small bowel remote from the site of the tumor are 
identical to those of coeliac disease with villous atrophy, crypt hyperplasia, and increase in 
intraepithelial lymphocytes.36, 40-42 In some cases of coeliac disease, the mucosal changes are 
much less severe. The villous architecture may be normal or near-normal and the only hint 
of coeliac disease is an increase in intraepithelial lymphocytes.42 This finding, previously 
thought to argue against a strict association of coeliac disease and EATL, indicates that Marsh 
I can be a premalignant condition witout interim progression through Marsh III.
Some authors showed agreement between histological findings of duodenal biopsies as 
compared with jejunal biopsies 41 while others have demonstrated that histology could 
reveal more severe mucosal changes in jejunal biopsies as compared with those of duodenal 
biopsies.13 Although the length of the small bowel being examined was not equal in all 
patients, Marsh III was in this series more frequently found in proximal than distal small 
bowel biopsies in agreement with earlier report.5 It is unclear if the five patients who fulfilled 
the definition criteria of refractory coeliac disease and yet showed signs of histological 
recovery in deeper segments of the small bowel virtually suffer from refractory coeliac 
disease or simply represent cases of slow recovery. The variability in histology of small bowel 
segments in several patients, who according to current definition were considered to have 
refractory coeliac disease, and the variability phenotypes of intraepithelial T-lymphocytes 
immunophenotypes among patients with ulcerative jejunitis, EATL, or refractory coeliac 
disease necessitate a consensus to define refractory coeliac disease and to define the value 
of T-cell flow cytometry in the management of patients with refractory coeliac disease. Such 
a consensus is required especially when new treatment lines are to be investigated.
Abdominal CT scan has shown shown limited effectiveness in detecting ulcerative jejunitis 
and EATL in patients with refractory coeliac disease or assessing the tumor load in affected 
patients 44, 45 because they develop initially as mucosal lesions that only in a later stage 
proceed into disseminated lymphoma with mass lesions. 18F-FDG PET scans, however, has 
been demonstrated higher sensitivity and specificity for detection of EATL compared to CT 
scanning technique.46
Push enteroscopy, a known widely available endoscopical method of the proximal small 
bowel 47, can be assumed to have identified most or all the lesions found by double-
balloon enteroscopy in this series. However, it has recently been shown that double-balloon 
enteroscopy is superior to push enteroscopy in patients with suspected mid-gastrointestinal 
bleeding with regard to the length of small bowel visualized, as well as the diagnostic 
yield.48 Complications such as perforation 49, mucosal stripping 48, 50, or pancreatitis 51 
have been reported to occur in 0.6-2% of patients undergoing push enteroscopy.47, 52 For 
patients undergoing double-balloon enteroscopy, a risk of perforation and pancreatitis has 
been reported in 1%, and 1.1% respectively.8, 21 Fortunately, no such complications were 
encountered in any of the double-balloon enteroscopy procedures in the present series despite 
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the high propensity for perforation at presentation in EATL.41 Therefore, the invasive nature 
of push enteroscopy and the restricted length of the proximal small bowel being examined 
(70 cm with push enteroscopy 12, 53 versus 310 cm with double-balloon enteroscopy in this 
series) disqualify this procedure as first method of choice when double-balloon enteroscopy 
is available. 
Full-length small bowel examination in patients with coeliac disease can currently be achieved 
by video capsule endoscopy.54 Moreover, the value of video capsule endoscopy has recently 
been reported in seven patients with small bowel lymphoma.55 Villous atrophy, erythema, and 
whitish villi were described as early manifestations of small bowel lymphoma in this series.55 
However, these conclusions were based on interpretations of macroscopic images obtained 
by video capsule endoscopy. In our series, the histological examination was the only reliable 
means to verify the nature of these indicative, but non-pathognomonic, endoscopic features. 
Screening patients with refractory coeliac disease by video capsule endsocopy followed by 
double-balloon enteroscopy for abnormal findings may be a reasonable and patient-friendly 
approach that warrants further investigation. Finally, laparoscopy is preserved for obtaining 
full wall thickness biopsy of small intestine or mesenteric lymph nodes resection when 
they appear suspicious on imaging studies. Double-balloon enteroscopy, however, that can 
examine deeper segments of the small intestine in a relatively safe and minimally invasive 
nature with associated morbidity of approximately 1% 21, should be considered before open 
surgery and intraoperative endoscopy.
Ulcerative jejunitis is considered as a premalignant condition due to the demonstration of TCRγ 
monoclonality in the ulcers and intervening mucosa in ulcerative jejunitis in the absence of overt 
lymphoma 35, while others have demonstrated, by careful histological, immunophenotypical 
and molecular examination, the presence of T-cell lymphoma in cases of ulcerative jejunitis.2 
As a result, many recommend a common management approach of ulcerative jejunitis like 
a haematological malignancy that requires to be treated by devised strategies.58 In this series 
one patient underwent surgical resection of stenotic segments and subsequently high dose 
chemotherapy followed by autologous peripheral stem cell transplantation. He showed an 
impressive clinical, histological an immunological recovery.38 
With respect to our previous report describing the broader use of double-balloon enteroscopy 
in a variety of situations, there was no difference with the technical details.21 However, more 
patients were considered to have ulcerative jejunitis due to the inclusion of patients with 
ulcers less than 5 mm. Furthermore, one patient with T-cell lymphoma was excluded from 
this series because the diagnostic work-up revealed the presence of normal small bowel 
histology and absence of the coeliac specific antibodies and HLA-DQ heterodimers. 
This study is the largest series of patients with refractory coeliac disease being investigated by 
a new method of small bowel endoscopy for detection or exclusion of EATL. The relatively 
limited number of patients, the patient selection in this referral center and the extended but 
not complete enteroscopy in most studied patients may be considered confounding factors 
to the main outcome. However, the prospective nature of the study validates to our opinion 
the reported results.
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The present study indicates that direct visualization of the small bowel and obtaining biopsy 
specimens for histological examination during double-balloon endoscopy in patients with 
refractory coeliac disease can efficiently detect or exclude complications like ulcerative 
jejunitis or EATL.
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Abstract
Background: Adult onset coeliac disease (CD) has a high risk of developing refractory CD 
and enteropathy associated T-cell lymphoma (EATL). 
Aim: We evaluated CT findings, useful to suggest the presence of RCD and EATL.
Design and Methods: CD patients were divided into two groups. Group I: uncomplicated CD 
(n=14) and RCD type I (n=10). Group II: RCD type II (n=15) and EATL (n=7). 
Results: Both groups showed classic signs of CD on CT. Intussusception was seen in 1 patient 
in group I vs. 5 in group II (p=0.06). Lymphadenopathy was seen in 5 patients in group II 
vs. no patients in group I (p=0.01). Increased number of small mesenteric vessels was noted 
in 20 patients in group I vs. 11 in group II (p=0.02). Eleven patients (50%) in group II had a 
splenic volume < 122 cm3 vs. 4 in group I (14%), 10 patients in group I had a splenic volume 
> 196 cm3 (66.7%) vs. 5 in group II (33.3%) p=0.028. 
Conclusions: CT scan is a useful tool in discriminating between CD and (pre)EATL. RCD II 
and EATL showed more bowel wall thickening, lymphadenopathy and intussusception, less 
increase in number of small mesenteric vessels and a smaller spleen ompared with CD and 
RCD I.
Introduction
Coeliac disease (CD) is one of the most common immunologically mediated gastrointestinal 
diseases. The prevalence varies between approximately 1:100 and 1:300 worldwide. 
Refractory coeliac disease (RCD) is considered when patients show persistent or relapsing 
symptoms and villous atrophy despite adherence to a GFD, especially those over the age 
of 50 years.1 Two forms of RCD can be discriminated, RCD I which is defined as RCD with 
normal intra-epithelial T lymphocytes (IEL’s) in intestinal biopsies and RCD II defined as RCD 
with aberrant IEL’s.2, 3 In RCD enteropathy associated T-cell Lymphoma (EATL) can evolve 
with a 20 time higher relative risk compared to the general population.4, 5, 6 Therefore it is 
necessary to be able to discriminate uncomplicated CD from its malignant complications.
Computed tomography (CT) is one of the first radiological examinations performed for 
different indications in patients with CD, especially those with RCD to exclude malignancy. A 
variety of findings like jenunoileal fold pattern reversal 7, small bowel intussusception 8 and 
(benign) mesenteric lymphadenopathy 9 have been recognized on CT images in patients with 
CD. However, no discriminating or specific CT signs have been recognized and described 
regarding RCD II or EATL. Therefore, we evaluated both the spectrum of abdominal CT 
findings, useful for suggesting CD and those findings which might be useful to suggest the 
presence of EATL in adult coeliac patients
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Patients and methods
Between January 2003 and January 2005 a total of 46 patients (18 M, 28 F; mean age 58 
years, range 18-88 years) with proven CD according to UEGW criteria (2001), were enrolled. 
All included patients were previously diagnosed as having CD, RCD I, RCD II or EATL by 
clinical evaluation, serology and intestinal biopsy.10 Patients were divided into two groups: 
Group I consisted of 24 patients with uncomplicated CD (n=14) and RCD type I (n=10), 
group II consisted of 22 patients with RCD type II (n=15) and EATL (n=7).
The indications for CT scan were assessment of unexplained recurrent abdominal complaints 
and/or suspicion of EATL. After overnight fasting, examinations were performed either on 
a 4-detector (Somatom ’Volume Zoom’, Siemens, Erlangen, Germany) or on a 64-detector 
(’Sensation 64’, Siemens, Erlangen, Germany) CT scanner using either a 2.5 mm or a 0.6 mm 
collimation, reconstructed in 5 mm contiguous axial slices. Forty-three out of 46 patients 
received an orally administered diluted solution of barium sulphate suspension (46 mg/g, 
49 mg/ml, 900 ml E-Z-CAT, E-Z-EM Canada Inc, Montreal Canada) divided into two doses 
(450 ml), the night before and the morning of the investigation. Forthy five minutes prior to 
imaging, patients received an extra 300-500 ml oral contrast. Because of severe abdominal 
symptoms or refusal of contrast, 3/46 patients did not receive oral contrast. Intravenous non-
ionic contrast (Ultravist, Iopromide (300 mI/l), Schering, Berlin, Germany) was administered in 
42/46 patients (2 patients refused intravenous contrast and 2 patients supposed to be allergic 
to contrast) at an injection rate of 3 ml/s (maximum total amount of 100 ml, depending on 
body weight) with CT acquisition after 70 seconds.
The following CT findings were evaluated: (a) abnormalities of intestinal fold pattern, (b) 
bowel dilatation, (c) air excess, (d) fluid excess, (f) bowel wall thickening, (g) intestinal 
intussusception, (h) ascites, (i) lymphadenopathy, (j) increased number of lymph nodes, (k) 
mesenteric vascular changes, (l) splenic size and (m) splenic vein thrombosis. 
Abnormalities of the intestinal fold pattern were defined quantitatively as a decreased 
number of jejunal folds and/or an increased number (‘jejunization’) of ileal folds, measured 
as the mean number of folds per 2.5 cm in three segments at different locations.7 Less than 
4 jejunal folds per 2.5 cm were considered to be decreased and more than 4 ileal folds per 
2.5 cm were considered to be increased.7 The presence of an equal number of intestinal 
folds in ileum and jejunum (ileum/jejunum fold ratio ≥1) was defined as ‘jejunoileal fold 
pattern reversal’ (JFPR).11, 12, 13 In cases of doubt, abdominal loops in the left upper quadrant 
were considered to be jejunal and loops in the right lower quadrant were considered to be 
ileal. Intestinal loops were considered dilated if more than three segments measured equal 
or more than 3 cm in diameter on transverse images.14 Fluid excess and air excess were 
scored directly in patients with dilated intestinal loops on a Likert scale (none/mild/moderate/
severe). Fluid excess was indirectly assessed by dilution of oral contrast (flocculation). Air 
excess was scored as present in case more than 3 segments were dilated with air. The bowel 
wall was considered thickened when it measured more than 3 mm in the transverse plane of 
a fully distended loop.15 Intussusception was denoted as a target mass or as a more complex 
layered mass within the bowel lumen.16 Lymph node enlargement was considered present if 
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nodes measured greater than 1 cm in diameter in their shortest axis. The number of lymph 
nodes within the mesenterium was scored on a Likert scale (none/mild/moderate/severe). 
Cavitation of nodes was present by showing a low-density center within the lymph node. 
Ascites was evaluated by visual inspection. Increase in splanchnic circulation was scored 
as the transverse diameter 2-3 cm caudal of the origin of the superior mesenteric artery. 
Also an increase of number of small vessels within the mesenterium was noted on a Likert 
scale (none/mild/moderate/severe). Splenic volume was calculated by the following formula; 
(30+0.58*(length x width x height). The longest axis in the transversal plane is considered 
as length, the perpendicular distance is considered the width and the longest cranio-caudal 
distance is considered as the height of the spleen.17 Splenic vein thrombosis was scored 
visually when a mass was noted within the lumen of a contrasted splenic vein. 
All CT scans were analyzed by two dedicated radiologists in consensus (MM and JHvW). 
Informed consent was obtained from all the patients who participated in this study. All 
procedures followed in this study were in accordance with the standards of the institutional 
ethical committee.
Statistical analysis 
Student’s paired t-test, Mann-Whitney, or Fisher’s exact test was used for data analysis when 
indicated. P values of less than 0.05 were considered to be statistically significant. All 
statistical analysis was performed using the Statistical Software Package version 11.0 (SPSS 
Inc., Chicago, Illinois, USA). 
Figure 1a. Axial CT image demonstrates EATL (arrow) and 
prestenotic dilation of jejunal loops. Figure 1b. Coronal reformation 
demon-strates dilated jejunum with infiltrated mesenterial fat (*) 
and multiple enlarged lymph nodes (arowheads) 
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Figure 3a-d. Axial CT images demonstrating abdominal EATL location. Figure 3a. duodenal localization of 
lymphoma (arrow). Figure 3b. Mesenterial localization showing “misty mesenterium” (*) and multiple lymph 
nodes Figure 3c. Jejunal localization of lymphoma (arrowhead) and multiple lymph nodes. Figure 3d. Ileal 
localization (arrowhead).
Figure 2a. Transverse CT images of a RCD I patient 
demonstrate multiple small lymph nodes (arrowheads). 
Figure 2b. Transverse CT images in same patient. 
Thickening of the ileal wall (arrows) with infiltration of 
the mesenteric fat (*).
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Figure 5a. Coronal reconstructed image of RCD II patient demonstrating ascites and thickening of ileal loops 
(arrows). Figure 5b. Coronal reconstruction in (other) RCD II patient showing cavitation of lymph nodes and 
smaller non cavitated lymph nodes in combination with infiltrated mesenterial fat (arrows).
Figure 4a & b. Hyposplenism in RCD I patient demonstrated 
on axial image and coronal reconstruction.
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Results
CT findings of all patients included in the study are summarized in Table 1. Because of lack of 
intraluminal contrast or lack of distension of the small bowel loops, jejunal fold pattern could 
only be analyzed in 26 patients whereas ileal fold pattern could be assessed in 29 patients. 
Ten out of 26 (38%) patients showed a decreased number of jejunal folds, 16 (62 %) showed 
an increased number of folds. Ileal folds were found increased in 5 out of 29 (17%) patients 
and decreased in 24 (83%) patients. No significant difference was found in JFPR between who 
both groups. Small bowel dilatation ranged from 30-35 mm and was found in 11/46 patients 
in total (p=ns). Excess of air was not visible in 24/46 patients, mild in 13 patients, moderate in 
7 patients and severe in 2 patients in total. Fluid excess and flocculation were scored as none 
in 20 (43 %) patients, mild in 8 (17 %) patients, moderate in 12 (26 %) patients and severe in 
6 (13 %) patients. All findings were equally distributed between the groups. Increased wall 
thickness ranged from 4 to 11 mm in group I (mean 7.7 mm, median 7 mm) and from 5 to 15 
mm (mean: 9.6 mm, median 10 mm) in group II. Nine patients in group II showed a thickness 
of more than one cm versus only 4 in group I (p=ns). Intussusception was observed in only 1 
patient in group I, compared to 5 patients in group II (p=0.06). Only one patient (RCD II, 67 
years old male) showed a small amount of intra-abdominal fluid in the rectovesical pouch. 
Table 1. CT findings according to the groups. All signs are described by the number of patients affected and 
mentioned otherwise in case of deviation
CT findings CD & RCDI RCD II & EATL Total
Number of patients 24 22 46
Gender (F;M) 18;6 10;12 28;18
Mean age (years) 56 61 58
Jejunal/ileal fold ratio (No of folds/2.5cm) 4.5/3.0 3.7/2.9 4.1/3.0
JFPR 3 6 9
Bowel dilatation 5 6 11
Air excess 14 8 22
Fluid excess 12 14 26
Increased wall thickness 10 14 24
Intussusception 1 5 6
Ascites 0 1 1
Lymphadenopathy 0 5 5
Increased No of lymph nodes 16 12 28
Lymph node cavitation 0 1 1
Increased splanchnic circulation 20 11 31
Splenic vein thrombosis 0 4 4
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Enlarged lymph nodes were only found in 5 patients in group II (p = 0.013). Both groups 
showed an increase in non-enlarged lymph nodes (p=0.295). Only one lymph node showed 
cavitation (59 year old male with RCD II). 
An increase in the number of small mesenterial vessels was observed in 20/24 (83%) 
patients in group I vs. 11/22 (50%) patients in group II (p=0.02). The diameter of the superior 
mesenteric artery was measured in a total of 23 patients and this varied from 4-7 mm.
Splenic volume of all patients ranged from 37-321 cm3 (mean 162 cm3) in normal distribution. 
No significant differences were found between mean volumes in both groups I and II (178 
cm3 vs. 144 cm3). However, after allocating the patients into 3 arbitrary groups according to 
the splenic volume as shown in table 2, the RCD II and EATL group showed significant more 
patients with a smaller spleen than RCD I and uncomplicated CD (p = 0.028).
Table 2. Splenic volume according to the groups
Splenic volume (cm3) CD & RCDI RCD II &EATL All
Group A: 37-122 cm3 (n=15)  4  (27%)w  11 (73%)  15
Group B: 124-196 cm3 (n=16)  10  (63%)  6  (38%)  16
Group C: 196-321 cm3 (n=15)  10  (67%)  5  (33%)  15
Mean volume (cm3) 178 144 162
Discussion
In patients clinically suspected of having CD, biopsies are mandatory to confirm or exclude 
the diagnosis.18 In uncomplicated cases, radiological examination is not required. However, 
in clinical practice pre-malignant and malignant complications of CD have to be excluded in 
patients who have persistent complaints despite strict adherence to a GFD. Furthermore CT, 
performed in patients presenting with atypical abdominal symptoms, can suggest a diagnosis 
of CD.13 The most striking features found in CD are jejunoileal fold pattern reversal, small 
bowel intussusception, and benign mesenteric lymphadenopathy.7, 8, 9, 12, 13 However, to our 
knowledge, no discriminating findings between CD/RCD I and (pre)EATL have been decribed 
using CT.
Regarding jejunal and ileal fold abnormalities; especially jejunoileal fold pattern reversal and 
total loss of jejunal folds may be considered specific findings in CD.7, 12, 13 In our study, only 
in 52% (24 out 46 patients) both jejunal and ileal folds could be assessed because of lack 
of contrast or lack in distention of small intestinal loops, probably due to suboptimal bowel 
preparation because of progressive abdominal complaints. In only 9 out 24 (38%) patients 
a jejunoileal fold pattern reversal was observed. This is a low percentage compared to that 
reported by Tomei et al7, however we included a high percentage of patients with RCD I, 
RCD II and EATL. Furthermore, increased ileal folds, decreased jejunal folds, and jejunoileal 
fold pattern reversal were equally distributed between the subgroups, which demonstrate 
that the number of folds is not a good discriminator between both groups. 
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Transient intussusception of the small bowel was present in 5 patients in group II compared 
to one patient in group I (p=0.06). The majority of patients showed an increase in the number 
of nodes (<1 cm), which was not significantly unequally distributed between both groups 
CD. However, mesenteric lymphadenopathy (short axis > 1 cm) was only found in the (pre) 
EATL group, whereas cavitation, which is considered to be a rare complication associated 
with a poor outcome 22, 23, 24, was found in one patient with RCDII. In this patient additional 
examinations, including 18F-FDG-PET scan and laparascopic mesenteric lymph nodes 
resection, did not show any evidence of EATL. 
Regarding non-specific signs, bowel dilatation and excess of fluid (with flocculation of 
contrast) and air, 13,19 bowel dilatation and increased splanchnic circulation, as measured 
using the diameter of the superior mesenteric artery 2-3 cm distal to its origo, we found 
no significant differences between the two subgroups. However mesenteric vascularity, 
as measured using a semi-quantative scale, was significantly increased in group I. We 
hypothesize that this increase of small vessels and small lymph nodes in group I may be due 
to the acute inflammatory process in this group. Also no significant difference in number of 
patients with increased wall thickness was found. However more patients in group II showed 
a wall thickness of more than 1 cm (p = ns).
Splenic atrophy occurs frequently in patients with CD and is related to the severity of the 
disease and degree of dietary control and shows a significant correlation with an impaired 
function with the incidence rising with increasing age of starting treatment.26 Although no 
correlation was observed in literature between splenic size and the duration of the GFD as 
well as the percentage of splenic size recovery after gluten withdrawal, hyposplenism in 
adult CD was improved by a GFD.27 Furthermore regarding group II, hyposplenism was not 
related to the development of malignant disease in small samples.28 In this study however, 
significantly more patients in the RCD II/EATL group showed a smaller splenic size.
In conclusion, both groups showed classic signs of CD on CT. Though small groups were 
analysed, group II showed more bowel wall thickening, lymphadenopathy, intussusception 
and more hyposplenism and less increase in splanchnic circulation than group I. Therefore, we 
conclude that bowel wall thickening, lymphadenopathy, intussusception and hyposplenism 
should raise suspicion for RCD II and the development of EATL
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Abstract
Background: Refractory Coeliac Disease (RCD) may be subdivided into RCD-I and type II 
with phenotypically normal and aberrant intraepithelial T-cell population respectively. In 
RCD-II transition into Enteropathy Associated T-cell Lymphoma (EATL) is frequently seen. We 
have evaluated the effect of cladribine (2-CDA), a purine analogue inducing T-cell depletion, 
on clinical, histopathological and immunological parameters as well as the toxicity and side 
effects in a group of RCD II patients.
Methods: Between 2000 and 2005, 17 patients were included (8 Males/9 Females). All 
patients had a clonal rearrangement of the TCRγ gene and immunophenotyping showed 
an aberrant T-cell population lacking surface expression of CD3, CD8 and TCR-αβ, in the 
presence of expression of surface CD103 and intracytoplasmic CD3. Treatment consisted 
of 2-CDA (0,1 mg/kg/day) intravenously for 5 days, given in 1-3 courses every 6 months 
depending on the response. 
Results: All patients tolerated 2-CDA without serious side effects. Six patients (35.8%) showed 
a clinical improvement (weight gain, improvement of diarrhoea and hypoalbuminemia). 
In 10 patients (58.8%) a significant histological improvement and in 6 patients (35.2%) a 
significant decrease in aberrant T-cells was seen. Seven patients (41.1%) developed EATL and 
died subsequently. One patient died from progressive refractory state with emaciation. 
Conclusions: 2-CDA-treatment in RCD type II is feasible, well tolerated and can induce 
clinical and histological improvement as well as a significant decrease of aberrant T-cells in a 
subgroup of patients, albeit does not prevent EATL-development. However, the earlier reported 
potential risk of precipitating an overt lymphoma should be taken in consideration.
Introduction
In a subgroup of patients with coeliac disease (CD) the clinical features and histological 
abnormalities persist or recur after initial improvement despite strict adherence to a gluten 
free diet (GFD). This syndrome is classified as “Refractory Coeliac Disease” (RCD), when other 
causes of malabsorption with a flat mucosa, such as tropical sprue, bacterial overgrowth, 
giardiasis, autoimmune enteropathy, eosinophilic enteritis, hypogammaglobulinemic sprue, 
intestinal lymphoma and carcinoma are ruled out.1 The prevalence of RCD is estimated to 
be 2-5% of all coeliacs diagnosed as adults.2, 3 In follow-up of these RCD patients a high 
incidence of enteropathy associated T-cell lymphoma (EATL) is reported (60-80% within 5 
years).4 
The small bowel mucosal inflammation in CD consists of lymphocytic infiltration of the lamina 
propria, expansion of the intraepithelial lymphocyte population, hyperplasia of the crypts 
and atrophy of the villi. In patients with CD there is ample evidence that strict adherence to 
GFD results in a decrease of chronic intestinal inflammatory activity.5 In RCD the number of 
intraepithelial lymphocytes (IEL) is markedly raised and it is from these IEL’s that EATL may 
arise.6, 7 Immunophenotyping of the IEL’s identifies two groups of RCD patients: those with 
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normal IEL’s (RCD I) and those with aberrant monoclonal IEL’s (RCD II).1, 2, 6, 7 The former 
group seems to have a low incidence of EATL and has a good response to azathioprine/ 
prednisone therapy.1 The latter group (RCD II) is usually refractory to any known therapy, 
including azathioprine/prednisone, cyclosporine and IL 10 therapy.1, 3, 7-11 In our population 
of RCD II patients the majority of patients developed EATL and died, despite chemotherapy 
with Cyclophosphamide, Adriamycin, Vincristine and Prednisone (CHOP).12 Therefore, we 
evaluate new treatment strategies for these RCD II patients before they develop overt EATL. 
Recognizing that some patients with RCD-II, and especially with ulcerative jejunitis are 
suffering from a low-grade EATL, we propose that these patients need to be treated with 
cytotoxic chemotherapy. Cladribine (2-Chlorodeoxyadenosine,2-CDA) is a synthetic purine 
nucleoside with cytotoxic activity. It is probably transformed by deoxycytidine kinase to 
cladribine triphosphate in cells with high levels of this enzyme, such as lymphocytes and 
monocytes.13 Accumulation of intracellular cladribine triphosphate causes cell death. 
Cladribine is of proven value in the treatment of Hairy Cell Leukaemia.13 Pathological cells in 
Hairy Cell Leukaemia are CD103 positive as in T-cells in RCD II.12 In the past few years clinical 
trials with 2-CDA have confirmed its effectiveness in selected autoimmune disorders.14, 15
2-CDA has a relatively low toxicity profile. Haematological toxicity consists of transient 
monocytopenia, prolonged and profound lymphopenia (especially of CD4-positive cells), 
and modest lowering of the platelet count and granulocyte count and of haemoglobin, with 
development of long-lasting macrocytes.16 
We evaluated the clinical efficacy and tolerance of 2-CDA in a group of RCD II patients as 
well as its effect on histopathological and immunological parameters.
Patients and Methods
This study was performed as an open-label prospective phase II pilot study. Between January 
2000 and April 2005, 17 patients with RCD II were included (8 males, 9 females, mean age 
63.9 years (range 54-76). They were referred for treatment to 2 tertiary referral centres for CD 
in the Netherlands- the Rijnstate Hospital in Arnhem and the VU University Medical Centre 
in Amsterdam. 
Diagnosis of RCD II and EATL
The diagnosis RCD II was based on clinical relapse or persisting malabsorption after at least 
a year of strict adherence to GFD and histopathology showing at least partial villous atrophy 
(Marsh IIIA, B, C, or ulcerative jejunitis) after excluding other causes of villous atrophy.2, 6, 16 
Immunophenotyping by T-cell flow- cytometry showed aberrant T-cell populations (surface 
CD3 negative, CD8 negative, CD30 positive and intracytoplasmatic CD3 positivity) of ≥ 25% 
of IEL.18, 19, 20 All patients had a clonal rearrangement of the TCRγ gene (see below). 
In those patients who developed or died from EATL, the diagnosis was established according 
to the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.21 
The immunohistochemical features of EATL are evidence of large or medium size T-cell 
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proliferation expressing a CD3+ CD8+/- and CD103+. All those who developed EATL had 
CD3+ CD8- CD30+ large cell lymphoma. 
Inclusion
Patients included were only those with aberrant T-cells ≥ 25% of IEL’s. The presence of EATL 
or other malignancies has been excluded using radiological (small bowel follow through, 
computed tomography (CT scan) scanning of thorax and abdomen and whole body positron 
emission tomography (PET scan),22, 23 endoscopic [ upper gastrointestinal endoscopy, video 
capsule endoscopy (VCE) and/or double-balloon enteroscopy (DBE)], as well as bone marrow 
aspirates.16 Those diagnosed in 2003 or earlier had negative small bowel follow through and 
CT scan (8 patients), while those diagnosed after 2003 had negative CT scan, PET,VCE and 
DBE (9 patients).
All patients had WHO performance status 0-1.24 Most of the patients had formerly been 
treated with prednisone for months before inclusion which was stopped before treatment 
with 2-CDA. Other immunomodulatory drugs were not allowed. 
Exclusion
Patients were excluded: if they had a history of any type of malignant disease; if they were 
known to have serious cardiovascular, renal disease or active infection; if abnormalities were 
found on imaging, endoscopy, histology and or bone marrow examination suggestive of 
malignant lymphoma; when having haemoglobin level < 5.0 mmol/l, WBC < 4000 /mm3, 
Platelets < 100,000 /mm3;female patients who are pregnant or breast feeding; serum anti-
HCV positive, serum HBsAg positive, serum anti-HIV positive; cyclosporin therapy in the last 
6 months; or the use of any experimental drug within 30 days of study entry. 
Assessment
Patients were evaluated two weeks before treatment, including clinical evaluation, laboratory 
tests, endoscopy, histopathology/ immunophenotyping of IEL, TCR gene rearrangement 
study, CT scanning of the abdomen and thorax, whole body PET scan and bone marrow 
aspiration. Body mass index (BMI), haemoglobin (Hb) and albumin were used as clinical 
malabsorption parameters and evaluated prior to treatment and at weeks 12, 24 and 48. 
HLA-DQ status of all patients was determined using Polymerase Chain Reaction (PCR) typing 
method.25 Similarly, serological tests including anti-endomysium antibodies and anti-tissue 
transglutaminase (anti-tTG) were performed at weeks 0, 24, 48. 
Small bowel biopsies
Upper gastrointestinal endoscopy was performed in all patients. At least 10 duodenal biopsies 
were taken for histological, immunohistochemical and flow-cytometric examination. 
Four to six biopsies were fixed and preserved in 10% formalin for histopathological and 
immunohistochemical evaluation. Three-4 biopsies for TCR gene rearrangement studies were 
taken separately, preserved on histocon and frozen at -20°C.26 For immunophenotypical 
evaluation 3-4 biopsies were taken and preserved in RPMI medium.
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Isolation of IEL and cell-staining for immunophenotyping
IEL and enterocytes were isolated from 3-4 small bowel biopsies (SIBs) by homogenising 
tissue samples and passing fragments through 100µm nylon sew (Becton Dickinson®, Cell 
strainer) in RPMI medium supplemented with 1% FCS. The released cells were subsequently 
washed and labelled by 4-color staining for 30 minutes on ice with various combinations of 
fluoescein isothiocyanate, phycoerythrin, peridinin chlorophyll protein and allophycocyanin 
labelled monoclonal antibodies against CD3, CD4, CD8, CD7, CD103, CD19, CD16/56, 
γδTCR and cytoplasmic CD3. The FACS method used in this study was in accordance with 
the manufacturer’s guidelines.
Cell surface immunophenotyping of IEL was performed on a 4 colour FACS Calibur flow 
cytometer (Becton Dickinson, BD, immunocytometry systems, San Jose, CA). Nonviable 
cells and debris were excluded based of forward and sideward light scatter properties and 
a gate on CD45 positive cells was used for selecting lymphocytes from all epithelial cells. 
Intraepithelial localisation of lymphocytes was confirmed by surface expression of CD103 
(αeβ7 integrin, a homing receptor). IEL’s were analysed, using CellQuest tm (KS Stat) based on 
their expression of cell markers: cytoplasmic CD3, surface CD3, CD4, CD7, CD8, CD16/56, 
CD19, CD103 and TCRγδ on CD45+gated IEL’s.18, 19, 20
Assessment of TCR gene rearrangement by Polymerase Chain Reaction (PCR)
DNA was extracted from cryosections of duodenal biopsies by a standard procedure using 
proteinase-K digestion and ethanol precipitation of the genomic DNA. T-cell receptor (TCR-
γ) gene rearrangements were analysed by multiplex PCR amplification under standarized 
conditions. Monoclonal and polyclonal controls were included in each experiment. Clonality 
assessment for TCR-γ gene rearrangements was done using the BIOMED-2 multiplex TCR 
PCR protocol.26-30 
Study protocol
Patients were hospitalized, and 2-CdA was given (0,1 mg/kg) intravenously for 2 hours daily 
for 5 days. Cotrimoxazole, 960 mg (gluten free suspension) orally two times daily and for two 
days a week starting at week 0 until 6 months after 2-CDA therapy, was used as prophylaxis 
against pneumocystis pneumonia. When indicated, patients had supplemental folic acid, 
vitamin B12 and/or iron. 
Ethical approval and informed consent
Approval for the study protocol was obtained from the local ethics committee, and all patients 
gave written informed consent.
Assessment of response
The patients were seen and evaluated at the outpatient clinic at weeks 4, 8, 12, 24 and 48. 
Upper gastrointestinal endoscopy and small bowel biopsies were taken at weeks 12 and 48 
after therapy. 
Primary efficacy parameters of the study were: clinical improvement; change of histopathology 
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in the small bowel (modified Marsh classification) analyzed in 4 specimens taken from the 
distal duodenum 6 and decrease of aberrant IEL’s of the small bowel. 
Clinical improvement was defined as disappearance of diarrhoea, improvement in the 
performance status according to the WHO scale, and at least 2 of the following three criteria: 
an increase of BMI >1 point; an increase in albumin level >10% of the baseline level and an 
increase of Hb >1 point.
A decline of ≥ 20% in the percentage of aberrant T-cells was regarded as significant.
Secondary efficacy parameters were: EATL development and mortality.
Safety parameters were registered, haematological as well as non-haematological laboratory 
data, febrile and infectious episodes, bleeding events and the need for transfusion of blood 
products.
Results
Table 1 shows the clinical and laboratory characteristics of the treated patients at baseline 
and 12 weeks after completing the first treatment course. Ten out of 17 (58.8%) patients were 
homozygous for HLA-DQ2 haplotype, 7 (41.2%) were DQ2 heterozygous.31
Side effects of treatment
All patients tolerated the 2-CDA treatment without significant adverse events. Three patients 
had nausea and vomiting, one developed diarrhoea, and one bronchitis. No significant 
haematological side effects were noted (table 2); particularly no significant lymphopenia, 
monocytopenia or anaemia requiring transfusion was reported.
Response to treatment:
All patients received 1 courses of therapy. Patients who had a clinical, histological and/or 
immunogical response received additional second course (6 patients) or third 2-CdA course 
(7 patients). The mean follow up period was 22 months (range 7- 67 months). The mean 
body mass index of all patients increased from 20.6 (±SD =2.12) to 21.2 (±SD =3.14) kg/m2. 
The mean albumin level increased from 30.0 (±SD=7.20) to 33.7 (±SD=7.49) g/l. The mean 
haemoglobin level remained unchanged 7.65 (±SD=1.35).
Table 3 shows the clinical condition and response of the patients on follow up 12 weeks after 
completing the first treatment course.
Clinical response
Six of 17 patients (35.8%) showed a clinical response, including weight gain and improvement 
of diarrhoea and hypoalbuminaemia. Two patients (10.5%) showed no improvement in their 
clinical condition and remained emaciated. Seven patients (41.1%) developed EATL (6 
months –38 months, mean 14 months) after the start of treatment and subsequently died. One 
patient (patient no.1) died from bronchiectasis caused by persisting postnasal discharge in 
association with EATL localization in the paranasal sinuses (>90% aberrant T-cells). Another 
patient (no.3) died from progressive refractory state with emaciation.
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Table 1. The characteristics of the patients. All patients had a clonal rearrangement of the TCRγ gene on TCRγ-
PCR analysis
Pa
tie
nt
s
Sex Age
HLA-
DQ Age    BMI Albumin     Hb    SIB
%Aberrant  
    T-cells
 CD RCD S E S E S E S E S E
1 F 54 DQ2 
homo
45 46 22 22 27 35 7.6 6.6 IIIC IIIA 73 43
2 M 69 DQ2 
homo
62 64 21.4 26 26 34 9.7 9.1 UJ IIIB 45 43
3 M 70 DQ2
homo
59 63 17.8 18 20 18 6.5 6.0 UJ IIIA 92 90
4 F 71 DQ2
homo
58 59 25.5 25.6 19 22 6.6 6.7 IIIB IIIA 90 91
5 M 66 DQ2
heter
58 59 23.6 23.8 34 40 10 9.5 IIIC IIIC 88 90
6 M 65 DQ2 
homo
60 61 17.3 17.6 16 29 6.7 6.7 IIIA IIIA 90 73
7 M 61 DQ2
homo
55 59 21.5 22.5 32 35 7.8 8.2 IIIC IIIC 33 4
8 M 61 DQ2
homo
56 59 20 21 34 39 8.7 8.8 IIIA IIIA 98 40
9 F 63 DQ2 
homo
59 60 18.7 19.8 40 46 8.9 9.8 IIIC I 70 15
10 F 64 DQ2 
heter
62 63 19.3 20.2 29 35 6.0 8.0 UJ IIIA 40 60
11 M 63 DQ2 
homo
59 63 23.4 24 36 40 8.7 9.4 IIIA IIIA 70 70
12 M 67 DQ2  
homo
66 67 22 23 30 38 6.6 5.7 IIIC II 40 40
13 F 76 DQ2
 heter
75 76 13.8 13.5 34 30 5.6 6.8 IIIC IIIA 94 94
14 F 58 DQ2 
heter
46 56 19.4 19.5 40 43 7.6 7.7 UJ IIIB 82 35
15 F 63 DQ2
 heter
56 58 20 20 23 30 6.2 6.5 IIIA IIIB 88 55
16 F 65 DQ2 
heter
63 64 22.5 22.8 35 35 9.1 8.0 IIIA IIIC 30 60
17 F 58 DQ2
heter
47 58 22.1 21 35 24 7.8 7.2 UJ IIIC 70 60
M=male, F=female, SIB=small bowel biopsy according to Marsh classification, S =before treatment, E= after treatment, 
BMI=body mass index (Kg/m2), Hb=haemoglobin mmol/l, albumin in g/l, UJ= ulcerative jejunitis.
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Table 2. Haematological parameters at baseline and at follow up after the first course of therapy
Parameters At baseline, mean (±SD) At follow up, mean(±SD)
Haemoglobin (mmol/L) 7.65 (1.35) 7.69 (1.29)
MCV *(FL) 85 (6.3)) 92 (6.9)
Leucocytes 7.27 ×109 /L (1.85) 7.07 ×109 /L (1.48)
Neutrophils 56% (12.0) 60% (13.0)
Lymphocytes 19.5 % (10.2) 21.7% (7.68)
Monocytes 7.9% (5.8) 8.2% (6.00)
Platelets 334×109 /L (94.9) 296×109 /L (89.5)
*MCV= Mean corpuscular volume 
Table 3. Condition of the patients on follow up after completing treatment
Pa
tie
nt
s
Survival 
(months) Status on follow up Cause of death Date ASCT
1 24 Died EATL, localization in the 
paranasal sinuses with 
bronchiectasis
-
2 67 Improved clinically and histologically - August 2004
3 34 died Progressive refractory 
state with emaciation
-
4 23 Died EATL -
5 38 Died EATL -
6 15 Died EATL -
7 22 Clinically stable - -
8 22 Clinically stable - March 2003
9 24 Complete remission - -
10 11 Clinically stable, improved histologically - April 2005
11 12 Clinically stable - August 2005
12 6 Died EATL -
13 7 Died EATL -
14 44 Clinically stable, histologically improved - November 2005
15 5 Died EATL - 
16 14 Clinical and histological deterioration Unsuccessful (CD34) leukopheresis. Unsuccessful 
treatment with alemtuzumab (Mabcampath)
17 10 Clinically stable, histologically improved - December 2005
ASCT= Autologous Haematopoietic Stem Cell Transplantation.
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Histological response
Ten patients (58.8%) showed improvement of the histological status including the 
disappearance of ulcerative jejunitis in all 5 patients (29.4%) who initially presented with 
this disease state (Patients 2, 3, 10, 14 and 17). Patient number 9 had complete clinical and 
histologic recovery (Marsh classification M-IIIC to M-I) and remained symptom free during 
3 years of follow up. Five patients (29.4%) had no change in the histology status and two 
patients deteriorated histologically (patients 15, 16). 
Immunological response
The mean percentage of aberrant T-cells changed from 72.7% (SD=23.3) at baseline to 57.7 
% (SD= 26.9) thereafter. In six patients (35.2%) a significant decrease in aberrant T-cell 
percentages was seen (≥20%). Two patients (patients 10 and 16) had a significant increase in 
aberrant T-cell percentages. 
Development of EATL
Concerning the 7 patients who developed an EATL and died: patient no.1 had a significant 
decrease of aberrant T-cell percentages (from 73% to 43%); patient no. 4 had a histological 
improvement but unchanged high percentages of aberrant T-cells (>90%); patient no. 5 
showed unchanged study parameters with high percentages of aberrant T-cells (>90%); patient 
no. 6 showed no significant change in study parameters although a decrease of aberrant T-
cell percentages was seen (from 90% to 73%); patient no.12 showed a clinical improvement 
and histological normalization of villi, but aberrant T-cell percentages remained unchanged 
(40%); patient no.13 had a histological improvement, but unchanged high percentages 
of aberrant T-cells (>90%); patient no. 15 showed a significant decrease of aberrant T-cell 
percentages (from 88% to 55%). All EATL’s were of the CD3+ CD8- CD30+ large cell type. 
Discussion
Closer investigation of refractory coeliacs suggests two subgroups, involving patients with and 
without aberrant, T-cell lines in the small bowel mucosa. Particularly patients with aberrant T-
cells (RCD type II) seem to be at high risk of developing an EATL and subsequent death.1, 2,7,14 
As the outcome of disease in patients with EATL is usually very poor, despite chemotherapy, 
it seems obvious that clinical focus should be on earlier diagnosis and intervention before 
progression to overt malignancy. The association between CD and malignancy is long 
established. The most frequent malignant complication is EATL.2,4,25 Most patients with EATL 
present with malaise, anorexia, weight loss and diarrhoea. A substantial number require 
diagnostic and sometimes therapeutic laparotomy to deal with complications such as 
perforation or obstruction.12
Earlier studies on treatment of RCD showed that steroids, cyclosporine and IL-10 had no 
effect on outcome in RCD II patients.1, 3, 7-11, 32-36 Table 4 summarizes the results of earlier 
reports on therapies in RCD patients. However, positive results in some of these studies can 
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not be adequately interpreted because no distinction has been made between RCD I and 
RCD II. Maurino et al 32 reported the results of treating 7 RCD II patients with azathioprine. 
Clinical and histologic improvement was noted in 5 of 7 treated patients, although 3 patients 
died (one from leucopenic fever and 2 died early). However, in their follow up report on 
treating 13 patients with azathioprine, they reported 46% mortality.33
Table 4. Summery of therapies on refractory coeliacs
Therapy/Reference Type of report Total Type RCD Results
Cyclosporine 8 Case report 1 (2 yrs old) ND Initial improvement, relapse after stopping 
treatment
Cyclosporine 9 Case report 1 ND Remission
Cyclosporine/ 
Azathioprine 34
Case report 1 ND Short term improvement
Azathioprine 35 Case report 1 ND Steroid tapering, died from infection 
Cyclosporine 10 Open- label 13 ND Clinical & histologic improvement (61%)
Interleukin 10 11 Open -label 10 ND Inconsistent response
Azathioprine 32,33 Open-Label 
prospective 
7 Yes Short term clinical and histologic 
improvement in 5 of 7 treated patients. 
Three died (one leucopenic fever). Long 
term follow up 46% mortality
Prednison/  
Azathioprine 1
Open-label 10 RCD/ 
8 RCD II
Yes 7 of 8 RCD II died (6 from EATL), while 
10/10 RCD I have long term survival
Infliximab 36 Case report 1 ND Remission
One recent report on using the anti-tumour necrosis factor (anti-TNF) agent Infliximab in 
treating RCD has been published, but again no data were provided on aberrant T-cells (T flow-
cytometry or immunohistology).36,37 In the present study, 2-CDA therapy was well tolerated 
without serious side effects. Six of 17 patients (35.8%) responded with clinical improvement 
and another 6 had a significant decrease in aberrant T-cell percentages. 
Interestingly, one of our patients developed a complete clinical, immunological (aberrant T-
cells percentage decreased from 70% to 15%) and histologic recovery (Marsh classification 
M-IIIC to M-I) and remained symptom free during more than 4 years of follow up. Furthermore, 
ulcerative jejunitis, an endoscopic feature of RCD-II, was seen to disappear in the 5 patients 
(29.4%) who had it initially and interestingly none of these 5 patients thus far developed 
EATL. 
Seven patients (41.1%) developed EATL within 6-38 months after starting treatment, 
subsequently died despite multi-agent chemotherapy (CHOP). Although EATL has been 
adequately been excluded at inclusion, three patients died of EATL within 5-7 months 
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after therapy. Whether 2-CDA has accelerated the development of lymphoma or not can 
not be confidently concluded. Few cases of secondary malignancies after 2-CDA through 
T-cell immunodepression have been reported.38 All our EATL- patients had a CD3+, CD8-, 
CD30+ large cell lymphoma. We might expect that patients who present with a surface CD3-, 
cytoplasmic CD3+, CD8+ and CD30- aberrant T-cells clone will develop a CD3+, CD8+, CD30- 
small cell lymphoma.12 
Therapy with 2-CDA, thus, seem to have a role, although based on our data less than optimal 
in the treatment of RCD with aberrant T-cells. It may be considered however as the only 
treatment thus far studied that demonstrated significant reduction of aberrant T-cells, seems 
to be well tolerated and may have beneficial long term effects in a subgroup of patients 
demonstrating significant reduction of the aberrant T-cell population. 
However, a search for a more successful treatment is strongly needed. Encouraging reports 
have been published on the effectiveness of high dose chemotherapy followed by Autologous 
Haematopoietic Stem Cell Transplantation (ASCT) in the treatment of patients with severe 
autoimmune disease refractory to conventional treatment.39 Therefore, seven of the treated 
patients have been included in an ASCT program in our institution.40
In conclusion, 2-CDA is successful in a minority of RCD II patients. It remains to be seen 
whether more intensive treatment (like ASCT) would be helpful in 2-CDA resistant or partially 
responsive RCD II patients. Furthermore, we think that a likely future indication for the use 
of 2-CDA in RCD-II may be stabilization of the clinical condition of patients as a bridge to 
ASCT.
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Abstract
Background and aim: Autologous Haematopoietic Stem Cell Transplantation (ASCT) is an 
increasingly accepted treatment for refractory autoimmune diseases. Refractory Coeliac 
Disease with aberrant T-cells (RCD-type II) is unresponsive to available therapies and carries 
a high risk of transition into Enteropathy Associated T-cell Lymphoma (EATL). This study 
reports on the feasibility, safety and efficacy of ASCT in RCD type II.
Methods: Thirteen patients with RCD-II were evaluated. Seven patients [4M, 3 F, mean age 
61.5 years (range 51-69 years)] were transplanted. After conditioning with fludarabine and 
melphalan, ASCT was performed. Patients were monitored for response, adverse effects and 
haematopoietic reconstitution. 
Results: All 7 patients completed the mobilization and leucopheresis procedures successfully 
and subsequently received conditioning and transplantation. Engraftment occurred in all 
patients. No major non-haematological toxicity or transplantation-related mortality was 
observed. There was a significant reduction in the aberrant T-cells in duodenal biopsies 
associated with improvement in clinical wellbeing, and normalization of haematological 
and biochemical markers (mean follow-up 15.5 months, range 7-30 months). One patient 
died 8 months post-transplant form progressive neurocoeliac disease.
Conclusions: These preliminary results showed that high-dose chemotherapy followed by 
ASCT seems feasible and safe, and might result in long-term improvement of RCD II patients 
whose condition did not respond promptly to available drugs.
Introduction
Autologous Haematopoietic Stem Cell Transplantation (ASCT) is an increasingly accepted 
effective treatment option for patients with severe autoimmune diseases refractory to 
conventional treatment 1 and has been used successfully in patients with multiple sclerosis,2 
rheumatoid arthritis,3 systemic sclerosis 4, systemic lupus erythematosus 5 and Crohn’s 
disease.6 The rationale for this strategy is based on the concept of immunoablation by intense 
immunosuppression using high dose chemotherapy, with subsequent regeneration of naïve T 
lymphocytes derived from reinfused haematopoietic progenitor cells.7 
In coeliac disease (CD), HLA-DQ molecules bind and present gluten peptides to antigen-
specific T-cells. These HLA-DQ-peptide complexes induce inflammatory responses in the 
small intestine consisting of lymphocytic infiltration of the lamina propria, expansion of the 
intraepithelial lymphocyte population, hyperplasia of the crypts and atrophy of the villi.8 In 
a small percentage (2-5%) of coeliac disease patients diagnosed as adults a refractory state 
develops despite strict adherence to a gluten-free diet (GFD).9 In refractory coeliac disease 
(RCD) the number of intraepithelial lymphocytes (IEL) is markedly raised and it is from these 
IEL’s that enteropathy associated T-cell lymphoma (EATL) may arise.9,10 Immunophenotyping 
of the IEL’s identifies two groups of RCD patients: those with normal IEL’s (RCD I) and those 
with aberrant IEL’s, lacking surface expression of CD3 and CD8 (RCD II).10,11 RCD II can be 
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regarded as a ‘cryptic’ lymphoma.9 There is now strong molecular and immunophenotypic 
evidence showing that a monoclonal neoplastic T-cell population may emerge from IEL’s in 
RCD. Clonal expansion of this monoclonal T-cell population eventually leads to frank EATL. 
The genesis and expansion of these monoclonal T-cells involve both inappropriate immune 
responses to gluten and acquisition of genetic abnormalities. Although the monoclonal 
IEL’s in patients with RCD are neoplastic, they are not cytologically abnormal and do not 
form tumour masses which differentiate these patients from EATL patients, in addition to the 
absence of radiological and bone marrow evidence of lymphoma.10,12,13,14
RCD II is usually resistant to any known therapy, including azathioprine/prednisone, 
cyclosporine and IL-10 therapy 15-18 and has a high risk of developing EATL (60-80% within 
5 years).10,19 This specific type of peripheral T-cell lymphomas has a very poor outcome with 
1- and 5-year survival rates in the range of 31-39% and 11-20% respectively.19,20,21 In a 
prospective multicentre study of 35 patients with EATL treated with six cycles of CHOP 
(Cyclophosphamide, Doxorubicine, Vincristine and Prednisone), the cumulative 2-year 
survival was only 28%.11 Therefore, new treatment strategies for patients with ‘’premalignant’’ 
CD (RCD-II) are urgently needed to improve their clinical condition with the ultimate goal of 
resetting the immune response which might prevent or delay development of overt EATL. 
This study reports on the feasibility, safety and efficacy of high dose chemotherapy followed 
by ASCT in patients with RCD type II.
Methods
Patients
Between March 2004 and March 2006 thirteen patients were evaluated for ASCT. Seven 
patients [4 males, 3 female, mean age 61.5 years (range 51-69 years)] with RCD-II underwent 
ASCT. Six other patients were excluded because of the presence of coexistent coronary 
artery disease and heart failure (NYHA classification III) (two patients), EATL found on pre-
transplantation evaluation (3 patients), and low performance status (one patient). One patient 
could not be treated due to unsuccessful leucophaeresis; she developed EATL and died 
subsequently despite chemotherapy and immunotherapy with antiCD52 (Alemtuzumab).22
The 2 patients with congestive heart failure died from: progressive disease, cachexia (one 
patient) and bronchiectasis (second patient). The 3 patients with EATL all died within few 
months, while the patient with low performance status died from cachexia. 
The baseline characteristics of the patients are shown in table 1. All patients received therapy 
with prednisone and cladribine (2-CDA) several months before receiving ASCT (not within 6 
months of transplantation). 
The first 3 patients (patients A, B and C) were diagnosed with CD at relatively advanced 
age, had persistent diarrhoea, weight loss and failed to respond to GFD, steroids and 
immunosuppressives. Because of the presence of active disease and high percentage of 
aberrant T-cells in the small bowel mucosa, they were included in this study protocol. Patient 
D was diagnosed with CD at the age of 48 years in association with dermatitis herpetiformis. 
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Furthermore, he had a clinical picture of neurocoeliac disease with ataxia. After exclusion of 
structural brain and infectious disorders, he received ASCT at the age of 63.5 years. 
Patient E has, in addition to CD with ulcerative jejunitis, Hashimoto’s thyroiditis, while patient 
F has CD with ulcerative jejunitis.
One patient (patient G) was included because of the presence of very extensive ulcerative 
jejunitis with multiple small bowel strictures necessating repeated resections although initially 
biopsies showed a low percentage of aberrant T-cells. He had clinically short bowel syndrome 
(remaining small bowel approximately100-150 cm) requiring total parenteral nutrition. 
Criteria for diagnosis of RCD
Patients with CD were considered to be refractory when symptoms of malabsorption due to 
villous atrophy persisted or recurred after a former good response despite strict adherence to 
a GFD for at least one year. Furthermore, possible underlying diseases such as autoimmune 
enteritis, bacterial overgrowth, giardiasis, amyloidosis, intestinal lymphangiectasia, Whipple’s 
disease, hypogamma-globulinaemia, eosinophilic enteritis, EATL and inflammatory bowel 
disease were excluded.11 The diagnosis of RCD was established as type II when ≥ 20% 
aberrant T-cells were present.10,11,15 
Inclusion criteria
Patients were only included when the diagnosis of true RCD with aberrant T-cells was 
confirmed (except one patient (patient G) was included on the basis of extensive ulcerative 
jejunitis with short bowel syndrome despite having only 10% aberrant T-cells), after verifying 
their strict adherence to a GFD, performance status according to the WHO criteria needed 
to be 0-2, if there was no severe concomitant cardiac, pulmonary, renal or hepatic disease. 
EATL was excluded by endoscopic examination with multiple biopsies, CT-scan, PET and a 
trephine bone marrow biopsy. Furthermore, neither active uncontrolled infection nor HIV 
positivity was permitted. 
Evaluation
Before proceeding to ASCT, the patients were extensively evaluated as to their performance 
status, the presence of concomitant diseases and extraintestinal disease or EATL. 
This evaluation included:
–  Clinical assessment noting particularly signs and symptoms of malabsorption, body mass 
index (BMI) and performance according to the WHO score, 23 
–  Evaluating the adherence to a GFD: Frequent consultation with dietician (advice and 
follow up); in addition to checking serology (anti-endomysium (EMA) and anti-tissue 
transglutaminase-antibody (anti-tTG), both of which usually revert to negative after strict 
adherence to the GFD,
–  Endoscopic evaluation by upper gastrointestinal (UGIE), video capsule endoscopy (VCE) 
and double-balloon enteroscopy (DBE). Duodenal biopsies (4 biopsies) were classified 
according to the modified Marsh criteria.24, 25 T-cell Receptor (TCR-) gene rearrangement 
study, 12, 13, 14 T-cell flow-cytometry and IEL phenotyping were performed, 15, 26, 27
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–  Laboratory evaluation: whole blood cell counts, serum levels of creatinine, bilirubin, 
liver enzymes, lactate deydrogenase, albumin, electrolytes, iron, ferritin, folic acid and 
vitamin B12. Anti-endomysium (EMA) and anti-tissue transglutaminase-antibody (anti-
tTG) assays, HLA-DQ typing, thyroid function tests, stool examination for Giardia and 
other parasites and HIV serology were also performed.28
–  Radiological evaluation: the patients underwent whole body computed tomography (CT-
scan), whole body positron emission tomography (PET) to exclude intestinal and extra-
intestinal localization of EATL.29, 30 
Immunophenotyping of IEL’s
IEL’s were isolated from 3 duodenal biopsies by passing them through nylon filters (1x100µm, 
1x 40µm, BD Falcon). Cells were stained with fluorescent labeled monoclonal antibodies to 
CD3, 7, 8, 45, 103, and TCRγδ, as well as with relevant isotype controls.
All monoclonal antibodies were from BD Falcon (BD biosciences, CA USA), except for 
CD103, which was from IQ-products, Groningen, The Netherlands) and analyzed by 4-color 
flow-cytometry (FACS-Calibur, BD). Leucocyte common antigen (CD45) was always included 
to identify the lymphocyte population. In some tubes cell surface CD3 staining (anti-CD3-
APC) was followed by permeabilization (Cytofix /cytoperm, BD Biosciences Pharmingen, CA 
USA) and subsequent cytoplasmic staining with anti-CD3-FITC or isotype control. 
Aberrant T-cells were defined either as CD7+ surface CD3- cells (expressed as % of CD103+ 
lymphocytes) or as cytoplasmic CD3+, surface CD3- cells (expressed as % of CD103+ 
lymphocytes).12, 26
All flow-cytometry analyses were performed by an analyst and interpreted by the same 
medical immunologist, while histopathology was performed by the same pathologist to 
ensure uniformity, reproducibility and consistency of results. 
Assessment of TCR gene rearrangement by Polymerase Chain Reaction (PCR)
T-cell receptor-gamma (TCR-γ) gene rearrangements studies were performed in separate 
three-four duodenal specimens that were preserved on histocon and frozen at -20°C. 
DNA was extracted from cryosections of duodenal specimens by a standard procedure 
using proteinase-K digestion and ethanol precipitation of the genomic DNA. TCR-γ gene 
rearrangements were analyzed by multiplex polymerase chain reaction (PCR) amplification 
under standardized conditions. A monoclonal and polyclonal control was included in 
each experiment. Clonality assessment for TCR-γ gene rearrangements was done using the 
BIOMED-2 multiplex TCR PCR protocol.12, 13, 14
Peripheral blood stem cells mobilization and collection
Mobilization of haematopoietic progenitor cells from the bone marrow into the peripheral 
blood was achieved using granulocyte-colony stimulating factor (G-CSF) 2×5 µgm/kg by 
subcutaneous injection for at least four days. Haematopoietic stem cells were harvested from 
the peripheral blood by leucopheresis and kept frozen until ASCT. The target CD34+ count 
was > 2×106/kg. 
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Conditioning and ASCT
The conditioning regimen consisted of fludarabine given orally for five days (40 mg/m2/day) 
and melphalan (intravenous, two days 70 mg/m2/day) (Figure 1). At day 0, the frozen stem-
cell suspension was thawed and reinfused. The rationale for this conditioning regimen was 
based on T-cell depletion by a purine analogue combined with a modified dose of melphalan 
(total dose 140 mg/m2) for myeloablation. 
Figure 1. Scheme of transplantation protocol
Supportive care 
Patients A, C and D were supported with parenteral feeding during the two week period of 
oral mucositis after ASCT, while patient G was receiving parenteral nutritional support before 
receiving the transplant. After discharge, all patients except one (patient G) were able to be 
fed enterally. Patient G was supported to gain weight for several months with a duodenal 
feeding tube and limited TPN (twice a week). 
During admission, all patients received standard antibacterial and antifungal prophy-
laxis. Pneumocystis jiroveci pneumonia prophylaxis was initiated (Trimethoprim-
sulphamethoxazole gluten-free syrup 480-960 mg daily) until six months posttransplant.
No patient received antidiarrhoeal or narcotic medications in the peri-transplantation period. 
Blood and platelet transfusions were given as indicated. 
Follow - up and criteria of response 
During follow up, WHO performance, nutritional status, changes in weight and stool 
frequency were noted, as well as relevant biochemical markers. An endoscopic and 
histological examination of the small bowel was performed (3, 12 and 24 months post ASCT). 
From the second part of duodenum, 4 biopsies were taken for histological assessment and 
4-6 for T-cell flow-cytometry study. Haematological data [Haemoglobin, White cell count 
(WBC), differential and platelets] were registered before inclusion, after preconditioning 
and after transplantation until recovery. The nadir WBC, duration of neutropenia, infectious 
complications, bleeding tendency, and the need for supportive therapies such as blood and 
platelet transfusions were documented.
Ethical approval and Informed consent
Approval of the medical ethics committee was obtained and all treated patients signed an 
informed consent. 
 Days  -8#       -7   - 6   - 5   - 4    - 3*           - 2       -1                                          0                                                   
            
             #Baseline                          *Admission      
        
Fludarabine 
40 mg/m2/day 
orally 
Melphalan 
70 mg/m2/day 
i.v. 
Reinfusion of 
Stem Cells 
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Results
Table 1 summarizes the demographic and clinical characteristics of the patients before 
ASCT. The mean age at diagnosis of CD was 52.5 years (range 47- 62 years) and for RCD-
II was 59 years (range 51-64 years). Four patients were DQ2 homozygous and three were 
heterozygous.31 The mean follow-up is 15.5 months (range 7-30 months). All patients had a 
WHO performance status of one except patient G (WHO performance 2). 
Four of our patients (patients B, E, F and G) had ulcerative jejunitis. Three patients (patients A, 
C and D) had splenic atrophy on CT scan. PET scan showed an increased uptake in the small 
intestine in 3 patients (patients A, B and C). At the time of diagnosis of CD, all patients were 
positive for anti-tTG and EMA, but all reverted to negative after GFD. Before and after ASCT 
all patients remained negative for anti-tTG and EMA. 
There was no transplantation-related mortality. The conditioning regimen seems feasible in 
this group of patients. The mean duration of hospitalization was 19,5 days (range 18-22 
days). ASCT-related toxicity was relatively mild. Patient B had transient diarrhoea and fever 
of undetermined origin which was treated with intravenous antibiotics. Three weeks after 
discharge from the hospital, he suffered from a transient visual disturbance caused by minor 
retinal bleeding, which was not related to thrombocytopenia. Patient D experienced fever of 
undetermined origin and recovered after intravenous antibiotics.
One month after ASCT, patient E developed self-limiting erythematous plaque skin lesions 
with central necrosis. Detailed histopathological tests excluded EATL and showed aberrant T 
lymphocyte infiltration (CD8- CD7+ CD30+). 
The mean time from the day of transplantation to neutrophil recovery was 17.8 days 
(range 10-21 days). Only one patient (patient B) had a transient a 5 days period of severe 
thrombocytopenia of 5×109/l, while all other patients had nadir platelets counts between 17-
32 ×109/l without need for platelet transfusions.
Clinical and laboratory tests before and after ASCT are shown in table 2. Patients A, C and 
D were supported with parenteral feeding during the period of oral mucositis. No patient 
received antidiarrheal or long term narcotic medications. Within 3 months after ASCT, all 
patients showed impressive clinical improvement with normalization of stools frequency, 
disappearance of abdominal pain and improvement of biochemical markers. Also 
improvement of BMI was documented [from mean 20,2 at baseline to 24,1 after ASCT]. 
Mean serum albumin level increased from 29 g/l to 40,7 g/l.
Patient G showed a remarkable clinical improvement 3-4 months after ASCT and was able to 
be fed partly enterally with parenteral nutritional support twice a week.
Table 3 shows the endoscopic and immunological results. All patients were monoclonal 
for the TCR-γ. Endoscopically there was disappearance of erosions and ulcerations in the 
jejunum in all patients (patients B, E, F and G) who had ulcerative jejunitis before ASCT, and 
histology of the small intestine showed significant regeneration as documented by down-
staging of the Marsh class (patients A, B, C, E, F and G). 
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Table 1. Baseline characteristics of the patients.
Patients
A
B
C
D
E
F
G
Age/gender
62/M
70/M
65/F
63/M
64/F
59/F 
51/M
Age CD (yrs)
56
62
61
48
44
47
50
Age RCD II (yrs)
59
64
63
63
56
58
51
Age ASCT (yrs)
60
68
64
63
64
59
51
Date ASCT
M
arch 2004
August 2004
M
ay 2005
August 2005
Nov.2005
Dec. 2005
M
arch 2006
HLA-DQ 2
Hom
ozygous
Hom
ozygous
Heterozygous
Hom
ozygous
Heterozygous
Heterozygous
Hom
ozygous
M
arsh at RCD diagnosis 
IIIA
IIIB
IIIA
IIIA
IIIC
IIIC
IIIA
BM
I (Kg/m
2)
19,4
18,9
17,1
24,1
20,1
21,3
20,5
Perform
ance 
1
1
1
1
1
1
2
Pred/2-CDA
Pred/2-CDA
Pred /2-CDA
Pred / 2-CDA
Pred / 2-CDA
Pred/2-CDA
Pred / 2-CDA
Pred / 2-CDA
Sym
ptom
s/Associations
Diarrhoea, pain, 
w
eight loss
Pain, diarrhoea
Diarrhoea, W
eight 
loss, Hypocalcem
ia 
Diarrhoea, W
eight 
loss, Derm
atitis 
herpetiform
is, 
neurological 
sym
ptom
s (ataxia)
W
eight loss, skin 
rash, Hashim
oto’s 
thyroiditis
W
eight loss, 
diarrhoea
Diarrhoea, 
Hypocalcem
ia, 
w
eight loss, 
extensive sm
all 
bow
el resection
Serology at CD diagnosis 
EM
A+, anti-TTG+
EM
A+, Anti-TTG+
EM
A+, anti-TTG+
EM
A+, anti -TTG+
EM
A+, anti- TTG+
EM
A+, anti- TTG+
EM
A+, anti- TTG+
Serology at RCD diagnosis 
EM
A-, anti-TTG-
EM
A-, Anti-TTG-
EM
A-, anti-TTG-
EM
A-, anti -TTG-
EM
A-, anti- TTG-
EM
A-, anti- TTG-
EM
A-, anti- TTG-
Endoscopy (GDS,VCE, DBE)
Nodular m
ucosa
M
osaic m
ucosa, 
erosions and 
ulcerations
M
osaic m
ucosa, 
visible vessels, no 
ulcerations
Nodular m
ucosa, 
disappearance of 
folds, erosions 
Ulcerative jejunitis
Ulcerative jejunitis
Ulcerative jejunitis 
w
ith m
ultiple 
stenosis
CT scan
Splenic atrophy, 
thickened SI w
all
Thickened SI loops
Splenic atrophy, 
dilated SI loops 
Splenic atrophy
No abnorm
ality
No abnorm
ality
Sm
all intestine 
ileus
PET scan
Increased uptake 
in SI
Increased uptake 
in SI
Increased uptake 
in SI
No abnorm
ality
No abnorm
ality
No abnorm
ality
No abnorm
ality
M
=m
ale, F= fem
ale, Pred=prednisone, 2-CDA=Cladribine, SI= sm
all intestine, GDS= Gastroduodenoscopy VCE=Video capsule enteroscopy, DBE= double-balloon enteroscopy
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Table 3. Histological and phenotypical flow-cytometric analysis of IEL’s in duodenal biopsies before (1-6 months) and 
after (3, 12 and 24 months) ASCT. All patients had a clonal rearrangement of the TCRγ gene on TCRγ-PCR analysis
Marsh category
CD7+CD3- % of 
CD103+ ly
Cyt CD3+surf CD3-% 
of CD103+ ly
CD8+% of  
CD103+ ly
Patient Before After
3-     12-  24m
Before After
3- 12- 24m
Before After
3- 12-  24m 
Before After
3-  12-  24m
A IIIA IIIA - IIIA - I 95 47- 48 -15 94 89 - 86 - 3 1 20-  7  -  52
B IIIB I   -    I -    I 51 7     4  - 8 51 2  -  6  -  4 28 68 - 62 - 67
C IIIC IIIA - IIIA 62 33 - 24 59 34 - 27 15 41 - 36
D IIIA IIIA 54 47 81 78 7 13
E IIIB I 44 68 30 36 22 2
F IIIB IIIA 71 40 50 31 23 11
G IIIC IIIA 11 30 10 27 63 52
Mean - - 63 38 61 42 23 30
ly= lymphocytes. Normal range for Cyt CD3+surf CD3- % of lymphocytes ≤ 10%. TCRγ-PCR analysis =T-cell receptor γ-
polymerase chain rearrangement. Mean* = calculated for values at 3 months post ASCT. 
Overall, the aberrant [CD7+CD3-] T-cell percentage of CD103+ lymphocytes decreased from 
a mean of 63% (range 11-95%) at baseline to 38% (range 7-68%) three to four months 
post-transplantation. Aberrant cytoplasmic CD3+ surface CD3- T-cell percentage of CD103+ 
lymphocytes has decreased from a mean of 61% (range 10-94%) to 42% (range 2-89%). 
Furthermore, the mean percentage of CD8+ cells has increased from 23% to 30% after ASCT. 
This was particularly noticeable in the first 3 patients. Patient D did not show a significant 
increase in CD8+ cells and the last 3 patients have not yet shown a significant change. Individual 
responses to ASCT differed from each patient as shown in table 3. Patient B showed the most 
impressive response with a virtual complete disappearance of aberrant T-cells. The fluorescent-
activated cell-sorting (FACS) data form patient B is shown in figure 2. Figure 3, Colour plate B-1 
shows the trend of aberrant T-cells and body weight for the first 4 patients who have a follow- 
up period of at least one year. Follow up of patients E, F and G is yet limited.
Two years after transplantation, our first patient (patient A) is showing further improvement in 
his immunopathology status as demonstrated in further decline in the percentage of aberrant 
T-cells to 3% and histologically improved from Marsh III-A to Marsh-I and the second patient 
(patient B) still showing persistent complete clinical and histological response.
Patient D had no significant change in the percentage of aberrant T-cells, showed no 
histological improvement and also no significant improvement in CD8+ percentage and he 
died 8 months post-transplantation. After ruling out structural and infectious (bacterial and 
viral) causes, we assumed that progressive disease of RCD-II with oligoclonal T lymphocytes 
infiltrating the brain was the cause of death in this particular patient. EATL could not be 
detected. Autopsy confirmed the presence of chronic encephalitis of the right temporal lobe 
with T-lymphocytes infiltration. Immunohistochemistry showed that the lymphocyte infiltrate 
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was CD3 positive and the majority of cells expressed CD8 positivity. TCR gene analysis 
showed the T-cells to be oligoclonal.
Figure 2. Flow-cytometric analysis of duodenal cells obtained from patient B, showing the change in the 
percentage of aberrant T-cell population pre- and post- ASCT. Aberrant population is shown as CD7+CD3- within 
CD103+ lymphocytes (left hand side) or as cytoplasmic CD3+ surface CD3- within lymphocyte gate (right hand 
side). Normal range for Cyt CD3+surf CD3- % of CD103+ lymphocytes ≤10%
Figure 3. The trend of aberrant T-cells and body weight per patient. Ly= lymphocytes. Before = 1-3 months. 
Normal range for Cyt CD3+surf CD3- % of lymphocytes ≤ 10%
Su
rf
ac
e 
CD
3
CD 7 Cytoplasmic CD3
Pre
Post
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Discussion
In this pilot study ASCT in RCD II patients was shown to be feasible. The conditioning regimen 
was well tolerated in all patients and there was a substantial clinical improvement. The 
rapid initial response (within 3 months) and the duration (2 years in patient A and B and 14 
months in patient C) of the remission up to now are promising. Complications included the 
occurrence of neutropenic fever in 2 patients and retinal bleeding in one patient not related 
to thrombocytopenia, all with full recovery. The nadir leucocytes and platelets counts and the 
duration of leucopenia and thrombocytopenia were comparable to our experience in patients 
with Non-Hodgkin lymphomas and multiple myeloma receiving ASCT after a combination 
of carmustine, etoposid, cytarabine, and melphalan (BEAM) or high dose melphalan (HDM, 
200 mg/m2).32 As there is no standard conditioning regimen for ASCT used in autoimmune 
disease 33, a standard regimen used in our institution was used. Fludarabine induces T-cell 
depletion while the alkylating agent melphalan was used to achieve myeloablation.
One patient was excluded due to unsuccessful leucopheresis. Although we could achieve 
successful leucopheresis in all patients despite earlier 2-CDA therapy, it is possible that the 
reason for failure of stem cell mobilization in one particular patient might be related to the use 
of 2-CDA.34 T-cells play an essential role in the pathogenesis of CD and RCD-II / EATL.8, 10, 15 
Through the activity of the enzyme tissue transglutaminase (tTG) glutamine residues in gluten 
are converted into glutamic acid.35, 36 Subsequently a multitude of gluten-derived peptides is 
generated, that, when bound to either HLA-DQ2 or DQ8 can induce T-cell responses in CD 
patients.8, 24 A particular glutamine and proline rich 33-mer α-gliadin peptide that contains 
6 different T-cell stimulatory sequences and is resistant to gastric and duodenal proteolysis 
might be the primary initiator of the inflammatory response to gluten. In the large majority of 
patients, even in children with CD, inflammatory T-cell responses to other gluten peptides are 
also observed, implicating multiple gluten peptides in the disease process.26, 27 
The definition of RCD I/ II has undergone refinement in recent years. It seems that the most 
reliable available method to differentiate between RCD I and RCD II is flow-cytometry of 
intestinal biopsies revealing the presence of aberrant T-cells. Detection of a clonal T-cell 
population by testing for TCR rearrangement was thought to be highly predictive of EATL 
development. However, oligo- or monoclonal IEL’s populations can be detected in the large 
majority of both RCD I and RCD II patients, also in patients that do not develop an EATL. 
Clonality is therefore of limited use in establishing the diagnosis of RCD and to predict the 
development of EATL.14, 37, 38
RCD II is usually resistant to any known immunosuppressive therapy, including azathioprine/ 
prednisone15, cyclosporine 16 and IL 10 therapy.17 Recently, we treated 17 patients with 2-
CDA on intention to induce remission. Within a mean follow up period of 22 months (range 
7- 67 months) 47% had a significant decrease in aberrant T-cell percentages with or without 
clinical response.39 However, another 41% did not respond clinically, histologically nor 
immunopathologically and subsequently died from EATL.
Remissions of autoimmune diseases have been described in adults after both allogenic and 
autologous ASCT 1-7 most probably due to the extreme immunosuppressive effects of these 
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strategies1, resulting in immunoablation with subsequent regeneration of naïve T lymphocytes 
derived from reinfused haematopoietic progenitor cells.7 Furthermore, recently, interesting 
insights into possible unsuspected mechanisms by which stem cell transplantation could affect 
the gut have emerged. In both animal and patient studies, sex mismatched allogeneic stem cell 
transplants have shown in both mice and women that a population of myofibroblast derived 
from the donor populates the intestinal mucosa. Given the importance of myofibroblasts in 
orchestrating the function of epithelial cells, these data suggest a mechanism other than one 
targeted at immunosuppression that could beneficially reset patient functions, for example 
enhancing barrier function following stem cell transplantation.40 
These positive results, the high risk of transforming into EATL and the absence of effective 
therapy for RCD with aberrant T-cells led us to introduce this new strategy with the ultimate goal 
of resetting the immune response which might prevent or delays development of overt EATL. 
On follow up, our patients showed improvement in the small intestinal histology, together 
with impressive clinical improvement as demonstrated by disappearance of diarrhoea and 
abdominal pain, normalization of serum albumin, electrolytes and haemoglobin, increase 
in BMI and improvement of the performance status. Two years after transplantation, our first 
patient is showing further improvement in his immunopathology status as demonstrated in 
further decline in the percentage of aberrant T-cells to 3% and histologically improved from 
Marsh III-A to Marsh-I. We propose that enhanced apoptosis of activated but aberrant T-cells 
has led to this late but remarkable decline.41 One patient died 8 months post ASCT from 
progressive neurological manifestations in association with CD. Autopsy had excluded any 
structural or infectious cause. One patient had developed self-limiting erythematous plaque 
skin lesions with central necrosis two months post ASCT. Detailed analysis had excluded the 
presence of EATL. Our most recent patient with clinically short bowel syndrome is showing 
remarkable clinical, endoscopical and immunological improvement. 
All our patients had negative serology before inclusion confirming their strict adherence to 
GFD and after ASCT all patients remained negative for anti-tTG and EMA.
Furthermore, the first 3 patients showed a significant increase in the percentage of CD8+ 
lymphocytes, which is seen as a marker of lymphocyte regeneration after ASCT.42 Patient D 
did not show a significant increase in CD8+ cells and the last 3 patients have not yet shown 
a significant change. Absence of a demonstrable improvement in the surface expression of 
CD8 on the IEL might be regarded as a poor prognostic indicator of response; this is only to 
be proved or disproved on longer term follow up.
Although the short term results in these patients are promising, follow up at present is too 
short to permit firm conclusions as to efficacy. The selection of patients for this treatment 
should be restricted to those patients with a substantial population of aberrant T-cells, even 
after therapy with 2- CDA who have a greater tendency to progress to highly lethal EATL. 
High-dose chemotherapy followed by ASCT seems feasible and safe, and might result in 
long-term improvement of disease activity in RCD patients with aberrant T-cells whose 
condition previously did not respond to available treatments. Longer-term follow up and 
additional pilot studies with larger groups of patients are needed to confirm the efficacy of 
this therapy.
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Addendum
At the time of writing the thesis manuscript our first patient (patient A) developed an EATL 
and currently receiving chemotherapy. The other 5 patients are currently in a very good 
clinical condition. The last 3 patients have completed more than one year of follow up after 
transplantation.They are clinically asymptomatic; all three showed marked endoscopic, histologic 
and immunologic recovery. The following table summarizes the data at last follow up.
Updated data. Histological and phenotypical flow-cytometric analysis of IEL’s in duodenal biopsies before and 
after ASCT. ly= lymphocytes.Normal range for Cyt CD3+surf CD3- % of lymphocytes ≤ 10%. 
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3-   12-  24m 3- 12- 24m 3- 12-  24m 3-  12-  24m
A* IIIA IIIA - IIIA - I 95 47- 48 -15 94 89 - 86 - 3 1 20-  7  -  52
B IIIB I   -    I -    I 51 7 -   4  - 8 51 2  -  6  -  4 28 68 - 62 - 67
C IIIC IIIA - IIIA- 62 33 - 24- 59 34 - 27 15 41 - 36 
D** IIIA IIIA 54 47 81 78 7 13
E IIIB I     - 0 44 68 - 40 30 36 - 28 22 2  -    5
F IIIB IIIA - 0 71 40 - 41 50 31 - 26 23 11 -  11
G§ IIIC IIIA - IIIB 11 30- 5 10 27 - 3 63 52 - 86 
* developed EATL 32 months after receiving ASCT. ** died 8 months after ASCT. § data after 6 months of ASCT 
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Abstract
Background: Despite treatment, enteropathy associated T-cell lymphoma (EATL) has a very 
poor outcome. Chemotherapy can be complicated by small bowel perforation, gastrointestinal 
bleeding and development of enterocolic fistulae.
Her we report on the feasibility, safety and efficacy of autologous stem cell transplantation 
(ASCT) in EATL patients after undergoing cytoreductive therapy including high dose 
chemotherapy with or without partial small bowel resection.
Methods: Four patients [(2 males, 2 females, mean age 65 years (range 60-69 years)] have 
received ASCT (3 patients received upfront transplantation and one was transplanted only 
after relapse). After partial small bowel resection (3 patients), induction chemotherapy and 
conditioning, ASCT has been performed. 
Results: All 4 patients completed the mobilization and leucopheresis procedures successfully 
and subsequently received conditioning chemotherapy and transplantation. Engraftment 
occurred in all patients. No major non-haematological toxicity or transplantation-related 
mortality was observed. One patient has ongoing complete remission 32 months after 
transplantation. Three patients died from progressive disease within few months after ASCT.
Conclusions: ASCT for patients with EATL seems unsatisfactory. Therefore, earlier diagnosis 
and the development of more effective treatments are urgently required to improve the 
prospects of these patients. In patients with disease limited to the small bowel, pre-transplant 
partial small intestine resection might improve the response rate. However, more intensive 
conditioning, more aggressive chemotherapy with/or without targeted immunotherapy as 
well as allogenous SCT needs to be explored.
Introduction
Enteropathy associated T-cell lymphoma (EATL) is a specific type of peripheral T-cell lymphoma 
associated with coeliac disease and it is known for its very poor outcome: 1- and 5-year survival 
rates in the range of 31-39% and 11-20% respectively.1, 2 In a prospective, multicentre study 
of 35 patients with EATL treated with six cycles of CHOP (Cyclophosphamide, Doxorubicine, 
Vincristine and Prednisone), the cumulative 2-year survival was only 28%.3
EATL is rare, except in the coeliac disease population, where the risk has been estimated to 
be as high as 19.2 times that of the general population.4 The annual incidence rate of EATL 
has been reported to be 0.5-1 per million people in Western countries.5 
Strict adherence to a gluten-free diet in coeliac disease for more than 5 years has been 
shown to reduce the overall cancer risk in the coeliac disease group to that of the general 
population.6 EATL can present in two different ways. There are patients with well-established 
coeliac disease who have responded to a gluten free diet but then deteriorate because of the 
development of refractory coeliac disease (RCD) type II or EATL. In the other group, patients 
are not known with coeliac disease and coeliac disease and EATL are diagnosed more or less 
simultaneously (de novo EATL).7
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An immunophenotypically aberrant clonal intraepithelial T-cell population has been found 
in up to 75% of patients with RCD.8 Clonal T-cell receptor (TCR) gene rearrangements 
have been found in patients with refractory coeliac disease without histologic evidence of 
lymphoma.9-11 It remains unclear whether chronic inflammatory conditions such as coeliac 
disease provoke an aberrant immune response or the underlying abnormal T-cell response is 
already present, creating the picture of refractory CD.12 Furthermore, identifying patients at 
risk can be difficult, as establishing the diagnosis of RCD itself takes time.13
In the largest case series investigating treatment and clinical outcomes in EATL, more than 
halve of the patients could not complete treatment secondary to poor nutritional status and 
chemotherapy was complicated by small bowel perforations, gastrointestinal bleeding, and 
development of enterocolic fistulae.14 
There have been few case studies of EATL patients treated with chemotherapy and upfront stem 
cell transplantation.1, 14- 18 These reports described very small groups of patients with a complete 
remission (CR) and disease-free survival ranging from (0 - 64 months post ASCT). Encouraging 
results came from a recent report 18 describing the treatment of six patients with upfront ASCT; 
four patients of them remain alive in CR at 1.83-4.32 years; two have relapsed. 
Here we report on the feasibility, safety and efficacy of ASCT in patients with EATL (3 upfront 
ASCT and one received transplantation only at relapse), after high dose chemotherapy with 
or without partial small bowel resection.
Patients and Methods
Patients
Four patients (2 males, 2 females) with a diagnosis of EATL received high dose chemotherapy 
followed by ASCT. 
Patient characteristics are summarized in table 1.
Patient A is a 69 year old female, known to have mononeuritis multiplex and Sjögren 
syndrome for more than 20 years. At the age of 64 years, a diagnosis of EATL and coeliac 
disease was established. She was treated with gluten free diet and partial small bowel 
resection followed by standard dose chemotherapy, which consisted of 8 courses CHOP 
therapy (without Vincristine because of the presence of peripheral neuropathy). Thereafter, 
she remained in complete remission (CR) for 18 months. Subsequently she developed relapse 
with localization in the jejunum. A second resection was necessary, and after recovery, second 
line high dose chemotherapy was initiated: Dexamethasone, Cytarabine and Cisplatinum 
(DHAP, two cycles), and Etoposide, Ifosfamide and Methotrexate (VIM, one cycle; DHAP-
VIM-DHAP). This treatment was followed by conditioning with BEAM (BCNU, Etoposide, 
cytarabine, melphalan) chemotherapy and ASCT. 
Patient B is a 60 year old female who was diagnosed with de novo EATL localized in the 
mesenteric lymph nodes. She was treated with 4 cycles CHOP chemotherapy and gluten free 
diet. Subsequently, she underwent ASCT preceded by conditioning therapy with fludarabine 
(40 mg/m2/day for 5 days) and melphalan (dose 70 mg/m2 at day -2 and day -1). 
Patient C is a 66 year old male. He was admitted because of pain in the epigastric region and 
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weight loss. On computed tomography (CT) scan of the abdomen, localized thickening of 
the small bowel wall was seen. He underwent en bloc resection of one meter small bowel 
segment and mesentery with primary anastomosis. Histopathologically, the diagnosis of EATL 
was confirmed. Subsequently, he was treated with CHOP chemotherapy (8 courses in total). 
Because of partial response after 4 courses (radiologic analysis showed multiple mesenteric 
lymph nodes), consolidation with ASCT after first line therapy followed. Conditioning was 
with fludarabine and melphalan. 
Patient D is a 66 year old male, known with coeliac disease and osteoporosis. He was 
on gluten free diet for one year. Video capsule enteroscopy (VCE) and double-balloon 
enteroscopy (DBE) were performed because of persistent weight loss. Both of these methods 
showed ulcerative jejunitis of the distal jejunum and ileum, but histopathology of endoscopic 
biopsies was not conclusive. An emergency laparotomy was performed because of persistent 
melaena and hemodynamic instability. Partial resection of small intestine was performed. In 
the resection specimen multiple localisations of a lymphoma had been identified in the wall 
of the ileum, but not in enlarged lymph nodes. The lymphoma expressed CD2, CD3 and in 
a part of the cells TIA-1 and CD30, but was negative for CD5, CD4, CD8 and B-cell markers 
(figure 1, Colour plate C-1) and ulcerative jejunitis with Marsh IIIA villous atrophy (figure 
2, Colour plate C-2). After recovery from laparotomy, he was treated with 8 cycles CHOP 
chemotherapy, combined with immunotherapy (antiCD52, alemtuzumab). Subsequently, he 
received conditioning with BEAM followed by ASCT. 
Figure 1. EATL in ileum resection specimen with a proliferation of middle-sized atypical lymphocytes (A) leading 
to villous atrophy and ulceration (B). (H&E, 12,5x and 630x)
Staging
The Ann Arbor staging system was used based on clinical assessment and the following 
investigations:
– Radiological evaluation: Chest x-ray, CT-scan [neck, chest, abdominal], Positron emission 
tomography (FDG-PET) 19, magnetic resonance (MR) enteroclysis,
– Evaluation by an Ear nose throat surgeon, to exclude nasopharyngeal and paranasal 
localization.
– Bone marrow trephine biopsy was performed to rule out bone marrow localization.
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Criteria of diagnosis
The diagnosis of EATL was established according to the WHO Classification of Tumours of 
Haematopoietic and Lymphoid Tissues.20 The immunohistochemical features of EATL are 
the presence of large or medium size T-cell proliferation expressing a CD3+ CD8+/- and 
CD103+.
EATL can be CD3+ CD8- CD30+ large cell lymphomas, CD3+ CD8+ CD30- small cell 
lymphomas or γδ- lymphomas. Diagnosis of EATL was confirmed by an expert- panel of 
pathologists.
Figure 2. EATL in ileum resection specimen expressing CD3 and partly also CD30. Residual small T-lymphocytes 
express CD4 or CD8, lymphoma cells virtually all negative.
Peripheral blood stem cells mobilization and collection
Mobilization of haematopoietic progenitor cells from the bone marrow into the peripheral 
blood was performed using granulocyte-colony stimulating factor (G-CSF). 
Haematopoietic stem cells were collected from the peripheral blood by leucopheresis. 
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Response criteria
Response to therapy was evaluated according to the Cheson criteria.21
Results
Patient characteristics
The baseline characteristics of the 4 patients are shown in table1. The mean age 65 years 
(range 60-69 years). Three patients had de novo type of EATL, while one patient was known 
to have coeliac disease one year before developing EATL (patient D). All patients had 
positive serology for coeliac disease at diagnosis. Endoscopically, 3 patients had evidence of 
ulcerative jejunitis. All patients had definite histological features of coeliac disease according 
to the Marsh criteria (3 had Marsh IIIA and one IIIB). A significant percentage (30-51%) of the 
intraepithelial lymhocytes was aberrant, defined as CD7+ surface CD3- cells (expressed as % 
of CD103+ lymphocytes) or cytoplasmic CD3+, surface CD3 negative cells (expressed as % 
of CD103+ lymphocytes) in all patients. 
Immunophenotypical testing of lymphoma tissues showed that these EATL‘s were 
CD3+CD8+CD30+ in 3 patients (patients A, B and C) and CD3+CD8-CD30+ in one patient 
(patient D).
Patient B had bone marrow involvement at diagnosis and also localization in the cerebrospinal 
fluid during relapse. All patients had stage IV at diagnosis characterised by intestinal or extra-
intestinal involvement.
Radiologically, the most prominent findings were mesenteric lymphadenopathy, bowel wall 
thickening and prestenotic dilatation. Mesenteric lymphadenopathy was seen in all patients; 
one patient (patient D) had also hilar lymphadenopathy. FDG-PET showed increased activity 
in all patients. 
Stem cell mobilization and leucopheresis
Mobilization of haematopoietic progenitor cells from peripheral blood was achieved 
successfully and uncomplicated in all patients using G-CSF. 
Toxicity of High dose chemotherapy
No transplantation-related mortality was reported. Blood and platelets transfusions were 
provided when needed. Conditioning regimens as used seemed feasible in this group of 
patients. The mean duration of hospitalisation was 20 days (range 18-24 days). 
Engraftment
Haematopoiesis recovered in all patients. The median time to reach neutrophils > 0,5×106/l 
and unsupported platelets > 20 ×106/l were 12 days (8-15) and 14 days (9-16), respectively.
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Response and survival after ASCT 
Three patients were in CR before receiving preconditioning regimens and one was in partial 
remission. 
One patient (patient A) was in remission for 18 months after standard chemotherapy and 
received ASCT after having a relapse. Since then (32 months) she is still in CR.
Four weeks after ASCT, patient B developed severe neurological complaints. A cauda equina 
syndrome was diagnosed. CSF examination confirmed the presence of lymphoma cells 
carrying the same immunological markers (CD3+CD8+CD30+). She received immediate 
palliative radiotherapy of the lower spine. Because of the rapid course of this relapse and her 
very poor clinical condition, no systemic therapy could be initiated. Unfortunately she died 
from CNS relapse two months after ASCT. 
Table 2. Treatment results. CR= complete remission, PR=partial remission, Flud+Mel= fludarabine and melphalan
Patients A B C D
Follow up (ms) after SCT 32 2 6 9
Resection performed Yes No Yes Yes 
Response to CHOP CR (18 m) followed 
by relapse
CR PR CR
Other therapies DHAP-VIM-DHAP - - Alemtuzimab
Preconditioning regimen BEAM Flud+Mel Flud+Mel BEAM
Relapse after transplantation No Yes Yes Yes
Patient C was admitted six months after ASCT because of persistent gastrointestinal bleeding 
and pancytopenia. He received supportive care (blood and platelet transfusions). Relapsed 
EATL was suspected but after explicit request of the patient and his family, all supportive care 
was withdrawn and he died several days later. Autopsy examination C showed the presence 
of a large amount of blood in the gastrointestinal tract and multiple mesenteric pathological 
lymph nodes (Figure 3, Colour plate C-3). Microscopic examination of these nodes confirmed 
the presence of EATL in relapse.
Patient D had shown initial response, but he developed a relapse 9 months after transplantation. 
He was admitted with bleeding per rectum. Colonoscopy showed multiple deep ulcerations 
in the ascending colon and terminal ileum. Histopathological examination confirmed EATL 
relapse. He died. Autopsy examination showed the presence of a large amount of blood in 
the gastrointestinal tract due to numerous ulcers in the small intestine and the colon with 
multiple mesenteric pathological lymph nodes. Microscopic examination of these nodes 
showed considerable depletion of lymphocytes, but the pathological lymphoid population 
could not be identified with certainty in the lymph nodes.
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Figure 3. Macroscopic picture showing multiple pathological mesenteric lymph nodes (A) and large amount of 
blood in the small intestine (B) 
Discussion
Intestinal T-cell lymphomas or EATL’s are rare, but highly aggressive in their clinical course. 
They are generally diagnosed in advanced stages and presenting as surgical emergencies. 
They respond poorly to available anti-lymphoma regimens. Results were better in patients 
with limited stages of disease.22 The most frequent complications of treatment were small 
bowel perforation, obstruction, gastrointestinal bleeding, and infection. The 1- and 5-year 
survival rates in the range of 31-39% and 11-20%, respectively.1, 2 
We report here our results of the treatment of 4 patients with an advanced stage of EATL 
diagnosis (stage IV). The induction chemotherapy and “debulking” were feasible as the 
patients were in good condition before undergoing ASCT. The conditioning regimen and 
ASCT were well tolerated in all patients. The nadir leucocytes and platelets counts and the 
duration of leucopenia and thrombocytopenia were comparable to that in patients with 
Non-Hodgkin lymphomas and multiple myeloma receiving ASCT after BEAM or high dose 
melphalan.23 There was no transplantation- related mortality.
Variable results were published dealing with ASCT in EATL and these are summarized in 
table 3. Encouraging results came form a recent report 18 describing the treatment of six 
patients with ASCT after receiving two cycles of IVE (ifosphamide, etoposide, epirubicin), 
followed by two cycles of high-dose methotrexate (3 g/m2) with folinic acid rescue and a 
BEAM (carmustine, etoposide, cytarabine, melphalan). Four patients remain alive in complete 
remission at 1.83-4.32 years; two have relapsed.
It is a well known that T-cell malignancies do not respond adequately to conventional 
chemotherapeutic treatment.24, 25 The introduction of monoclonal antibodies for the 
treatment of cancer has changed the outlook for patients with T-cell malignancies.26 Recent 
studies with single-agent alemtuzumab, an anti-CD52 monoclonal antibody, have shown 
improved response rates and survival in patients with T-cell prolymphocytic leukaemia and 
cutaneous T-cell lymphoma.27 Preliminary data also suggest that alemtuzumab may have 
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activity in patients with heavily pretreated peripheral T-cell lymphoma who are refractory 
to conventional chemotherapy.28 Preclinical studies with mice bearing human adult T-cell 
leukemia/lymphoma cells suggest that alemtuzumab may have a potential therapeutic 
role in this setting.29 Therefore, treatment of EATL with alemtuzumab in combination with 
chemotherapy could be promising.
In addition, an earlier institution of treatment and combination with chemotherapeutic agents 
may improve treatment outcome for patients with these patients and allow for consolidation 
with stem cell transplant strategies in selected patients.24
Furthermore, it has been shown that the use of intensified and high dose chemotherapy 
with ASCT may improve the outcome in high-risk NHL 30 and that patient who undergo 
allogeneic SCT for refractory or indolent NHL have lower relapse rates than those who 
undergo autologous SCT.31, 32
In this report, two different conditioning regimens were used. Because of the small cohort of 
patients treated, no conclusions could be made of the best conditioning regimen. 
Cytoreductive therapy, using chemotherapy and partial small bowel resection, seems logical. 
We have recognized that the patients’ condition improves before chemotherapy and also 
prevents the occurrence of complications as perforations, fistulas and bleeding.
The only long term survival we have is the patient with no bone marrow involvement at 
the time of diagnosis. The results of the other 3 patients were disappointing. Intervention at 
an earlier stage in the evolvement of lymphoma at the premalignant phase (RCD II) could 
theoretically prevent or delay the development of the malignant phase. Recently we reported 
on our experience in treating RCD II patients with high dose chemotherapy followed by 
ASCT and the results thus far are promising in six of the 7 transplanted patients.33
Conclusions
It seems that current chemotherapy, preconditioning regimens and ASCT do not improve the 
survival in this type of aggressive lymphoma. Relapse can occur within weeks to months post-
ASCT. Therefore, earlier diagnosis, the development of more effective treatments including 
antiCD52 agents, better preconditioning regimens and possibly the use of T-cells depleted 
grafts or allogeneic stem cell transplantation with or without primary central nervous system 
prophylaxis are urgently required to improve the prospects of these patients.
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Abstract
Background:  Coeliac disease (CD) may be regarded as refractory disease (RCD) when 
symptoms persist or recur despite strict adherence to a gluten free diet. RCD may be 
subdivided into types I and II with a phenotypically normal and aberrant intraepithelial T-cell 
population, respectively. RCD I seems to respond well to azathioprine/prednisone therapy. 
RCD II is usually resistant to any known therapy and transition into Enteropathy-Associated 
T-cell Lymphoma (EATL) is common. 
Aim:  The aim of this study is to provide further insight into RCD and the development of 
EATL, by reporting on long term survival, risk of transition of RCD into EATL in what is likely 
the largest cohort of patients with complicated coeliac disease in a single center. 
Design and Methods:  We have retrospectively compared responses to therapy in four groups 
of patients with complicated coeliac disease: 43 RCD-I, 50 RCD II (total), of whom 26 RCD II 
who developed EATL after a period of refractoriness to a gluten free diet (secondary EATL) and 
13 EATL patients without preceding history of complicated coeliac disease (de novo EATL). 
Every effort was made to ensure correct classification and accurate patient allocation.
Results: No coeliac disease related mortality is recognized in the RCD I group. The overall 
five year survival in RCD I is 96%, in RCD II (total) is 58% and in RCD II after developing 
EATL is only 8%. The 2 year survival in the de novo EATL is 20% versus 15% in secondary 
EATL (P=0.63). Twenty eight (56%) from 50 patients with RCD-II died, 23 (46%) due to 
EATL and 4 due to progressive refractory state with emaciation and one from neurocoeliac 
disease. 
Conclusion: Remarkably, no patient with RCD I developed RCD II or EATL within mean 
follow up of five years (range 2-15 years). Fifty two percent of the RCD II patients progressed 
to/ developed EATL within 4-6 years after the diagnosis of RCD II. More aggressive therapies 
seem necessary in RCD II and EATL.
Introduction
Coeliac disease is a life-long gluten sensitive enteropathy that commits the patient to a 
permanent gluten free diet, which is sufficient to treat the overwhelming majority of patients. 
However, in a small percentage (2-5%) of adult onset coeliac disease patients serious 
complications develop in the form of refractoriness or development of pre- and malignant 
complications.1 Patients with coeliac disease may be regarded as suffering from refractory 
coeliac disease (RCD) when symptoms persist or recur after a former good response despite 
strict adherence to a gluten free diet.1,2,3 We define RCD as persisting villous atrophy with 
crypt hyperplasia and increased intraepithelial T-lymphocytes in spite of a strict gluten free 
diet for more than 12 months or when severe symptoms necessitate intervention independent 
of the duration of the gluten free diet.2,4 Immunologically, two types of RCD are recognized 
depending on the presence or absence of aberrant intraepithelial lymphocytes in the 
small bowel mucosa. When normal expression of T-cell surface markers occurs (RCD I), 
the prognosis is less dismal than when an aberrant intraepithelial lymphocyte population 
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is present (RCD II).2,4,5 Patients with RCD II are known to be at a greater risk of developing 
malignancy, particularly enteropathy-associated T-cell lymphoma (EATL).2,5,6,7 
RCD II can be regarded as a ‘cryptic’ lymphoma.4 There is now strong molecular and 
immunophenotypic evidence showing that a monoclonal neoplastic T-cell population may 
emerge from IEL’s in RCD. Clonal expansion of this monoclonal T-cell population eventually 
leads to frank EATL. The genesis and expansion of these monoclonal T-cells involve both 
inappropriate immune responses to gluten and acquisition of genetic abnormalities. Although 
the monoclonal IEL’s in patients with RCD are neoplastic, they are not cytologically abnormal 
and do not form tumour masses which differentiate these patients from EATL patients, in 
addition to the absence of radiological and bone marrow evidence of lymphoma.2, 8,9,10
RCD II is usually resistant to any known therapy that has thus far been tested, including 
azathioprine/prednisone, cyclosporine, IL-10 and cladribine (2-Chlorodeoxyadenosine) 
therapy.2,11-17 EATL has a very poor outcome with current therapies, with 1- and 5-year survival 
rates in the range of 31-39% and 11-20%, respectively.18,19 In a prospective multicentre study 
from Germany on 35 patients with EATL treated with six cycles of CHOP (Cyclophosphamide, 
Doxorubicine,Vincristine and Prednisone) cumulative 2-year survival was only 28%.19
So far, no systematic analysis of the survival of this group of patients has been reported. The 
aim of this study is to provide further insight into the understanding of refractory coeliac 
disease and the development of EATL, by reporting on what is likely the largest cohort 
of patients with complicated coeliac disease in a single centre. We have retrospectively 
compared the survival in four groups of patients with complicated coeliac disease: RCD-I, 
RCD II total, secondary EATL and de novo EATL. Since correct disease allocation of these 
patients is crucial, we have applied state-of-the-art methodologies to ensure that our patients 
were classified according to the internationally accepted criteria by employing clinical, 
endoscopical, radiological and molecular techniques. 
Patients and Methods
Patients
We performed a retrospective analysis of response to therapies, providing long term follow 
up data on 4 categories of patients with complicated forms of coeliac disease in a tertiary 
referral centre for coeliac disease. From 1992 to 2005 forty-three patients with RCD I (12 
males and 31 females; mean age at diagnosis of RCD 49 years, range 23-86), 50 patients 
with RCD II (19 M: 31 F; mean age at diagnosis 59 years, range 47-88) of whom 26 patients 
with secondary EATL (11 M:15 F; mean age at diagnosis of EATL 61.5 years, range 52-79) 
and 13 patients with de novo EATL (11M:2 F; mean age at diagnosis 64.3, range 56-72) were 
studied. In the de novo EATL, there is no history of complicated coeliac disease and none of 
them have followed gluten free diet. A small group of patients with RCD have been excluded 
from the analysis, they were treated with cyclosporine or interleukin 10.14, 15 
From the RCD-I patients 31 were treated with prednisone alone and 12 with a combination of 
prednisone and azathioprine.11 Thirty four from RCD-II patients were treated with prednisone 
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and azathioprine 11 and subsequently 23 of them received cladribine because of persistent 
unsatisfactory responsiveness.17 From the cladribine treated group 7 were included in our 
pilot study using high dose chemotherapy followed by autologous peripheral stem cell 
transplantation. These patients were in persistent refractory state with high percentage of 
aberrant T-cells and most of them (5/7) have ulcerative jejunitis. Stem cells were collected 
by leucopheresis. After conditioning with fludarabine and melphalan, autologous stem cell 
transplantation was performed.17
Patients with EATL were treated with multiagent chemotherapy according to standard lymphoma 
treatment protocols and when indicated partial small bowel resection has been performed. 
Four patients with EATL (3 de novo EATL and one with secondary EATL) received high dose 
chemotherapy followed by autologous peripheral stem cell transplantation. Three patients have 
partial small bowel resection before transplantation. (CJJ Mulder: unpublished data).
The patients with RCD I and II were followed for evidence of transition to a more severe state 
(i.e., the transition from RCD I to RCD II and /or EATL, and from RCD II to EATL) over a mean 
period of 5 years (range 2-14 years). 
Diagnostic criteria 
The diagnostic criteria of the different groups have been summarized in table 1. The diagnosis 
of coeliac disease was confirmed by histological examination with a documented histologic 
response to gluten withdrawal.3, 18 Patients were considered to be refractory when symptoms 
of malabsorption due to villous atrophy persisted or recurred after a former good response 
despite strict adherence to a gluten free diet, histopathology showing at least partial villous 
atrophy (Marsh IIIA) according to the modified Marsh criteria and after excluding other 
causes of villous atrophy.3, 4 Taking in consideration that a significant number of patients 
(around 50%) with RCD I may indeed have inadvertent gluten ingestion.
The diagnosis of RCD was established as type I when no or less than 10% aberrant T-cells were 
present in small bowel biopsy specimens and type II with ≥ 20% aberrant T-cells detected by 
immunophenotyping using flow-cytometric analysis of the intestinal mucosa 2,11,22. In RCD I 
the intraepithelial lymphocyte phenotype is normal with the expression of surface CD3, CD8 
and TCR. In RCD II the intraepithelial lymphocytes have normal morphological features, but 
they exhibit an aberrant phenotype with the normal expression of CD103 and CD7 but with 
downregulation of surface CD3 to intracytoplasmic CD3, and the lack of classical surface 
T-cell markers such as CD4, CD8 and, as a consequence of CD3 downregulation, TCR.2, 22 
In the RCD patients the presence of EATL has been confidently excluded using radiological 
and endoscopic methods (small bowel follow through, computed tomography scanning 
of thorax and abdomen 23, whole body positron emission tomography scan 24, upper 
gastrointestinal endoscopy, video capsule endoscopy and/or double-balloon enteroscopy 25 
as well as trephine bone marrow biopsies. Those patients diagnosed in 2003 or earlier have 
negative small bowel follow through and computed tomography scan, while those diagnosed 
after 2003 have negative computed tomography scan, positron emission tomography scan, 
video capsule endoscopy and/or double-balloon enteroscopy.
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The diagnosis of EATL was established according to the WHO Classification of Tumours of 
Haematopoietic and Lymphoid Tissues.26, 27 The immunohistochemical features of EATL are 
evidence of large or medium size T-cell proliferation expressing a CD3+ CD8+/- and CD103+. 
Thirty five patients out of 39 had CD3+ CD8- CD30+ large cell lymphomas, 2 patients had 
CD3+ CD8+ CD30- small cell lymphomas16 and another 2 had γδ- lymphomas.
Table 1. Summarizes the diagnostic criteria 
Disease category Diagnostic criteria References
RCD I - Villous atrophy persisted or recurred despite strict adherence to a gluten free 
diet.
-  At least partial villous atrophy (Marsh IIIA) according to the modified Marsh 
criteria 
-  Excluding other causes of villous atrophy.
-  When ≤ 10% aberrant T-cells in intestinal biopsy.
-  Intraepithelial lymphocyte phenotype is normal with the expression of surface 
CD3, CD8 and TCR
2,3,4,,8,19
RCD II - The same as RCD I, in addition to the presence of ≥ 20% aberrant T-cells in 
intestinal biopsy. 
- The intraepithelial lymphocytes have normal morphology, but exhibit an 
aberrant phenotype (normal expression of CD103 and CD7, downregulation of 
surface CD3 to intracytoplasmic CD3, and the lack of surface T-cell markers: 
CD4, CD8 and TCR).
-  EATL has been confidently excluded.
2,3,4, 8,19
Secondary EATL -  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.
- The patient is already known to have coeliac disease or RCD.
23, 24
De novo EATL -  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.
- No previous history of coeliac disease or use of gluten free diet.
23, 24
Evaluation
Clinical, laboratorial (haematology, biochemistry and serology), endoscopic and histological 
examination of the small intestine was performed at regular intervals (3-6 months). Clinically, 
patients were followed at the outpatient clinic at regular intervals and their adherence to the 
gluten free diet was checked by a dietician. Particular attention was paid to clinical response 
including symptoms and signs of malabsorption, body mass index and performance status; 
and adverse effects of therapies.
Antiendomysium antibodies (EMA) and anti-tissue transglutaminase antibodies (anti-tTG) 
were tested at diagnosis and at follow up. HLA-DQ2/8 typing 28 and immunophenotyping of 
intraepithelial lymphocytes were performed in all patients.
Endoscopy using upper gastrointestinal endoscopy, video capsule endoscopy and/or double-
balloon enteroscopy with small bowel biopsies was performed as indicated.
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Computed tomography scan, positron emission tomography scan, magnetic resonance 
enteroclysis and dual energy X-absorptiometry were performed as indicated. The techniques 
for the video capsule endoscopy, double-balloon enteroscopy and MR enteroclysis are 
available in our centre only since the beginning of 2003. 
Small bowel biopsies
Upper gastrointestinal endoscopy was performed in all patients. At least 10 duodenal 
biopsies were taken for histological, immunohistochemical and flow cytometric examination. 
Four to six biopsies were fixed and preserved in 10% formalin for histopathological and 
immunohistochemical evaluation. Three-4 biopsies for T-cell receptor gene rearrangement 
studies were taken separately, preserved on histocon and frozen at -20°C. For 
immunophenotypical evaluation 3-4 biopsies were taken and preserved in RPMI medium.
Isolation of intraepithelial lymphocytes and cell-staining for immunophenotyping
Lymphocytes and enterocytes were isolated from 3-4 small bowel biopsies by homogenising 
tissue samples and passing fragments through a 100μm nylon cell strainer (Becton Dickinson_) 
in RPMI medium supplemented with 1% FCS. The released cells were subsequently washed 
and labelled by 4-color staining for 30 minutes on ice with various combinations of fluorescein 
isothiocyanate, phycoerythrin, peridinin chlorophyll protein and allophycocyanin labelled 
monoclonal antibodies against CD3, CD4, CD8, CD7, CD103, CD19, CD45, CD16/56, 
γδTCR and cytoplasmic CD3. The FACS method used in this study was in accordance with the 
manufacturer’s guidelines.
Cell surface immunophenotyping of intraepithelial lymphocytes was performed on a 4 
colour FACS Calibur flow cytometer (Becton Dickinson, BD, immunocytometry systems, San 
Jose, CA). Nonviable cells and debris were excluded based of forward and sideward light 
scatter properties and a gate on CD45 positive cells was used for selecting lymphocytes. 
Intraepithelial localisation of lymphocytes was confirmed by surface expression of CD103 
(αEβ7 integrin, a gut homing receptor for E-cadherin). Intraepithelial lymphocytes were 
analysed, using CellQuesttm (KS Stat) based on their expression of cell markers: cytoplasmic 
CD3, surface CD3, CD4, CD7, CD8, CD16/56, CD19, CD103 and TCRγδ on CD45+gated 
intraepithelial lymphocytes.29 Arbitrarily, a percentage of aberrant cells CD7+CD3- of CD103+ 
intraepithelial lymphocytes or cytoplasmic CD3+ surface CD3- % of CD103+ intraepithelial 
lymphocytes of ≤ 10% has been regarded as normal, and more than 20% as definitively 
abnormal. A percentage between 11% and 20% were regarded as borderline but none of our 
patients had such percentages. 
Assessment of TCR gene rearrangement by Polymerase Chain Reaction (PCR)
DNA was extracted from cryosections of duodenal biopsies by a standard procedure using 
proteinase-K digestion and ethanol precipitation of the genomic DNA. T-cell receptor-gamma 
(TCR-γ) gene rearrangements were analysed by multiplex PCR amplification under standarized 
conditions. Monoclonal and polyclonal controls were included in each experiment. Clonality 
assessment for TCR-γ gene rearrangements was done using the BIOMED-2 multiplex TCR PCR 
protocol.26, 27
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Statistical analysis
Kaplan-Meier survival curves were constructed using SSPS software (SPSS Inc. 
Chicago, Illinois, USA) for comparison between the groups. Chi square test, odds ratio, log 
rank and logistic regression tests were used to assess the statistical significance between 
variables. A p value ≤ 0.05 is considered statistically significant.
Results
Table 2 shows the baseline demographic characteristics according to the disease group. 
Regarding gender distribution in the studied groups, there is no difference between the RCD I 
and RCD II groups. In contrast the de novo EATL group showed a statistically significant increase 
in the male: female ratio as compared to the RCD I (P< 0.001) and secondary EATL group 
(P<0.025). Patients with RCD I are younger than RCD II and EATL patients, but no transition has 
been documented from RCD I to RCD II or EATL during the period of follow up.
HLA-DQ2 genotype is present in 80% of RCD I, 92% of total RCD II , 96% of secondary 
EATL and 92% of de novo EATL groups. 
HLA-DQ2 homozygosity is significantly higher in secondary EATL and de novo EATL compared 
to RCD I, odds ratio= 2,6 (CI: 1,94 - 5,33) and OR=2,06 (CI: 1,88 - 4,78) respectively.30 
Table 2. The baseline demographic characteristics and therapies received according to the disease group
Characteristic RCD-I RCD-II  Total Secondary EATL De novo EATL
Total (Male: Female) 43  (12:31) 50  (19:31) 26  (11:15) 13  (11:2)
Age at Dx CD (±SD) (range) in years 47  (±13.5) 
(21-75)
57  (±6.5)
(40-69)
59  (±11.2) 
(40-69)
64.3  (± 4.5) 
(56-72)
Age at Dx RCD/EATL (±SD) (range) 
in years
49  (±14) 
(23-86)
59  (±9.5)
(47-88)
61.5  (±6.5)  
(52-79)
64.3  (±3.4) 
(56-72)
Follow up (mean, range) in months 72  (24-240) 44  (8-146) 10  (3 - 50) 12  (3-36)
DQ2 Total 
- Heterozygous
- Homozygous
34  (80%)
23  (54%)
11  (26%)
46  (92%)
23  (46%)
23  (46%)
25  (96%)
7   (27%)
18  (69%)
12  (92.3%)
4  (30.7%)
8  (61.5%)
Aberrant T-cells at Dx of RCD and/or 
EATL (mean % ± SD)
3.0 ± 1.9 60 ± 25.9 68 ± 24.4 9 ± 13
Dx= diagnosis, 2-CDA= cladribine. * P =0.025 
Serologically, all patients with positivity for EMA and/or anti-tTG at the time of diagnosis 
of coeliac disease reverted to negative after the gluten free diet, confirming their strict 
adherence to diet (in addition to clinical assessment by a dietitian). Those with de novo EATL 
have negative serology at the time of diagnosis. 
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Concerning the mean percentage of aberrant T-cells at the time of diagnosis of the RCD and/
or EATL, the difference between RCD I (3%) versus RCD II (60%) and between secondary 
EATL (68%) versus EATL de novo (9%) is extremely statistically significant (P < 0.0001). 
Table 3 shows the treatments received and summarizes protocols. From all EATL patients 23 
(59%) were treated with chemotherapy (Cyclophosphamide, Doxorubicine, Vincristine and 
Prednisone) (CHOP), while the other 16 patients were not eligible for chemotherapy because 
of a very bad general condition at the time of diagnosis. Fourteen (36%) have undergone 
partial resection of the small bowel. Laparotomy was needed in 3 patients to establish a 
diagnosis and 11 were operated for complications (5 for perforations and 6 for obstructive 
symptoms). Seven patients were treated both by chemotherapy and resection. Eight patients 
(61.5%) of the de novo EATL group have undergone partial small bowel resection compared 
to only 6 (23%) of secondary EATL group (P= 0.025). Three other RCD II patients had surgery 
because of ulcerative jejunitis with perforations. Four patients with EATL were treated with 
high dose chemotherapy followed by autologous peripheral stem cell transplantation (3 with 
de novo EATL and one with secondary EATL) and 3 of them died within few months thereafter 
(CJJ Mulder: unpublished data).
Table 3. Summary of treatments received and protocols. * P =0.025
Treatment RCD I RCD II
Secondary
 EATL
De novo  
EATL Treatment protocol
GFD 43 50 26 0 -
Prednisone /
topical steroids only 
31 (72%) 16 (32%) 0 0 Prednisone 40 mg /day 6 weeks, 
tapered to 10 mg/day over 6 weeks 
and, if possible, tapered to 2.5-0 mg 
daily after 3 months
Prednisone +
 Azathioprine (8)
12 (28%) 34 (68%)* 0 0 Prednisone (as above) + Azathioprine 
2 mg/kg/day for ≥ 52 weeks
Prednisone+
 Azathioprine followed 
by 2-CDA (14)
0 23 (46%) 0 0 Prednisone + Azathioprine as above.  
2-CDA (0,1 mg/kg/day) for 5 days, 
in 1-3 courses every 6 months 
depending on response
CHOP 0 0 16 (61.5%) 7 (53%) Standard CHOP 6-8 cycles 
ASCT (17) 0 6 (12%) 1 3 (30%) Pretreatment with 1-3 courses of 2-
CDA, leucopheresis, preconditioning 
(Melphalan+Fludarabine) + ASCT 
Partial small bowel  
resection 
0 9 (18%) 6 (23%) * 8 (61.5%)* -
Total 43 50 26 13 -
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Table 4 shows causes of death according to patients’ categories. In the RCD I group, only 3 
patients died during follow up, all of them from unrelated illnesses. In the RCD II 26 patients 
(52%) developed EATL within 4-6 years after the diagnosis RCD II had been made, 23 RCD II 
patients (46%) died after developing EATL. Four (8%) died due to progressive malabsorption 
with emaciation, one of them developed extensive multifocal squamous cell carcinoma 
of the skin(> 15 lesions). One patient died because of progressive neurocoeliac disease 8 
months after stem cell transplantation. Nine of 13 (69%) patients with de novo EATL and 23 
of 26 (88.4%) with secondary EATL died within months of diagnosis. 
Figure 1 (A and B) shows the Kaplan -Meier curve of survival according to the disease group. 
The 5- year survival is 96% in RCD I versus 58% in RCD II (total) (P= 0.001). On the other 
hand, the 2-year survival in the de novo EATL group is 20% versus 15% in the EATL (RCD II) 
group (P=0.63). Interestingly, the most significant drop in survival in these groups is observed 
in the first 2 years after diagnosis. The longest survival thus far in the de novo EATL is 26 
months. 
Table 4. Causes of death according to the patients categories. * P value= 0.63
RCD-I RCD-II (total) EATL (RCD II) De novo EATL
EATL 0 23  (46%) 23  (88.4%) 9  (69%)
Refractory state and emaciation 0 4   (8%) 0 0
Other coeliac- related 0 1 neurocoeliac 0
Unrelated 3  (6.9%) 
(1 alcoholic cirrhosis,
1 COPD, 1 lung 
cancer)
0 0 0
Alive 40  (93.1%) 22  (44%) 3  (11.6%)* 4 (21%)*
Total 43 50 26 13
Since this is not a randomized study, it is not possible to make definitive conclusions about 
the success of different treatments. However, in the prednisone alone group the 5 year 
survival is 25%, in the prednisone and azathioprine group 36% (P= 0.43) and the cladribine 
(2-CDA) group 22 % (43 % at 36 months) P=0.97. With respect to EATL development, there 
is no statistically significant difference between the groups. 
RCD II patients who received autologous peripheral stem cell transplantation completed 
the mobilization and leucopheresis procedures successfully and subsequently received 
conditioning and transplantation. Engraftment occurred in all patients. No major non-
haematological toxicity nor transplantation related mortality was observed. The mean 
follow-up duration is 16 months (range 8-31 months). Within 3-4 months of autologous 
stem cell transplantation all patients had normalization of stools frequency, disappearance 
of abdominal pain and improvement in biochemical markers. Also improvement of the 
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body mass index, serum albumin, endoscopical findings and histology was documented. 
One patient with preexistent neuro-coeliac disease mimicking multiple sclerosis developed 
progression and died 8 months post transplantation. The protocol, inclusion and detailed 
results (clinical, laboratory and endoscopy) are described in our recent article 17.
Figure 1. Shows the Kaplan -Meyer curve of survival according to the disease group. (A) The 5- years survival is 
96% in the RCD I group versus 58% in RCD II (P= 000.1). (B) The 2 year survival is 15% in secondary EATL versus 
20% in de novo EATL (P=0.63). Censored= Not lost for follow up
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Discussion
The development of a refractory state in patients with coeliac disease may herald the start of 
a very serious stadium in the evolution of the disease state particularly in RCD patients with 
aberrant T-cells (RCD II).1, 2 Particular attention should be paid to detect non-compliance or 
inadvertent gluten ingestion. Persistent positive serology may point to the last mentioned 
scenario.31-33 
Regarding gender distribution in the studied groups, there is a female: male predominance 
in the RCD I, RCD II total and secondary EATL group, while in the de novo EATL group there 
is a reversed ratio with more males than females. The difference is not significant between 
the RCD I and RCD II groups (p= 1.05). However, it is highly significant in the de novo EATL 
versus RCD I (P< 0.001) and versus secondary EATL (P<0.025). Other studies also reported 
predominance for EATL in males, with a peak in the 6th decade of life 7, 33, 34; however the 
majority of patients with uncomplicated coeliac disease are females.35, 36 
HLA-DQ2 homozygosity is significantly higher in the secondary EATL and de novo EATL 
compared to RCD I, Odds ratio= 3,6 (CI:2,64 - 6,33) and OR=2,06 (CI: 1,88 - 4,78), 
respectively.  As we reported earlier there is an association between DQ2 homozygosity and 
complicated forms of coeliac disease.30 
A combination of prednisone and azathioprine is usually sufficient to treat RCD I patients.11, 
16 None of our RCD I patients has progressed to RCD II during follow up. This underscores the 
value of performing T-cell flow-cytometry in these patients, since the absence of aberrant T-
cells in small bowel biopsies at diagnosis of the refractory state seems to indicate a favorable 
prognosis and conventional treatment with prednisone with or without azathioprine is 
usually sufficient.
In view of the poor prognosis of EATL, the question has always been: can the diagnosis 
of lymphoma be made earlier to allow more effective treatment, thereby improving the 
prognosis. Despite state-of the-art technologies used, we can only assume that Lymphoma 
has been excluded in these RCD II patients. The question remains whether a “subclinical” 
lymphoma was actually present and/or its development can be accelerated by available 
therapies.37 
RCD II seems to be ‘’prodromal’, a prelymphoma condition and should be treated aggressively. 
Different therapies have been evaluated, but there is no effective therapy available for 
these patients yet.2, 11-17 Reports claiming good response are difficult to interpret because of 
absence of clear distinction between RCD I and RCD II in these case reports and small series. 
Maurino et al 16 reported clinical and histological improvement in 5-7 patients, treated with 
azathioprine, although 3 patients subsequently died (one from leucopenic fever after therapy, 
and 2 died during therapy). However, in their follow up report on treating 13 patients with 
azathioprine, they reported 46% mortality.38 Cladribine (2-CDA) therapy might be promising 
in stabilizing patients’ condition and improves the performance status and the histological 
picture as seen in 58% of our group. However, it does not prevent EATL.17 Nine patients (39%) 
of 23 treated patients died from EATL. High dose chemotherapy followed by autologous 
stem cell transplantation after stabilization with cladribine might be an alternative approach 
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in these prelymphoma patients. Our experience with the first 7 patients is encouraging in 
improving the clinical condition, but it remains to be proved if development of EATL can be 
delayed or prevented.17
Factors that seem to be associated with a high risk for EATL development in coeliac disease 
are old-age presentation, male sex, ulcerative jejunitis, presence of aberrant T-cells in biopsies 
and DQ2 homozygosity.30,39,40 However, we have seen disappearance of the ulcerative lesions 
after cladribine therapy in five patients and none of them has developed EATL thus far.17 Thus, 
in case of early intervention in the high risk RCD II group, specifically ulcerative jejunitis, 
EATL development might be prevented.
Patients with EATL can present in two ways. There are patients with well-established 
coeliac disease who have responded to a gluten free diet but then deteriorate because of 
the development of RCD II and/or EATL. In the other group patients develop EATL without 
a preceding history of complicated coeliac disease, these patients often present with 
perforation or obstruction (de novo EATL). At the time of establishing the diagnosis, the 
percentage of aberrant T-cells in patients with de novo EATL is significantly lower than that in 
EATL developing after known RCD II (P<0.0001) possibly suggesting a different pathogenesis 
pathway. 
Nine of 13 (69%) of de novo EATL and 23 of 26 secondary EATL (88.4%) died despite 
therapy. The 2-year survival in the de novo EATL group is 20% versus 15% in the EATL 
(RCD II) group (P=0.63). Interestingly, in our patients 61.5% of de novo EATL had undergone 
resection compared to 23% of secondary EATL (P= 0.025). Howdle et al 7 reported a 
laparotomy rate of 73% in lymphomas associated with coeliac disease. It may be necessary 
to resort to laparotomy when malignant lymphoma is suspected and the diagnosis can not 
be established with less invasive methods. Overall, surgery was needed in 3 patients to 
establish a diagnosis and 11 had surgery for complications (5 for perforations and 6 for 
obstructive symptoms). Surgery, radiotherapy and chemotherapy may be used depending 
on stage and clinical condition. EATL is often disseminated at diagnosis and has almost 
always a dismal outcome. However, if EATL is confined to part of the small bowel and if the 
affected segment (or segments) can be resected, the prognosis might be reasonable; some 
patients survive more than 5 years.41, 42 Debulking by surgery might be mandatory; however 
prospective studies are lacking in current literature. Three of 4 EATL patients who received 
high dose chemotherapy and autologous stem cell transplantation died within months after 
transplantation (CJJ Mulder: unpublished data).
Although the studied groups of patients seem to be rather heterogeneous and not entirely 
exclusive but we think that we provided here a detailed description of the prognosis and 
response to currently available therapeutic options in the whole spectrum of complicated 
forms of coeliac disease, ranging from RCD I with its relatively benign course, RCD II which 
has a definite pre-lymphoma potential to the frankly malignant EATL. In addition, these 
groups of patients are the largest ever experience reported from a single centre dealing with 
coeliac disease and its complications. 
In conclusion, an aggressive management approach and extensive evaluation using recently 
available small bowel endoscopy, radiology and immunophenotyping on small bowel biopsies 
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might be helpful in dealing with complicated forms of coeliac disease. Studies are needed 
to define more precisely the cut-off point between acceptable normal and pathologically 
increased percentage of aberrant T-cells. Multicentre cooperation and studies are required to 
further increase the understanding of RCD in general. 
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Summary
This thesis provides a detailed overview on the management of complicated forms of 
coeliac disease, particularly refractory coeliac disease in its currently recognized two major 
categories (RCD types I and II) and enteropathy associated T-cell lymphoma (EATL). The 
distinction between RCD I and II is currently based on T-cell flow- cytometry analysis of 
small bowel biopsies looking for the presence of significant percentage of aberrant T-cells. 
RCD I patients have very low or undetectable percentage of aberrant cells compared to RCD 
II. The latter is regarded as a pre-lymphoma because of the high potential to progress to EATL. 
Chapter 1 provides an overview of the historical landmarks in the diagnosis, classification 
and treatment of coeliac disease and RCD; in addition to the recognition of the link or 
relationship between coeliac disease and EATL. 
Chapter 2 gives a detailed account of the current management of RCD and EATL, incorporating 
all recent advances in diagnostic techniques and therapeutic measures. Concerning diagnosis, 
particular attention was devoted to recent advances in small bowel enteroscopy (both video 
capsule endoscopy and double-balloon enteroscopy) and computed tomography of the small 
bowel. Therapeutically, the use of immunosuppressives is discussed. More prominently, we 
introduced our pioneer work in the management of refractory coeliac disease type II in the 
form of using high dose chemotherapy followed by Autologous Stem Cell Transplantation. 
The 2 accompanying articles are respectively: a general and detailed review of the technique 
and application of double-balloon enteroscopy in the first article, while the second article 
reviews the current applications and gives a future perspective of stem cell transplantation in 
the field of gastroenterology in general and RCD in particular. 
Chapter 3 looks at the epidemiology of EATL in the Netherlands. A survey in the nationwide 
network and registry of histo- and cytopathology in the Netherlands (abbreviated as PALGA) 
was conducted. The data on patients diagnosed with EATL between 2000 -2004 were 
analysed. EATL is seen in patients older than 50 years old. In the majority of patients, it has 
been found in the proximal small bowel. 
Chapters 4, 5 and 6 deal with the advances in diagnostic approach in both RCD and EATL. 
Chapter 4 describes our findings on the relationship between HLA-DQ2 haplotyes and the 
risk of developing a complicated form of coeliac disease. Molecular HLA-DQ typing was 
performed on 43 RCD-I, 43 RCD-II, and 30 EATL patients, and compared with age-matched 
groups of 121 patients with histologically defined uncomplicated coeliac disease and 183 
healthy controls. HLA-DQ2 was present in 79% of RCD I, 97.7% of RCD II, and 96.6% of 
EATL patients. Homozygosity for HLA-DQ2 was observed in 25.5% of RCD I, 44.1% of RCD 
II, and 53.3% of EATL patients versus 20.7% of uncomplicated coeliac disease patients and 
2.1% of controls. We concluded that homozygosity for HLADQ2 is associated with RCD II 
and EATL. Early identification of HLA-DQ2 homozygous coeliac disease patients may help 
to recognize patients at risk for developing severe complications. 
Chapter 5 deals with the role of the double-balloon enteroscopy in the diagnosis of RCD 
and EATL. The small bowel endoscopy was performed in a total of 21 consecutive patients 
for lesions like ulcerations. Twenty-four procedures were successfully performed without 
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complications. EATL was found in five patients (24%). In three of them Marsh III was found 
while in the other two patients with EATL Marsh I was found. Double-balloon endoscopy 
could exclude the presence of EATL in four patients that was suggested by abdominal 
computerized tomography. We concluded that complications of refractory coeliac disease 
like ulcerative jejunitis or EATL could efficiently be detected, its extent delineated or excluded 
by double-balloon endoscopy.
Chapter 6 deals with the role of computed tomography in the diagnosis of RCD and EATL. CT 
scans of 28 women and 18 men were analysed. Our findings confirmed the useful role of CT 
scan in discriminating between uncomplicated coeliac disease and (pre)EATL. Patients with 
complicated coeliac disease showed more bowel wall thickening, lymphadenopathy and 
intussusception, less increase in number of small mesenteric vessels and a smaller splenic 
volume compared with uncomplicated coeliac disease. 
Chapter 7 provides an account of our results in treating RCD II patients with cladribine (2-
CDA), a purine analogue inducing T-cell depletion. Between 2000 and 2005, 17 patients 
were included (8 Males/9 Females). All patients tolerated 2-CDA without serious side effects. 
Six patients (35.8%) showed a clinical improvement. In 10 patients (58.8%) a significant 
histological improvement and in 6 patients (35.2%) a significant decrease in aberrant T-cells 
was seen. Seven patients (41.1%) developed EATL and died subsequently. 2-CDA-treatment in 
RCD type II is feasible, well tolerated and can induce clinical and histological improvement 
as well as a significant decrease of aberrant T-cells in a subgroup of patients, albeit does not 
prevent EATL-development. 
Chapter 8 provides a detailed description of the first ever cohort of RCD II patients treated with 
autologous stem cell transplantation (ASCT) after receiving high dose chemotherapy. Thirteen 
patients with RCD-II were evaluated. Seven patients [4M, 3 F, mean age 61.5 years (range 
51-69 years)] were transplanted. After conditioning with fludarabine and melphalan, ASCT 
was performed. All 7 patients completed the mobilization and leucopheresis procedures 
successfully and subsequently received conditioning and transplantation. Engraftment 
occurred in all patients. No major non-haematological toxicity or transplantation-related 
mortality was observed. There was a significant reduction in the aberrant T-cells in 
duodenal biopsies associated with improvement in clinical wellbeing, and normalization of 
haematological and biochemical markers (mean follow-up 15.5 months, range 7-30 months). 
These results showed that high-dose chemotherapy followed by ASCT seems feasible and 
safe, and might result in long-term improvement of RCD II patients whose condition did not 
respond promptly to available drugs. The ultimate goal of resetting the immune response 
which might prevent or delay development of overt EATL remains to be proved.
Chapter 9 deals with the application of ASCT in EATL patients. Between 2001 and 2006, 
we have treated four adult patients (2Males:2Females) with a diagnosis of EATL with high 
dose chemotherapy followed by ASCT. The mean age was 65 years (range 60-69 years). The 
first patient still has complete remission 30 months post transplantation, while the other 
3 patients died because of recurrence within few months post transplantation. Combining 
immunotherapy (adalimumab) with chemotherapy in the preconditioning regimen was also 
not successful in the one patient who received this combination. We concluded that the 
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current treatments of patients with intestinal T-cell lymphomas are unsatisfactory with only 
a few long-term survivors. Earlier diagnosis, the development of more effective treatments 
including antiCD52 agents, better preconditioning regimens and possibly the use of T-cells 
depleted grafts or allogeneic stem cell transplantation with or without primary central nervous 
system prophylaxis are urgently required to improve the prospects of these patients. 
Chapter 10 provides a comprehensive analysis of the response of different groups of 
complicated coeliac disease to available therapies and giving insight on the long term survival 
in these patients. In our coeliac disease patients, no patient with RCD I developed RCD II or 
EATL within mean follow up of five years (range 2-15 years). Fifty two percent of the RCD II 
patients progressed to/developed EATL within 4-6 years after the diagnosis of RCD II. More 
aggressive therapies seem necessary in RCD II and EATL.
In conclusion, this thesis provides a comprehensive overview of the diagnostic and therapeutic 
possibilities in what is usually difficult to manage clinical situations. Recent advances in 
immunophenotyping of intraepithelial lymphocytes have made distinction between different 
forms of refractory coeliac disease possible. HLA-DQ2 homozygosity is associated with high 
a risk of development of refractory state and lymphoma. Recent advances in small bowel 
enteroscopy and radiology have provided more insight and better understanding of the 
pathology of both RCD and EATL.
RCD with aberrant T-cells is difficult to treat and usually refractory to steroids and 
immunosuppressives; however, high dose chemotherapy followed by stem cell transplantation 
might be regarded as the treatment of choice for those who are usually desperate and critically 
ill patients. The theoretical possibility of delaying or preventing EATL development using 
ASCT is an intriguing concept and worth of more explorative effort. 
EATL remains difficult to treat despite cytoreductive therapy with chemotherapy and partial 
small bowel resection. Still more work need to be done to find the best preconditioning 
regimen and/ or studying the added benefit of immunotherapy with or without high dose 
chemotherapy. 
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Nederlandse samenvatting
Dit proefschrift geeft een gedetailleerd overzicht van het management van gecompliceerde 
vormen van coeliakie, met name refractaire coeliakie, met de huidige onderverdeling in 
twee categorieën (RCD type I en II), en enteropathie geassocieerd T-cel lymfoom (EATL). 
Het onderscheid tussen RCD I en II is momenteel gebaseerd op T-cel flow-cytometrische 
analyse van dunne darm biopten, ter detectie van een significant percentage aberrante T-
cellen. RCD I patiënten hebben een siginificant lager tot onmeetbaar percentage aberrante 
T-cellen vergeleken met RCD II. Deze laatste wordt beschouwd als pre-lymfoom vanwege 
het aanzienlijke risico op EATL progressie. 
Hoofdstuk 1 geeft een overzicht van de historische mijlpalen in de diagnose, classificatie en 
behandeling van RCD; als toevoeging op het herkennen van de connectie tussen coeliakie 
en EATL. 
Hoofdstuk 2 geeft gedetailleerd het huidige management van RCD en EATL weer, inclusief alle 
recente vooruitgang in diagnostische technieken en therapeutische middelen. Met betrekking 
tot de diagnose, is speciaal aandacht besteed aan recente ontwikkelingen in dunne darm 
enteroscopie (zowel video capsule endoscopie als dubbele- ballon enteroscopie) en computed 
tomografie van de dunne darm. Therapeutisch wordt het gebruik van immuunsuppressiva aan 
de orde gesteld. Ook van belang is een introductie van ons ‘pionier werk’ in de behandeling 
van refractaire coeliakie type II, middels hoge dosis chemotherapie gevolgd door Autologe 
Stam Cel Transplantatie. De 2 begeleidende artikelen zijn respectievelijk: een algemene en 
een gedetailleerde review van de techniek en toepassing van dubbele-ballon enteroscopie 
in het eerdergenoemde artikel en in het tweede artikel worden de huidige toepassing en 
toekomstperspectieven van stamcel transplantatie in het veld van de gastroenterologie in het 
algemeen en RCD in het bijzonder beschreven. 
Hoofdstuk 3 beschrijft de epidemiologie van EATL in Nederland. Een onderzoek is verricht 
in het Pathologisch Anatomisch Landelijk Geautomatiseerd Archief, een landelijk computer-
netwerk van alle pathologie-laboratoria in Nederland en de verslagen. het landelijke systeem 
(afgekort als PALGA). De data van patiënten gediagnosticeerd met EATL van 2000 -2004 zijn 
geanalyseerd. EATL wordt gezien in patiënten ouder dan 50 jaar. In de meerderheid van de 
gevallen wordt het gevonden in de proximale dunne darm. 
Hoofdstuks 4, 5 en 6 gaan over de ontwikkelingen in diagnostische benadering van RCD en 
EATL. Hoofdstuk 4 beschrijft onze bevindingen van de relatie tussen HLA DQ2 haplotypes 
en het risico op het ontwikkelen van een vorm van gecompliceerde coeliakie. Moleculaire 
HLA-DQ typering werd verricht bij on 43 RCD I, 43 RCD II, en 30 EATL patiënten, en 
vergeleken met leeftijd-gematchte groepen van 121 patiënten met histopathologisch 
gedefinieerde ongecompliceerde coeliakie en 183 gezonde controles. HLA-DQ2 was 
aanwezig bij 79% van de RCD I patiënten, 97.7% van RCD II, en 96.6% van EATL patiënten. 
Homozygotie voor HLA-DQ2 werd geobserveerd in 25.5% van RCD I, 44.1% van RCD II, 
en 53.3% van EATL patiënten versus 20.7% van uncompliceerde coeliakie patiënten en 
2.1% van controles. We concludeerden dat homozygotie voor HLA-DQ2 is geassocieerd 
met RCD II en EATL. Vroege identificatie van HLA-DQ2 homozygote coeliakie patiënten 
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zou kunnen helpen bij de herkenning van patiënten met een hoog risico op het ontwikkelen 
van ernstige complicaties. Hoofdstuk 5 en Hoofdstuk 6 beschrijven, respectievelijk, de rol 
van de dubbele- ballon enteroscopie en computed tomografie in het stellen van de diagnose 
van RCD en EATL.
Hoofdstuk 7 verschaft een overzicht van onze resultaten van de cladribinebehandeling van 
RCD II patiënten. 
Hoofdstuk 8 geeft een gedetailleerde beschrijving van het eerst beschreven cohort RCD 
II patiënten behandeld met autologe stam cel transplantation (ASCT) na hoge dosis 
chemotherapie. Dertien patiënten met RCD-II werden geëvalueerd. Zeven patiënten [4M, 3V, 
gemiddelde leeftijd 61.5 jaar (range 51-69 jaar)] werden getransplanteerd. Na conditionering 
met fludarabine en melphalan, werd ASCT verricht. Alle 7 patiënten voltooiden succesvol 
de mobilisatie en leucoferese procedures en ondergingen vervolgens conditionering 
en transplantatie. ‘Engraftment’ gebeurde in alle patiënten. Er werden geen grote non-
hematologische toxiciteit of transplantatie-gerelateerde mortaliteit geobserveerd. Er was 
een significante reductie in de aberrante T-cellen in de duodenum biopten geassocieerd 
met verbetering in klinisch welzijn, en normalisatie van hematologische en biochemische 
markers (gemiddelde follow-up 15.5 maanden, range 7-30 maanden). Deze resultaten 
laten zien dat hoge-dosis chemotherapie gevolgd door ASCT haalbaar en veilig lijkt, en 
zou kunnen resulteren in lange termijn verbetering RCD II patiënten wiens conditie niet 
reageerde op direkt beschikbare medicatie. Het uiteindelijke doel van het ‘resetten van 
de immuun respons’ om de ontwikkeling van EATL te voorkomen of vertragen moet nog 
bewezen worden.
Hoofdstuk 9 beschrijft ASCT in EATL patiënten. Tussen 2001 en 2006, hebben we vier 
volwassen patiënten (2M:2V) met de diagnose van EATL behandeld met hoge-dosis 
chemotherapie gevolgd door ASCT. De gemiddelde leeftijd was 65 jaar (range 60-69 jaar). 
De eerste patient had complete remissie 30 maanden na transplantatie, terwijl de 3 andere 
patiënten overleden vanwege van een recidief enkele maanden na transplantatie. Het 
combineren van immunotherapie (adalumimab) met chemotherapie bij de preconditioning 
was ook niet succesvol bij de patiënt die deze combinatietherapie ontving. We concludeerden 
dat de huidige behandeling van patiënten met intestinale T-cel lymfomen onvoldoende zijn, 
met slechts enkele overlevenden op de lange termijn. Het eerder stellen van de diagnose, de 
ontwikkeling van effectievere behandelingen inclusief anti-CD52, betere preconditionering 
en mogelijk het gebruik van T-cel gedepleteerde grafts of allogene stam cel transplantatie 
(met of zonder primaire centraal zenuwstelsel prophylaxe) zijn vereist om de prognose van 
deze patiënten te verbeteren.
Hoofdstuk 10 geeft een uitgebreide analyse van de respons op beschikbare therapieën door 
de verschillende groepen gecompliceerde coeliakie en geeft inzicht in de lange termijn 
overleving van deze.
Concluderend geeft dit proefschrift een uitgebreid overzicht van de diagnostische en 
therapeutische mogelijkheden in wat gewoonlijk moeilijke klinische situaties zijn. Recente 
ontwikkelingen in immunofenotypering van de intraepitheliale lymfocyten hebben 
onderscheid mogelijk gemaakt tussen verschillende vormen van refractaire coeliakie. 
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HLA-DQ2 homozygotie is geassocieerd met een verhoogd risico op de ontwikkeling van 
refractaire coeliakie en een lymfoom. Recente ontwikkelingen in dunne darm enteroscopie 
en radiologie hebben meer inzicht in en beter begrip van de pathologie van zowel RCD als 
EATL gegeven.
RCD met aberrante T-cellen is moeilijk te behandelen en meestal steroid- en 
immuunsuppressiva-refractair; hoe dan ook, zoals aangetoond in ons pionier werk, zouden 
hoge dosis chemotherapie gevolgd door stam cel transplantatie beschouwd kunnen worden 
als de behandeling van keus voor de patiënten in kritieke toestand. De theoretische 
mogelijkheid om EATL ontwikkeling te vertragen of voorkomen door ASCT is een intrigerend 
concept en de moeite waard om verder te exploreren. EATL blijft moeilijk te behandelen 
ondanks debulking met partiële dunne darm resectie. Er moet nog steeds veel werk verricht 
worden om het beste preconditioneringsmiddel te vinden en om het additionele voordeel 
van immunotherapie met of zonder hoge dosis chemotherapie te onderzoeken.
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